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 ABSTRACT 
 
COMBINATION REGIMENS USING DIETARY COMPONENTS FOR THE 
CHEMOPREVENTION OF COLORECTAL CANCER 
AND INFLAMMATION 
SEPTEMBER 2018 
 
CHRISTINA DIMARCO-CROOK, B.S., IMMACULATA UNIVERSITY 
M.S., DREXEL UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Hang Xiao  
 
Dietary components have been found to effectively modulate multiple deregulated 
signaling pathways associated with the initiation and progression of carcinogenesis and 
inflammation in cellular and animal models.  However, clinical studies have shown 
mixed results when examining the efficacy of individual dietary components, perhaps 
suggestive of the synergism that exists between multiple components within a particular 
food and the diet as a whole.  Additional research is needed to identify and characterize 
the unknown interactions and potential chemopreventive and anti-inflammatory 
properties within combination regimens using dietary components.  
Nobiletin a polymethoxyflavone (PMF) found primarily in the peel of sweet (C. 
sinensis) and bitter (C. aurantium) orange has demonstrated significant anti-cancer and 
anti-inflammatory effects in both cellular and animal models of colon cancer; therefore it 
is important to investigate the biological activities and interactions of its metabolites with 
other dietary components in order to better understand the possible mechanisms of 
nobiletin in vivo.  One of the primary metabolites of nobiletin in the mouse 3',4'-
didemethylnobiletin (DDMN), has been identified as the metabolite with the strongest 
anti-proliferative effects in HCT116 wild-type p53 colon cancer cells.  Colonic 
concentration of nobiletin in the mouse is also much lower than its primary metabolites, 
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of which DDMN is reported to exhibit stronger anti-cancer and anti-inflammatory effects 
than its parent compound nobiletin.  In addition, curcumin, apigenin and luteolin have 
each been shown individually to exhibit significant anti-carcinogenic and anti-
inflammatory effects in various colon cancer model systems; however the interaction of 
these dietary components in combination with DDMN has yet to be explored.  Our results 
find for the first time apigenin or luteolin, two flavones though similar in structure, to 
have strikingly different responses when combined with DDMN in HCT116 wild-type 
p53 colon cancer cells.  Apigenin and DDMN are additive in combination with no 
apparent interaction whereas luteolin when combined with DDMN exhibits an 
antagonistic response with diminished anti-proliferative effects.  Remarkably, in sharp 
contrast to these findings the combination of curcumin and DDMN in HCT116 wild-type 
p53 colon cancer cells demonstrates strong synergism with enhanced anti-proliferative 
effects which greatly exceed the effects of individual treatments.   
Additional examination of the synergistic combination of curcumin and DDMN 
reveals significant cell cycle arrest and extensive apoptosis induced by the combination, 
which were much stronger than the effects induced by the treatments with curcumin or 
DDMN alone.  Proteins associated with cell cycle arrest and apoptosis were analyzed by 
Western Blot to confirm the change in expression of these proteins were much greater in 
response to the combination treatment of curcumin and DDMN than each compound 
alone.  The synergy between curcumin and DDMN offers a possible novel mechanism for 
nobiletin in combination with curcumin and warrants further investigation on their 
combination to determine its chemopreventive and anti-inflammatory potential for colon 
cancer in vivo.  
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CHAPTER 1 
REVIEW OF COMBINATION REGIMENS USING DIETARY COMPONENTS 
FOR CANCER CHEMOPREVENTION 
 
1.1   Abstract 
 Chemopreventive agents that the general population can consume for prolonged 
periods of time with minimal risk of any side effects are of great interest to all in search 
of a solution to the pervasive incidence of cancer.  Dietary bioactive components have 
been found to modulate many deregulated molecular pathways associated with the 
initiation and progression of different types of cancer.  Combination regimens with 
dietary bioactive components are a promising strategy for cancer chemoprevention 
because they may offer enhanced protective effects against cancer development but cause 
little or no adverse effects.  This article provides an overview of studies examining the 
combination of dietary bioactive components for the chemoprevention of major types of 
cancer.  A better understanding of existing research on the combination of dietary 
bioactive components will provide an important basis for the rational design of future 
combination studies and the successful development of cancer chemoprevention 
strategies. 
 
1.2   Keywords 
Dietary bioactive components, cancer chemoprevention, combination, synergy, whole 
foods, colorectal cancer, prostate cancer, breast cancer, lung cancer, dietary supplements 
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1.3   Introduction 
 Cancer is currently estimated to be responsible for one out of every four deaths in 
the United States, a staggering number that reflects its far-reaching impact on society 
(Jemal, Siegal et al. 2010).  Although many advances have been made in the early 
diagnosis and treatment of cancer, significant challenges to lowering cancer mortality 
rates still remain.  Accumulating evidence suggests that a promising strategy for 
controlling cancer mortality rates is to prevent cancer from progressing to the advanced 
malignant stages during which available treatment options are very limited.   Cancer 
chemoprevention is the use of natural or synthetic chemicals to reverse, suppress, or 
prevent cancer development, thereby reducing an individual’s risk of cancer (Greenwald 
2002).  Dietary bioactive components have been investigated intensely for their potential 
chemopreventive effects in different cancers.  One major advantage of dietary 
components as chemopreventive agents is that they generally have none or few of the 
adverse effects frequently associated with pharmaceutical drugs after long-term 
administration (Chen and Kong 2005; Ramos 2008; Davis, Emenaker et al. 2010; 
Neergheen, Bahorun et al. 2010). 
There is a growing body of evidence suggesting that the combination of cancer 
chemopreventive agents with distinct mechanisms of action may produce a synergistic 
type of interaction (Xiao and Yang 2008).  The synergy among these agents can result in 
considerably stronger cancer chemopreventive effects than those produced by each agent 
individually.  The enhanced efficacy of the combination regimen can also lower the dose 
required for each agent in the combination which lowers the cost of the regimen and 
offers a positive economic impact on society.  Moreover, the lowered doses of 
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chemopreventive agents can potentially reduce or eliminate unwanted side effects 
frequently associated with long-term administration of high-dose chemopreventive 
agents.  Numerous studies have explored the benefits of combining multiple 
pharmaceutical drugs and combining dietary bioactive components with pharmaceutical 
drugs to fight cancer (Schwartz, Birk et al. 2004; Tsuda, Ohshima et al. 2004; 
Constantinou, White et al. 2005; Fresco, Borges et al. 2006; Martin 2006; Xiao and Yang 
2008).  However, less is understood about the combination of dietary bioactive 
components for cancer chemoprevention.  Herein, the combination studies on dietary 
bioactive components are reviewed to investigate their ability to alter the pathology of 
cancer.  The principle and methods of determining the modes of interaction (i.e., 
synergistic, additive, and antagonistic) among multiple agents have been discussed 
elsewhere (Greco, Bravo et al. 1995; Chou 2006; Lee, Kong et al. 2007).  In this review, 
the interaction among dietary bioactive components is examined on the basis of the 
combination index (CI) or relevant statistical analyses (Xiao and Yang 2008).  This 
review summarizes existing research for the potential use of dietary bioactive 
components in combination for cancer chemoprevention.   
 
1.4   Colorectal Cancer 
 Accumulating research in colorectal cancer models suggests dietary bioactive 
components in combination may enhance the anticarcinogenic effects attributed to each 
individual component (Table 1.1).  The estimated transition from precancerous cells to a 
malignant colorectal tumor takes, on average, 10-15 years (Boursi and Arber 2007).  
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Aberrant crypt foci (ACF) are believed to be the first identifiable precursor lesions of 
colorectal cancer (Bird 1995).   
 
1.4.1 Aberrant Crypt Foci (ACF)and Familial Adenomatous Polyposis (FAP) 
 The chemopreventive efficacy of curcumin (a major bioactive component found 
in turmeric), green tea catechins [mainly (-)-epigallocatechin-3-gallate, EGCG], and their 
combination was determined in male Wistar rats in which colon carcinogenesis was 
induced by 1,2-dimethylhydrazine (Xu, Ren et al. 2010).  After 12 weeks of dietary 
treatments, the formation of colonic ACF was significantly decreased by the combination 
treatment of curcumin and tea catechins.  This inhibitory effect was stronger than that of 
the treatments with individual components.  Furthermore, following 32 weeks of dietary 
treatments, the colonic tumor incidence of the combination treatment group was 
significantly lower than that of the curcumin or catechin treatment groups.  These results 
suggest that the combination treatment with curcumin and green tea catechins produces 
enhanced inhibitory effects on both the initiation and progression stages of colon 
carcinogenesis.  Studies using whole foods in combination have also demonstrated strong 
anticarcinogenic effects on ACF formation (Challa, Rao et al. 1997; Sengupta, Ghosh et 
al. 2004).  A study using the azoxymethane-induced rat model showed that the garlic and 
tomato combination dietary treatment produced a stronger effect on the inhibition of 
abnormal cell proliferation, the induction of apoptosis, and greater decreases in ACF 
formation than garlic or tomato alone (Sengupta, Ghosh et al. 2004).  The pronounced 
inhibitory effect on ACF formation by the combination of garlic and tomato has been 
attributed in part to the reduction of cyclo-oxygenase-2 (COX-2) and induction of  
5 
 
Table 1.1  Studies examining the combination of dietary bioactive components on 
colorectal cancer  
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Indol-3-carbinol 
Genistein* 
HT29 colon cancer cells, ↓autophagy, ↓Akt 
phosphorylation, ↑caspase-dependent 
apoptosis 
 
HCT116 Clone colon cancer cells, 
↑G2/M cell-cycle arrest, ↓cell proliferation 
 
DLD-1 and HCT116 colon cancer cells, 
↓cell proliferation 
   
 
LS-174 colon cancer cells, 
↓single-strand DNA breaks 
 
Caco-2 colon cancer cells, 
↑UGT1A1↓cell proliferation 
 
Caco-2 colon cancer cells, 
↓Cox-2, ↑apoptosis, ↓cell proliferation 
 
 
HCT116 colon cancer cells, ↑, ↑Bax,  
↓Bcl-2, ↑apoptosis, ↓cell proliferation 
 
HCT116 colon cancer cells, ↓pEGFR,  
↓pHER-2, ↓pHER-3, ↓pIGF-IR, ↑S phase 
cell-cycle arrest 
 
HCT116 and HT29 colon cancer cells,  
↓cell proliferation 
 
HCT116 and HT29 colon cancer cells, ↓cell 
proliferation, ↑apoptosis, ↓lipid peroxidation 
 
CaCo-2 colon cancer cells,  
↑UGT1A1 
 
HCT116 colon cancer cells, 
↑apoptosis↑ mitochondrial Ca2+ 
 
 
Nakamura 
et al  
 
 
Sulforaphane, 3,3'-
diindolymethane* 
 
Indole-3-carbinol, 4-
methoxyindole-3-
carbinol 
 
 
Pappa et al  
 
 
Kronbak et al  
 
 
 
Isothiocyanates 
Indoles 
 
Bonnesen et al  
 
Resveratrol, Chrysin, 
Curcumin 
 
Iwuchukwu  
et al  
 
Butyrate 
Carnitine 
 
Roy et al  
 
 
 
Resveratrol 
Grapeseed extract* 
 
Radhakrishnan 
et al  
Resveratrol 
Curcumin* 
 
Majumdar  
et al 
 
 
Total Cranberry Extract 
Polyphenols 
 
 
Seeram et al 
 
Pomegranate Juice 
Polyphenols 
 
Seeram et al 
 
Sulforaphane 
Apigenin 
 
Docosahexaenoic acid 
(DHA), Butyrate 
Svehlikova  
et al  
 
Kolar et al 
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Table 1.1  Continued 
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Sulforaphane, Iberin 
Selenium 
Caco-2 and HCT116 colon cancer cells,  
No effect on abnormal methylation 
 
Azoxymethane treated Sprague-Dawley rats, 
↓DNMT1, ↑histone H3 acetylation, ↓ACF,  
↓cell proliferation, ↓CyclinD1, ↑SFRP5  
 
Dimethylhydrazine induced Wistar rats, 
↓bioavailability  
   
ApcMin/+ mice, 
No significant effects as compared to 
individual components 
 
ApcMin/+ mice, ↓tumor occurrence, ↓large 
tumors, ↓PGE2, ↓nuclear β-catenin, ↓p-Akt 
 
Azoxymethane treated  F344 rats,  
No significant effects as compared to 
individual components 
 
Dimethylhydrazine induced Wistar rats, 
↓ACF, ↓tumor incidence, ↓cell proliferation 
 
Azoxymethane treated Fisher 344 rats,  
↓ACF incidence 
  
Azoxymethane treated Sprague Dawley rats, 
↓cell proliferation, ↓apoptosis, ↓ACF 
 
Azoxymethane induced Sprague Dawley rats, 
↑↓ACF, ↑p21, ↑↓apoptosis  
 
SW-480 colon cancer cells, 
↓cell proliferation  
 
HT29 colon cancer cells, ↓cell proliferation,  
↓p-Akt, ↓p-mTOR, ↑Bax, ↑Fas  
Barrera et al  
 
Green Tea  
Selenium 
 
 
β-ionone 
geraniol 
 
Hu et al  
 
 
 
Viera et al  
 
 
Sulforaphane 
Dibenzoylmethane 
Shen et al  
 
 
(-)-Epigallocatechin-3-
gallate, Fish oil 
 
 
 
Bose et al  
Diosmin 
Hesperidin 
Tanaka et al  
  
 
Curcumin 
Green Tea Catechins 
 
 
Xu et al  
Green Tea 
Phytic acid 
 
Challa et al 
 
Tomato 
Garlic 
 
Sengupta et al 
 
Fish oil, Corn oil, 
Butyrate 
 
Peppermint, Sage 
Rosemary* 
 
Eicosapentaenoic acid 
(EPA), Lycopene 
 
 
 
Crim et al 
 
 
Yi et al  
 
 
Tang et al 
 
 
*This study used the Combination Index (CI) to determine synergism 
(CI) 
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glutathione-S-transferase (Sengupta, Ghosh et al. 2003).  Examination of the flavonoids 
diosmin and hesperidin in combination revealed a significant decrease in ACF formation 
in azoxymethane-treated rats (Tanaka, Makita et al. 1997).  However, the combination 
effect on ACF was not statistically stronger as compared to treatments with individual 
agents. 
 The ApcMin/+ mouse model has been used frequently to determine 
chemopreventive effects of dietary components against intestinal tumoigenesis.  The 
ApcMin/+ mouse model is a model for human familial adenomatous polyposis (FAP), 
which is a hereditary disease characterized by the inactivation of one allele of the 
adenomatous polyposis coli (APC) gene.  Individuals diagnosed with FAP experience 
multiple colonic polyps that without removal may eventually progress to colon cancer 
(Rao and Reddy 2004).  Although FAP only accounts for a small portion of diagnosed 
cases of colorectal cancer, APC gene mutations are a common early occurrence in the 
carcinogenesis process of the majority of colorectal tumors; therefore, use of the ApcMin/+ 
mouse model can offer insight into these early genetic events and aid in the development 
of future chemopreventive agents (Powell, Zilz et al. 1992).  The combination of 
sulforaphane and dibenzoylmethane (a compound found in licorice) was investigated in 
the ApcMin/+ mouse model (Shen, Khor et al. 2007).  The combination treatment caused a 
significant inhibition of tumor development as compared to the control.  However, when 
the chemopreventive effects of half-dose combinations of sulforaphane and 
dibenzoylmethane were compared with those produced by full-dose combinations of 
sulforaphane and dibenzoylmethane alone, no statistical difference was found; therefore, 
further studies are required to examine a broad range of doses to determine the mode of 
8 
 
interaction (additive or synergistic).  A combined treatment of EGCG (a major green tea 
polyphenol) and fish oil was used in the high fat diet of female ApcMin/+ mice to 
determine if the combination decreased tumors more effectively than either agent alone 
(Bose, Hao et al. 2007).  The combination treatment for nine weeks resulted in a 
significant decrease in the number of large tumors as compared to the control, a greater 
effect than individual treatments.  A combination treatment of EGCG and fish oil resulted 
in tumors with decreased levels of prostaglandin E2 (PGE2), nuclear B-catechin, and 
phosphorylated Akt, three potential procarcinogenic factors for colorectal cancer.  The 
combination of dietary components has also been found effective in inhibiting human 
FAP.  For example, in a case study of five FAP patients, all were found to have a 
reduction in the number and size of adenomas following a six-month dietary treatment of 
480 mg of curcumin and 20 mg of quercetin (a flavonol found in many fruits, vegetables, 
and grains) in combination three times a day (Cruz-Correa, Shoskes et al. 2006), 
highlighting the promising potential of dietary combination regimens for cancer 
chemoprevention.  
 
1.4.2   Fish Oil –Docosahexaenoic and Eiosapentaenoic Acid 
 Besides the aforementioned study on the combination of fish oil and EGCG in 
ApcMin/+ mice, several other studies have focused on the combination of fish oil with 
other dietary factors.  In azoxymethane-treated rats, the dietary combination treatment of 
fish oil plus butyrate for 11 weeks resulted in inhibition on colonic ACF formation 
accompanied by increased apoptosis.  In contrast, the combination of corn oil plus 
butyrate led to increased ACF formation and had no effect on apoptosis (Crim, Sanders et 
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al. 2008).  Although both combinations increased the expression of p21, the fish oil plus 
butyrate combination was chemopreventive, whereas the corn oil plus butyrate 
combination was promotive of colon carcinogenesis.  These findings highlight the 
important role of interactions between dietary components and their effects on biological 
outcomes.  Studies evaluating fish oil components such as docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA) offer clues to possible mechanisms involved in 
combinations with fish oil.  In human colon cancer cells and primary cultures of rat 
colonic crypts, enhanced induction of apoptosis observed with the combination of 
butyrate and DHA appeared to occur through a p53-independent mechanism that relied 
on the upregulation of the mitochondrial Ca2+ -dependent pathway (Kolar, Barhoumi et 
al. 2007).  Lycopene and EPA in combination demonstrated a significant reduction of cell 
proliferation in HT29 colon cancer cells (p<0.05), which was associated with inhibition 
of the phosphatidylinositol 3-kinase/Akt signaling pathway (Tang, Cho et al. 2009).   
 
1.4.3 Glucosinolates  
 One group of compounds under frequent investigation for their chemopreventive 
effects against colon cancer are glucosinolates, in particular the glucosinolate breakdown 
products such as sulforaphane, indole-3-carbinol, and their related derivatives.  The main 
source of glucosinolates in the human diet is cruciferous vegetables, some of which 
include broccoli, cauliflower, Brussels sprouts, kale, and cabbage (Lund 2003; McGrath 
and Spigelman 2008).  Indole-3-carbinol and genistein (a soy isoflavone) in combination 
were found to synergistically inhibit cell viability of HT29 human colon cancer cells 
(CI<1) (Nakamura, Yogosawa et al. 2009).  This inhibition was associated with 
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inactivation of Akt, an important protein involved in the key signaling pathways known 
to be overactive in colorectal cancer (Osaki, Oshimura et al. 2004).  Synergistic 
inhibitory effects on cell proliferation were also found in a combination study examining 
the interaction between two glucosinolate products, 3,3'-diindolylmethane (DIM) and 
sulforaphane, in a colorectal cancer cell line (Pappa, Strathmann et al. 2007).  DIM, a 
condensation product and dimer of indole-3-carbinol, is formed in the acidic environment 
of the stomach and is the primary form of indole-3-carbinol absorbed in humans.  In the 
cell proliferation assay, a dose response effect was observed as lower concentrations of 
the sulforaphane plus DIM combination became synergistic in its effects on decreasing 
cell proliferation.  The authors postulated the antagonistic interaction was due to the 
induction of phase II enzyme expression by sulforaphane at low concentrations, which 
increased metabolism of DIM and decreased its activities.  Others have found less 
pronounced effects on cell proliferation by the combination of glucosinolate products 
such as indole-3-carbinol and 4-methoxyindole-3-carbinol in HCT116 colon cancer cells 
(Kronbak, Duus et al. 2010).  Glucosinolate products can be protective in the early stages 
of carcinogenesis by diminishing the effects of genotoxic compounds (Bonnesen, 
Eggleston et al. 2001).  Sulforaphane and indolo[3,2b]carbazole (ICZ, a condensation 
product of indole-3-carbinol) were studied in LS-174 colon cancer cells to determine 
their effects on carcinogen/genotoxin exposure of benzo(a)pyrene or H2O2.  In each case, 
the combination treatment with sulforaphane and ICZ prior to carcinogen/genotoxin 
exposure achieved greater DNA protection than either agent alone.  It is notable that the 
protection against DNA damage did not occur if the combination treatment followed 
benzo(a)pyrene or H2O2 exposure.  Multiple studies also suggest glucosinolate 
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derivative combinations and other polyphenol combinations are more effective than their 
individual components in halting initiation of the carcinogenesis process through the 
induction of phase II enzymes (Nho and Jeffery 2004; Svehlikova, Wang et al. 2004; 
Iwuchukwu, Tallarida et al. 2011; Saw, Cintron et al. 2011). 
 
1.4.4 Multiple Component Interaction based on Food Source 
 One area of interest is the interaction of components within a specific food.  
Butyrate and carnitine, both present in milk, have been found in combination to induce 
apoptosis in colon cancer cells by increasing the expression of proapoptotic proteins Bax 
and Bak and decreasing the expression of the COX-2 protein (Roy, Dionne et al. 2009).  
Although the proapoptotic effects of butyrate and carnitine in combination were 
significant as compared to the control, these enhanced effects were not significant when 
compared to those exhibited by butyrate alone.  Resveratrol and grape seed extract, both 
found in grapes, have demonstrated synergistic effects in combination on the inhibition of 
cancer cell proliferation and induction of apoptosis through a p53-dependent mechanism 
in insulin-like growth factor-1 (IGF-1) stimulated HCT116 colon cancer cells 
(Radhakrishnan, Reddivari et al. 2011).  These findings may have important implications 
for future chemopreventive strategies, as IGF-1 appears to play a pivotal role in the 
development of obesity-driven colorectal cancer and p53 is characteristically intact in 
colonic polyps, thereby offering a measureable outcome of treatment efficacy.  The 
combination of one agent with different agents may elicit distinct mechanisms of actions.  
For example, when resveratrol was combined with a compound not found within grapes, 
such as curcumin, the combination elicited a synergistic response that was p53-
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independent (Majumdar, Banerjee et al. 2009).  This was different from the combination 
of resveratrol and grape seed extract.   
 
1.4.5 Whole Foods – Fractions and Extracts 
 The combination effects of dietary components on colon cancer have been 
demonstrated in studies where the whole food and its fractions were compared.  Total 
cranberry extract was examined and separated into fractions of sugars, organic acids, total 
polyphenols, proanthocyanidins, and anthocyanins to compare the efficacy of different 
fractions in the inhibition of colon cancer cell growth (Seeram, Adams et al. 2004).  The 
greatest antiproliferative effect occurred with the total polyphenol fraction in HCT116 
colon cancer cells, thereby suggesting a possible synergistic interaction among several 
polyphenol components.  In a similar study, pomegranate juice demonstrated greater 
inhibition on HT-29 and HCT116 colon cancer cells than isolated individual polyphenol 
components of pomegranate juice (Seeram, Adams et al. 2005).  Upon further 
examination, the pomegranate juice was found to have a significant effect on the 
induction of apoptosis in HT-29 cells but no significant effect on apoptosis in the 
HCT116 cell line.  However, the individual polyphenol components of pomegranate juice 
significantly increased apoptosis in HCT116 cells, suggesting different mechanisms are 
responsible for the inhibitory effects of pomegranate juice in HT-29 colon cancer cells.  
Whole food extracts have also been investigated for their combination effects.  A 
peppermint extract plus sage extract combination treatment synergistically inhibited the 
growth of SW-480 colon cancer cells.  However, rosemary extract and sage extract alone 
was much stronger than peppermint extract in its inhibitory effects (Yi and Wetzstein 
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2011).  Notably, studies using crude food extracts in cell culture models have very 
limited physiological relevance in terms of bioavailability and biotransformation of 
different dietary components in humans.  Nevertheless, these types of studies may 
provide potential leads for further investigations using experimental models of better 
physiological relevance. 
 
1.4.6 Epigenetic Effects 
 Epigenetic events have been shown to play critical roles in regulating 
carcinogenesis.  Recent studies have examined epigenetic biomarkers to determine if the 
combination of bioactive dietary components elicits enhanced epigenetic responses in 
colorectal cancer models.  Aberrant methylation frequently reported in colorectal cancer 
was unaffected by the combination of isothiocyanates and selenium in Caco-2 and 
HCT116 colon cancer cells (Barrera, Johnson et al. 2013).  In contrast, a marked 
reduction of abnormal methylation was indicated with decreased expression of DNA 
methyltransferase-1 (DNMT1) following green-tea-plus-selenium combination treatment 
in a rat colorectal cancer model (Hu, McIntosh et al. 2013).  Interestingly, the same 
combination also exhibited a greater induction of histone H3 acetylation than green tea or 
selenium alone, an important finding as deacetylated histone H3 has been positively 
associated with colorectal cancer development.  Given the importance of epigenetic 
events, the role of epigenetic mechanisms in the combination of dietary components in 
colorectal cancer warrants further investigation. 
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1.5     Prostate Cancer 
 As a cancer of high frequency, prostate cancer has been frequently investigated as 
a target of combination treatments (Table 1.2).  Effective modulation of the pathways 
mediated by androgens (such as testosterone) and their products is an important strategy 
for the inhibition of prostate carcinogenesis.   
 
1.5.1 Soy Isoflavones and Soy Phytochemical Concentrate (SPC) 
 Both soy and selenium have shown the ability to individually work within these 
androgen mediated pathways in animal models, thereby altering the course of disease.  
Efficacy of soy isoflavones and selenium in combination was investigated in a Noble rat 
model of hormone-induced prostate cancer (Legg, Tolman et al. 2008).  The two oral 
dosages of soy isoflavones were based on either the high consumption of soy among the 
Asian population (often associated in epidemiological studies with a decreased risk of 
prostate cancer) or the lower consumption of soy in the Western diet.  The high 
concentration combination treatment of selenium plus isoflavones was found to 
significantly lower 5a-reductase activity as compared to the low concentration 
combination treatment in the male Noble rats.  The enzyme 5a-reductase is involved in 
the reduction of testosterone to dihydrotestosterone (DHT), often elevated in prostate 
cancer.  Moreover, results from a complementary study in male Noble rats demonstrated 
that combined dietary treatment with selenium and isoflavones produced stronger effects 
in reducing prostate cancer risk factors than either agent individually, and timing of 
dietary supplementation can greatly impact treatment efficacy (Tolman, Lephart et al. 
2008).  The combination of soy isoflavone genistein and resveratrol was investigated in 
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SV-40 tag rats, a transgenic model of spontaneously developing prostate cancer (Harper, 
Cook et al. 2009).  The low-dose dietary combination regimen of genistein plus 
resveratrol (both at 83 mg/kg diet) did not affect cancer outcome, whereas the high-dose 
combination (both at 250 mg/kg diet) was effective in reducing the overall occurrence of 
prostate cancer.  However, there was no evidence of a synergistic interaction between 
genistein and resveratrol that may increase chemopreventive effects of the individual 
agents.  The expression of the androgen receptor (AR) protein was significantly increased 
by the single treatment of resveratrol, but the high-dose combination of genistein and 
resveratrol exhibited no increase in the expression of the AR protein.  These findings 
suggest a potential opposing mechanism exists between genistein and resveratrol in 
regulating the expression of the AR protein.  Cancer chemopreventive effects on 
androgens and their products have also been observed in the combination of soy and tea.  
A soy phytochemical concentrate (SPC) was used in combination with tea infusions of 
black or green tea as the sole source of drinking water in severe combined 
immunodeficiency (SCID) male mice inoculated with LNCaP human prostate cancer 
cells (Zhou, Yu et al. 2003).  The SPC plus tea combinations were more effective in the 
reduction of tumor weight and metastasis to lymph nodes than individual treatments.  Of 
particular interest, green tea alone elevated serum levels of DHT, whereas the SPC plus 
green tea combination significantly reduced serum levels of DHT, thereby suggesting a 
modulatory role of the androgen system as one of the mechanisms responsible for the 
combinatorial anticarcinogenic effects between SPC and green tea. 
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Table 1.2  Studies examining the effects of the combination of dietary bioactive 
components in prostate cancer 
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Genistein, Quercetin, 
Biochanin A 
PC-3, LNCaP, DU-145 prostate cancer cells, 
↑bax, ↑caspase-3, ↓bcl-2, ↑ER-β, ↑p-JNK, ↓p-
ERK, ↓PCNA, ↓cell proliferation↑apoptosis 
 
PC-3 and LNCaP prostate cancer cells, 
↓MMP-2, ↑apoptosis, ↓cell growth 
 
PC-3 prostate cancer cells, ↓ROS,  
↓prostaglandin, ↓cell growth  
   
CWR22Rv1 prostate cancer cells, ↑p53, 
↓cell proliferation, ↑NQO2, ↑AR 
   
CD44+ and CD133+ cancer stem cells 
isolated from PC-3, LNCaP and prostate 
cancer tumors 
↑apoptosis, ↓cell proliferation,↓cell viability, 
↓colony formation, ↓migration, ↓invasion 
 
PC-3 prostate cancer cells, ↓cell growth, 
↑G2/M phase cell cycle arrest  
 
DU 145 and PC-3 prostate cancer cells,  
↓cell proliferation, ↓PLA2, ↓invasion  
 
 
PC-3 prostate cancer cells,  
↓cell proliferation  
 
PC-3 prostate cancer cells,  
↓cell proliferation 
 
LNCap and C4-2B prostate cancer cells, 
↓cell proliferation, ↑apoptosis 
 
PC-3 and LnCap prostate cancer cells,  
↑apoptosis, ↑ sub-G1 cell population 
 
 
Kumar et al  
 
 
Genistein 
Selenium 
 
Resveratrol  
β-sitosterol 
 
 
 
Kumi-Diaka  
et al   
 
Awad et al  
 
 
Epigallocatechin gallate, 
Genistein, Quercetin 
Hsieh et al  
 
Quercetin 
Epigallocatechin gallate 
 
Tang et al  
 
 
 
 
Thearubigin 
Genistein 
 
 
 
 
Sakamoto et al  
  
Pomegranate juice 
polyphenols,seed oil, 
peel polyphenols* 
 
Lansky et al  
Ellagic acid 
Urolithin A* 
 
Vicinanza et 
al 
 
Ginger Biophenolics* 
 
Brahmbhatt  
et al  
 
Daidzein 
Genistein 
 
 
Dong et al 
 
Whole soy extract 
Daidzein, Genistein 
 
Hsu et al  
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Table 1.2  Continued 
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Isoflavones 
Selenium 
Noble rats hormone induced prostate  
Cancer, 5alpha-reductase activity  
 
Noble rats hormone induced prostate cancer, 
↓IGF-1, ↑leptin, ↓weight   
 
SCID mice, ↓dihydrotestosterone, 
↓tumor weight, ↓metastasis to lymph nodes  
   
 
Noble rats implanted with estradiol and 
testosterone, ↓p50, ↓IL-6, ↓IL-1β, ↓TNF-
alpha, ↓infiltrating inflammatory cells 
 
Copenhagen rats Dunning R3327-H, 
↓tumor weight, ↓tumor growth 
 
Mouse prostate TRAMP model, 
No significant effects as compared to 
individual components 
 
Copenhagen rats Dunning R3327-H, 
No significant effects as compared to 
individual components 
 
Lady transgenic mice model,  
↓PCNA, ↑apoptosis, ↓prostate cancer 
incidence 
 
Phase II clinical trial men w/prostate cancer, 
Opposing effects on PSA stabilization 
 
AT3 rat prostate cancer cells,  
No significant effects as compared to 
individual components 
 
SV-40 Tag rats, 
opposing effects on AR receptor  
↓cell proliferation 
Legg et al  
 
Selenium 
Isoflavones 
 
Soy phytochemical 
extract(SPC), green  
and black tea 
 
 
Tolman et al  
 
 
Zhou et al  
 
 
Green Tea 
Soy  
Hsu et al  
 
 
Tomato  
Broccoli  
 
 
 
Canene-Adams 
et al  
Tomato Powder 
Soy Germ 
Zuniga et al  
  
 
Lycopene, Vitamin E, 
Selenium 
 
 
Lindshield  
et al  
 
Lycopene, Vitamin E 
Selenium 
 
 
Venkateswaran  
et al  
 
Lycopene 
Soy Isoflavones 
 
Vaishampayan  
et al  
  
Lycopene 
Lutein 
 
Gunasekera  
et al  
 
 
Genistein 
Resveratrol 
 
 
 
Harper et al  
 
  
 
*This study used the Combination Index (CI) to determine synergism 
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 A substantial amount of research suggests soy isoflavones exhibit the ability to 
modulate multiple pathways involved in the pathology of prostate cancer.  Genistein was 
shown to demonstrate strong combinatorial effects with different agents in the 
downregulation of cell proliferation and induction of apoptosis in both hormone-
dependent and –independent prostate cancer cell lines.  For example, genistein and 
selenium in combination significantly decreased cell proliferation and increased 
apoptosis and caspase-3 activity as compared to individual treatments in PC-3 (hormone-
independent) and LNCaP (hormone-dependent) prostate cancer cells, thus implying the 
effects of the genistein plus selenium combination are not hormone dependent within 
these cell lines (Kumi-Diaka, Merchant et al. 2010).  The interaction of genistein plus 
quercetin plus biochanin A was studied in LNCaP, DU-145, and PC-3 prostate cancer 
cells (Kumar, Verma et al. 2011).  The triple combination was found to be more 
efficacious in the inhibition of cell proliferation in both estrogen receptor (ER)-dependent 
and –independent pathways than each component alone.  Further mechanistic 
investigation in PC-3 cells demonstrated that the combination treatment of genistein plus 
quercetin plus biochanin A induced apoptosis, increased the activation of caspase-3, and 
up-regulated the expression of the ER-B gene (a gene important for the regulation of 
tumor repressor activity in prostate cancer).  Indeed, the triple combination was more 
effective than individual or double combinations in modulating some of the key 
regulatory proteins, including BAX, bcl-2, pJNK, pERK-1/2, and PCNA in PC-3 prostate 
cancer cells. 
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1.5.2 Tea Components 
 Other studies point to the increased anticarcinogenic effects that occur when 
quercetin or genistein are combined with tea components.  The combination of quercetin 
and EGCG was examined in prostate cancer stem cells and was found to produce 
pronounced inhibitory effects on cell viability, colony formation, metastasis, and cell 
invasion (Tang, Singh et al. 2010).  Likewise, combined treatment of thearubigin (a tea 
component) plus genistein in PC-3 prostate cancer cells resulted in a substantial decrease 
in cell growth, and this inhibitory effect was stronger than that produced by thearubigin 
or genistein alone (Sakamoto 2000).  Different mechanisms of action by thearubigin and 
genistein in the regulation of the G2/M cell cycle phase were proposed to be responsible 
for the observed suppression of cell proliferation.  A triple combination of genistein plus 
EGCG plus quercetin was found to produce an enhanced inhibition of cell proliferation in 
CWR22Rv1 prostate cancer cells, a model reflective of the transition from androgen 
dependence to hormone refractory prostate cancer (Hsieh and Wu 2009).  Although the 
known mechanisms of the individual components within a combination can complement 
each other and result in a potentiated effect, a new mechanism that is not evident to the 
individual components within the combination can also be revealed from the combination 
treatment.  For example, in the Noble rat model of prostate carcinogenesis, the 
combination of soy and green tea produced an anti-inflammatory interaction that is not 
apparent for soy or green tea individually (Hsu, Bruno et al. 2011). 
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1.5.3 Multiple Component Interaction within the Same Food 
 The results from studies where components from the same food are subjected to 
investigation must be interpreted carefully.  For example, fermented pomegranate juice 
polyphenols, pomegranate peel polyphenols, and the pomegranate seed oil were analyzed 
to determine their effects individually and in combination on the proliferation of DU-145 
prostate cancer cells (Lansky, Jiang et al. 2005).  It was found that both the oil plus juice 
and peel plus juice combinations exhibited synergistic effects on diminishing 
proliferation of the cancer cells.  However, the pomengranate juice and peel contained 
many of the same compounds.  Therefore, the combination effects produced by the peel 
plus juice combination could be merely a dose response rather than a meaningful 
interaction.  However, research findings continue to show that multiple dietary 
components from the same food in combination cause greater anticarcinogenic effects 
than individual components.  For example, the antiproliferative effects of the 
pomegranate metabolites ellagic acid and urolithin A in combination were determined in 
PC-3 prostate cancer cells, and the combined treatment was found to result in a marked 
synergistic decrease in cell proliferation (Vicinanza, Zhang et al. 2013).  Similarly, the 
combination of ginger biphenolic compounds exhibits a strong synergism of 
antiproliferative effects in PC-3 prostate cancer cells (Brahmbhatt, Gundala et al. 2013).  
Furthermore, combined treatment of soy isoflavones (genistein plus daidzein) was found 
to be more effective in the induction of apoptosis and suppression of proliferation than 
individual isoflavones in a prostate cancer progression model (Dong, Xu et al. 2013).   
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1.5.4 Whole Foods 
 Recent studies examining whole foods have revealed enhanced anticarcinogenic 
effects that are attributed to the combination of multiple components present in the whole 
food or several foods combined (Basu and Imrhan 2007).  Some studies have reported 
inhibition of prostate carcinogenesis by lycopene, the bioactive compound found in 
tomatoes (Siler, Barella et al. 2004).  However, other studies have found that the whole 
tomato was more efficacious.  Indeed, whole tomato powder at 10% of the diet 
significantly decreased tumor weight in a Dunning R3327-H prostate adenocarcinoma 
model, whereas lycopene as part of the diet at a very high dose did not exhibit any 
significant effect in decreasing tumor weight.  Whole broccoli powder at 10% of the diet 
significantly decreased tumor weight.  Most interestingly, the combination of whole 
tomato powder plus broccoli powder had an even greater effect on diminished tumor 
weight (Canene-Adams, Lindshield et al. 2007).  In another study, the combination of 
whole tomato powder and soy germ was effective in diminishing prostate cancer 
incidence in the mouse prostate TRAMP model, but the inhibitory effects were not 
significantly different from those produced by each individual treatment (Zuniga, Clinton 
et al. 2013).  Notably, whole soy extract significantly increased apoptosis in LnCap and 
PC-3 prostate cancer cells as compared to single treatment of individual soy isoflavones, 
genistein and daidzein.   
 
1.5.5 Clinical Outcome vs Preclinical Findings 
 Recent prostate cancer clinical trials utilizing combinations warrant caution when 
extrapolating preclinical findings to a human population.  A Phase II clinical trial 
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investigated the consumption of lycopene alone and in combination with soy isoflavones 
to determine their efficacy in the modulation of rising serum prostate-specific antigen 
(PSA) levels of 71 men with prostate cancer (Vaishampayan, Hussain et al. 2007).  
Treatment groups were randomized with 38 subjects receiving 15 mg of lycopene alone 
and 33 subjects receiving 15 mg of lycopene plus 40 mg of a soy isoflavone mixture 
twice daily for six months.  Surprisingly, PSA stabilization for a minimum of three 
months occurred for 95% of the lycopene group but occurred for only 67% of the 
combination group.  These results may suggest an antagonistic effect between lycopene 
and soy isoflavone mixtures in stablilizing PSA.  The Selenium and Vitamin E Cancer 
and Prevention Trial (SELECT) examined the efficacy of the combination of selenium 
and vitamin E for prostate cancer prevention (Klein, Thompson et al. 2011).  Although 
preclinical studies of prostate cancer have reported anticarcinogenic effects of vitamin E 
and selenium alone and in combination, the clinical outcome has proven to be quite 
different as vitamin E was found to increase the occurrence of prostate cancer when used 
alone and to a lesser degree in combination with selenium (Venkateswaran, Fleshner et 
al. 2004; Reagan-Shaw, Nihal et al. 2008).  In agreement with these clinical findings, an 
animal study using the Lady transgenic model indicated that the combination of vitamin 
E and selenium was not chemopreventive but rather causative of an increased occurrence 
of prostate cancer (Venkateswaran, Klotz et al. 2009).  Interestingly, when lycopene was 
added to the combination of vitamin E and selenium, the results were quite different such 
that the triple combination treatment significantly decreased the occurrence of prostate 
cancer in mice.  However, the same triple combination of vitamin E plus selenium plus 
lycopene showed no inhibitory effect in male Copenhagen rats transplanted with 
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androgen-dependent Dunning R3327-H rat prostate adenocarcinomas (Lindshield, Ford 
et al. 2010).  These conflicting results exemplify how an accumulation of cellular and 
animal findings is not always indicative of clinical outcome.   
 
1.6     Breast Cancer 
 Table 1.3 summarizes the major studies on breast cancer and the 
chemopreventive effects of combination treatments with dietary components.  
Epidemiological studies suggest certain foods commonly consumed in the Asian diet may 
be protective against the development of breast cancer (Butler, Wu et al. 2010).   
 
1.6.1 Soy, Tea and their Components 
 Two foods that encompass a prominent position within the Asian diet that have 
been explored for their inhibitory effects on breast cancer are soy and tea.  In one such 
study, a soy phytochemical concentrate (SPC) was used in combination with either green 
tea or black tea infusions as part of the diets of female SCID mice bearing implanted 
tumors of MCF-7 breast cancer cells (Zhou, Yu et al. 2004).  The soy concentrate plus 
green tea combination was found to be more effective in tumor weight reduction as 
compared to the control.  Potential mechanisms underlying the actions of the combination 
treatment were proposed to include downregulation of ER-a, reduction of serum IGF-1 
levels, and inhibition of angiogenesis.  Another study reinforced the effects of the 
combination on IGF-1and ER-a by showing a substantial reduction in serum IGF-1 and 
estrogen concentration following a soy concentrate plus green tea combination treatment 
in FVB/N mice (Zhou, Li et al. 2007).  When EGCG was added to the resveratrol plus y-
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tocotrienol combination, it did not result in any increase in the inhibition of proliferation 
of MCF-7 breast cancer cells (Hsieh and Wu 2008).  However, a pronounced increase 
was noted in the induction of quinone reductase NQO1 (a phase II enzyme) following 
exposure to the triple combination treatment of EGCG plus resveratrol plus y-tocotrienol.  
Evaluation of the combination effects on the Rb/E2F protein complex, an important 
regulatory complex of the cell cycle progression, revealed greater inhibition of the Rb 
protein by each of the two component combinations tested than by individual treatment 
alone.  Surprisingly, a diminished inhibitory effect on the Rb protein occurred following 
the exposure to the triple combination of EGCG plus resveratrol plus y-tocotrienol in the 
breast cancer cells.  These findings highlighted the complexity that is involved when 
combining multiple components for cancer inhibition and underscored the need for more 
combination studies to evaluate the variable interactions that can exist between different 
dietary bioactive components.   
 Soy isoflavones have been investigated for their use in combination treatments to 
determine their ability as phytoestrogens to suppress breast cancer through the regulation 
of the ERs and estrogen-responsive genes (Willard and Frawley 1998).  The effects of 
genistein and indole-3-carbinol in combination were studied on the expression of BRCA1 
and BRCA2 in estrogen-responsive MCF-7 breast cancer cells (Fan, Meng et al. 2006).  
Both BRCA1 and BRCA2 have been identified as tumor suppressor genes for hormone-
responsive breast cancer, and the absence or decrease in the expression of BRCA1 has 
been observed in a significant proportion of sporadic breast cancers, suggesting its 
protective role against breast carcinogenesis.  Combination treatment of genistein and  
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Table 1.3  Studies examining the effects of the combination of dietary bioactive 
components on breast cancer 
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Eicosapentaenoic acid 
Genistein* 
MDA-MB-231 and MCF-7 breast cancer 
cells, ↓cell proliferation 
 
MCF-7 breast cancer cells, 
↑NQO1, opposing effects on Rb/E2F protein 
 
 
MCF-7 breast cancer cells, 
↑BRCA1, ↑BRCA2 
   
MDA-MB-231 breast cancer cells, 
↓CXCR4, ↓chemoinvasion  
 
 
MCF-7 breast cancer cells, 
↓cell growth↑apoptosis 
 
MCF-7 breast cancer cells,  
↓cell proliferation 
 
MCF-7 breast cancer cells, ↑Q3G 
stabilization, ↑bioavailability, ↓cell 
proliferation 
 
SK-BR-3 breast cancer cells, ↑bioavailability, 
↓cell proliferation, ↑p-53, ↑PPARγ 
 
SCID mice model of MCF-7 tumor growth, 
↓tumor weight, ↓estrogen receptor-α, 
↓serum insulin-like growth factor (IGF)-I 
 
FVB/N mice, ↓serum estrogen, 
↓serum insulin-like growth factor (IGF-I) 
 
Dimethylbenz[a]anthracene (DMBA) treated 
Sprague-Dawley,  
↓tumor incidence 
Nakagawa 
et al  
 
Epigallocatechin, 
Resveratrol, γ-
tocotrienol 
 
Indole-3-carbinol 
genistein 
 
Hsieh et al  
 
 
 
Fan et al  
 
 
Genistein,3,3'-
diindolylmethane  
(DIM) 
Hsu et al  
 
Pomegranate extract 
Genistein 
 
Jeune et al  
 
Curcumin 
Genistein 
 
Verma et al  
  
Quercetin 3-β-D-
glucoside 
(Q3G), Apple extract* 
 
Yang et al  
Docosahexaenoic acid 
Curcumin* 
 
Altenburg  
et al  
Soy phytochemical 
concentrate (SPC), 
Black tea, Green tea 
 
Zhou et al  
Soy, Green Tea, Black 
Tea components 
 
Zhou et al  
Diallyl sulfide,  
ellagic acid, Se-
methylselenocysteine, 
Selenomethionine, 
Quercetin 
 
 
Ip et al  
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Table 1.3  Continued 
Combination 
Treatment 
Model System  
Mechanism/Effect  
References 
    
Flaxseed 
Soy protein 
Ovariectomized athymic nude mice with 
MCF-7 tumor, ↓tumor growth, ↓pMAPK, 
↓IGF-1Rβ 
 
Sprague-Dawley rats, 
↑apoptosis  
   
Nude mice model of green fluorescent  
protein tagged (GFP) MDA-MB-435 tumors, 
↑metastasis to lung, liver, heart, kidney,  
Bones 
 
Ovariectomized athymic nude mice with  
MCF-7 tumor, ↓cell proliferation, ↓tumor 
growth, ↑apoptosis 
 
 
Power et al  
 
 
Soy protein 
Fish oil 
 
Genistein 
Daidzein 
 
 
 
Flaxseed 
Soy protein 
 
 
 
Kramer et al  
 
 
Martinez-
Montemayor  
et al  
 
 
Saarinen et al  
 
 
 
 
indole-3-carbinol in MCF-7 breast cancer cells resulted in a significant increase of the 
levels of BRCA1 and BRCA2 protein, and these effects were greater than those produced 
by genistein or indole-3-carbinol treatment alsone.  These pronounced chemopreventive 
effects were speculated to be initiated by the activation of the endoplasmic reticulum 
stress response signaling pathway, thereby leading to the expression of downstream target 
genes by genistein and DIM, a metabolite of indole-3-carbinol.  Interestingly, the 
combination treatment of genistein and DIM also demonstrated anticarcinogenic effects 
in estrogen-negative MDA-MB-231 breast cancer cells(Hsu, Chen et al. 2009).  Genistein 
and DIM in combination were efficacious in inhibiting the chemoinvasion of cells toward 
CXCL12, a chemokine receptor and ligand necessary for the metastasis of breast cancer.  
ER-positive MCF-7 breast cancer cells were found to be highly responsive to the 
*This study used the Combination Index (CI) to determine synergism 
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combination treatment of genistein plus pomegranate extract that led to stronger 
inhibition of cell growth and induction of apoptosis as compared to individual 
components (Jeune, Kumi-Diaka et al. 2005).  Genistein and curcumin in combination 
exhibited a strong inhibitory effect on cell proliferation in MCF-7 breast cancer cells 
following 17-B estradiol and estrogenic pesticide exposure (Verma, Salamone et al. 
1997).  The combination treatment of genistein plus EPA has been reported to 
synergistically inhibit the growth of both MCF-7 and MDA-MB-231 breast cancer 
cells(Nakagawa, Yamamoto et al. 2000).  The MCF-7 cells showed a greater sensitivity 
to the combination of genistein and EPA than the MDA-MB-231 cells.  This variation in 
response appeared to be independent of ER status, thereby suggesting different 
mechanisms at work in ER-positive and ER-negative breast cancer cells. 
 
1.6.2 Increased Bioavailability and Cellular Uptake 
 Many of the synergistic effects observed in the combination treatments have been 
attributed to complementary mechanisms, some of which suggest increased 
bioavailability as a possible mechanism for enhanced anticarcinogenic effects.  Apple 
extract and quercetin 3-B-glucoside (Q3G) in combination synergistically decreased cell 
proliferation of MCF-7 breast cancer cells (Yang and Liu 2009).  The synergistic 
antiproliferative effects of the combination were speculated to entail mechanisms 
associated with stabilization and increased bioavailability of Q3G.  These findings are of 
particular interest in the use of compounds with poor bioavailability such as curcumin, as 
only a very small fraction of ingested curcumin are absorbed in humans; indeed, only a 
low micromolar concentration is present in the bloodstream from the ingestion of several 
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grams of curcumin (Garcea, Berry et al. 2005).  For example, curcumin in combination 
with DHA was found to synergistically inhibit cell proliferation of ER-negative HER-2 
positive SK-BR-3 breast cancer cells (Altenburg, Bieberich et al. 2011).  A combination 
treatment of curcumin plus DHA in SK-BR-3 cells increased phosphorylation of p53 and 
expression of PPARy more than each compound alone.  In the presence of DHA, the 
cellular uptake of curcumin in SK-BR-3 cells was greatly increased, perhaps through 
changes in the lipid membrane by DHA.  This increased cellular uptake of curcumin 
within the SK-BR-3 cells could be a key mechanism for the enhanced anticarcinogenic 
effects of the curcumin plus DHA combination.  Indeed, this combination could have 
important clinical implications.  It utilized a targeted treatment strategy to offer enhanced 
bioavailability of anticancer agents within a particular phenotype of cancer cells, which 
in turn led to a greater anticancer efficacy. 
 
1.6.3 Combinatorial Mechanisms Offset Negative Effects 
 Dietary bioactive components may work as chemopreventive agents at different 
stages of carcinogenesis, and the combination of these components may produce stronger 
inhibition on carcinogenesis.  Three different combination treatments were studied in a 
dimethylbenz[a]anthracene (DMBA)-induced mammary tumor model in Sprague-Dawley 
rats, including diallyl sulfide plus Se-methylselenocysteine, ellagic acid plus 
selenomethionine, and diallyl sulfide plus quercetin (Ip and Ganther 1991).  Selection 
criteria for the combination were based on the inclusion of one compound effective prior 
to carcinogen exposure and another compound effective post initiation; the individual 
compound was given either before or after DMBA exposure, based on the mode of 
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action.  Each of the three combinations achieved a greater degree of tumor suppression 
than individual compounds.  Indeed, only the combination treatment significantly 
decreased both tumo incidence and number as compared to the control.  The combination 
of flaxseed and soy, which was based on the premise that flaxseed may modulate the 
effects of soy to offset the negative effects attributed to the ingestion of soy by at-risk 
populations, provides a recent example of a complementary combinatorial mechanism of 
dietary components (Power and Thompson 2007).  Although soy isoflavones have been 
touted for their many health benefits, accumulating o data point to the potential adverse 
effects of these compounds for postmenopausal women and those with existing breast 
cancer (Martinez-Montemayor, Otero-Franqui et al. 2010).  Flaxseed in combination with 
soy protein has been shown to reduce the tumor-stimulating effects of soy in 
ovariectomized athymic mice (Saarinen, Power et al. 2006; Power, Chen et al. 2008).  
Therefore, this combinatorial interaction could be beneficial in allowing women at 
increased risk of breast cancer to ingest soy with flaxseed, thereby obtaining the health 
benefits of soy without the added risk.  Along this line of findings, a complementary role 
of fish oil was identified in another study when it was combined with soy protein and 
found to offset the overexpression of ER-a, thus diminishing the potential negative 
tumorigenic effects of soy protein (Kramer, Johnson et al. 2009). 
 
1.7     Lung Cancer 
 Lung cancer is the most commonly occurring cancer; however, few combination 
studies have been conducted to investigate multiple dietary bioactive components and 
their influence on lung carcinogenesis.  Tea components in combination with other 
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compounds have been studied and have exhibited enhanced chemopreventive effects.  
Lung cancer cell lines expressing wild-type p53 were found to be more sensitive than cell 
lines not expressing p53 to the combination treatment of EGCG plus luteolin (Amin, 
Wang et al. 2010).  Notably, the combination of EGCG plus luteolin induced extensive 
apoptosis in lung cancer cells expressing wild-type p53, and these effects were stronger 
than those produced by EGCG or luteolin alone.  Indeed, knockdown of p53 expression 
in lung cancer cells resulted in a great inhibition of apoptosis induced by the combination 
treatment, thereby suggesting a p53-dependent mechanism for inducing apoptosis by the 
combination.  Importantly, the efficacy of the EGCG plus luteolin combination was 
further confirmed in vivo in a xenograft tumor model in nude mice that showed a 
significant inhibition of tumor growth by the combination treatment.  Another tea 
polyphenol, (-)-epicatechin (EC), was combined with curcumin in the treatment of PC-9 
and A549 lung cancer cells (Saha, Kuzuhara et al. 2010).  EC alone had no suppressive 
effect on either cell line in the test concentrations.  However, EC in combination with 
curcumin exhibited approximately four times greater suppression of the growth of PC-9 
cancer cells than curcumin alone.  Similar results were observed in A549 cells.  The 
enhanced anticancer effects were ascribed to the modulation of MAPK signaling by the 
combination treatment.  Theaflavin-3-3'-digallate plus ascorbic acid and EGCG plus 
ascorbic acid, both combination treatments using tea polyphenols, were found to exhibit 
synergism in the inhibition of cell proliferation of SPC-A-1 lung cancer cells (Li, Wu et 
al. 2010).  Cell cycle arrest at G0/G1 phase is responsible for the synergistic effects.  
Chemopreventive effects of green tea polyphenols have been demonstrated in many 
studies, but these beneficial effects were limited due to poor bioavailability of tea 
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polyphenols.  One factor contributing to the poor bioavailability of tea polyphenols is that 
they undergo extensive biotransformation such as methylation, which may decrease their 
bioactivities.  Interestingly, in the presence of quercetin, methylation of EGCG was 
significantly reduced in cancer cells.  Consequently, the combination of quercetin and 
EGCG produced enhanced inhibitory effects on proliferation of lung cancer cells (Wang, 
Heber et al. 2012).  To confirm these findings in vivo, SCID mice were given brewed 
green tea and quercetin alone or in combination for two weeks.  In agreement with the in 
vitro results, the quercetin treatment greatly reduced the amount of methylated EGCG in 
the lung and kidney of mice.  Indole-3-carbinol and silibinin, a flavonoid of milk thistle, 
have been used in combination to inhibit lung cancer, both in vitro and in vivo (Dagne, 
Melkamu et al. 2011).  Low concentrations of indole-3-carbinol and silibinin in 
combination exhibited much stronger inhibitory effects on lung cancer cells than those 
produced by the individual compounds at higher concentrations.  The inhibitory effects 
by the combination were associated with inactivation of Akt and ERK.  These findings 
were confirmed in A/J mice where combination treatment of indole-3-carbinol and 
silibinin significantly inhibited lung carcinogenesis and downregulated Akt and ERK 
pathways.  Moreover, the effects produced by the combination treatment were stronger 
than those of individual compounds.   
 
1.8     Other Cancers 
As discussed above, combination treatments with dietary bioactive components 
have demonstrated enhanced anticarcinogenic effects in colon, prostate, breast, and lung 
cancer models, but few studies have examined the efficacy of these combinations in less 
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frequently occurring cancers.  Some of the key dietary components used in 
aforementioned combination studies appear to exhibit similar chemopreventive actions in 
other less common cancers. 
 
1.8.1 Curcumin, Soy Isoflavone and Tea Components 
 Curcumin in combination with carnosic acid displayed a strong synergism in 
inhibiting acute myeloid leukemia cells accompanied by enhanced activation of apoptotic 
pathways (Pesakhov, Khanin et al. 2010).  Combination treatment of curcumin plus 
isoflavone synergistically inhibited cell growth of BxPC-3 pancreatic cancer cells (Wang, 
Desmoulin et al. 2008).  Furthermore, the combination treatment produced stronger 
inhibition on Notch 1 and NF-kB-mediated pathways than that attained by either 
compound alone. 
 EGCG in combination with curcumin showed pronounced synergism in an oral 
cancer cell model and exhibited underlying mechanisms involving G1 and G2 cell cycle 
arrest.  The combination treatment of tea catechins EC plus EGCG induced apoptosis 
more than twofold that of the individual compounds in gastric carcinoma cells, 
suggesting a synergistic interaction as EC alone had almost no effect on apoptosis (Horie, 
Hirabayashi et al. 2005).  Additionally, the combination of black tea polyphenol and 
resveratrol caused an enhanced inhibition of tumor incidence, tumor size, and tumor 
number in a two-stage mouse skin carcinogenesis model. 
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1.8.2 Resveratrol and Glucosinolates 
 Resveratrol was studied in combination with polyphenolic compounds ellagic 
acid and quercetin in MOLT-4 leukemia cells (Mertens-Talcott and Percival 2005).  The 
resveratrol plus quercetin combination resulted in a greater-than-additive effect in 
inducing apoptosis and less-than-additive effect in decreasing cell proliferation; the 
resveratrol plus ellagic acid combination, however, produced a greater-than-additive 
effect in both inducing apoptosis and decreasing cell proliferation.   Examination of 
resveratrol in combination with indole-3 carbinol in SK-OV-3 ovarian cancer cells 
revealed a significant increase of G1 and G2 arrest by the combination treatment (Raj, 
Abd Elmageed et al. 2008).  Enhanced proapoptotic effects were produced by the 
combination of resveratrol with sulforaphane in human U251 glioma brain cancer cells, 
which was accompanied by a pronounced decrease of Akt activation and an increase of 
caspase-3 activation. 
 In PANC-1 pancreatic cancer cells, sulforaphane plus benzyl isothiocyanate 
combination treatments produced a potent inhibition of cell viability that was associated 
with inactivation of STAT3 and increase of apoptosis (Hutzen, Willis et al. 2009).  
Substantial reductions in the growth of mouse melanoma (B16F10) cells in vitro and in 
vivo with diminished MMP-9 expression were observed following a combination 
treatment of sulforaphane plus quercetin.  The combination treatment showed strong 
inhibitory effects on melanoma both in vitro and in vivo, and these effects were stronger 
than those of each individual treatment (Pradhan, Mishra et al. 2010).   
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1.8.3 Garlic Components 
 Combinations of S-allylcysteine (an organosulfur component in garlic) and 
lycopene in vivo produced a greater induction of apoptosis in gastric cancer of Wistar rats 
in comparison to individual treatments (Velmurugan, Mani et al. 2005).  Another garlic 
compound, diallyl sulfide, in combination with pomegranate fruit extract demonstrated a 
marked inhibition of a two-stage skin carcinogenesis in a mouse model (George, Singh et 
al. 2011).  Combined treatment led to a significant regression in tumor volume; however, 
no effect was found on tumor number.   
 
1.9     Concluding Remarks and Future Directions 
Accumulating studies have demonstrated the potential of combination regimens 
with dietary bioactive components as a promising strategy for cancer chemoprevention. 
However, much remains to be explored for establishing a better understanding of the 
mechanisms of action of different dietary components in combination.  Important 
information on the efficacy of combination regimens in humans is currently lacking.  
Additionally, more retrospective and prospective epidemiological studies should be 
conducted to determine the combinatorial effects of dietary bioactive components in 
inhibiting carcinogenesis of different organs.  The promising leads identified in the 
epidemiological studies can be further validated in animal carcinogenesis models, 
especially for whole foods and their crude fractions; in vitro models such as cell culture 
assays offer very limited ability to account for the bioavailability and biotransformation 
of dietary components in humans.  For example, results obtained with dietary compounds 
at concentrations too high to be achievable in human blood or specific tissues have a low 
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probability of being realized in humans.  Ultimately, randomized, double-blind, placebo-
controlled trials are needed to clearly demonstrate the efficacy of the combinations of 
dietary bioactive components. 
Currently, only a small fraction of existing studies employ combination index-
based statistical methods to design combination studies and to determine the modes of 
interaction among different dietary bioactive components (Tables 1.1-1.3).  This is far 
from adequate to provide important information that can be conveniently compared and 
analyzed to establish efficacy and mechanisms of action of specific combination 
regimens.  Therefore, standardization of protocols for combination studies is essential.  
Use of the same statistical method such as the combination index-based method provides 
a consistent interpretation of interactions allowing meaningful cross-examination of 
results from different laboratories. 
Although numerous studies show that complementary mechanisms of individual 
dietary components can result in enhanced anticarcinogenic effects when used in 
combination, caution is warranted as certain dietary component combinations can be 
antagonistic with diminished anti-cancer effects and in some instances can even act as a 
promoter of carcinogenesis.  In these cases, it is critical to understand how these 
components interact within the particular combinations so that recommendations can be 
made to avoid potential adverse effects.  These types of recommendations are of 
particular importance to consumers taking dietary supplements, as many bioactive 
components are already combined in dietary supplement products, which is further 
complicated by consumers’ tendency to consume multiple supplements at the same time.   
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CHAPTER 2 
NON-SYNERGISTIC ANTI-PROLIFERATIVE EFFECTS OF SELECTED 
FLAVONOIDS AND FLAVONOID METABOLITE IN COMBINATION FOR 
CHEMOPREVENTION OF COLORECTAL CANCER 
 
2.1 Abstract 
Flavonoids and their metabolites have been highlighted for their anti-carcinogenic and 
anti-inflammatory properties in colorectal cancer animal and cellular models, however 
many of their effects in combination have yet to be explored.  Herein, we examine the 
anti-proliferative effects of two structurally similar flavones, luteolin or apigenin 
(differing only in hydroxylation at 3' of the B-ring) in combination with 3',4'-
didemethylnobiletin (DDMN), a primary metabolite of nobiletin in the mouse.  The 
individual anti-proliferative order of potency in HCT116 colon cancer cells was found to 
be apigenin > luteolin > DDMN.  Our findings suggest the methoxylated A-ring on the 
DDMN structure is associated with a lower anti-proliferative effect than observed in 
luteolin which differs structurally only in the A-ring containing a hydroxyl group at the 5- 
and 7-position with no methoxyl group.  Moreover, results indicate that apigenin and 
DDMN are additive when combined in a 1:1 ratio in HCT116 colon cancer cells at 1.5, 3, 
4.5, 6 and 7.5 µM with no apparent interaction; whereas luteolin in combination with 
DDMN in a 1:1 ratio at 1.5, 3, 4.5, 6 and 7.5 µM exhibits an antagonistic response with 
diminished anti-proliferative effects in a dose dependent manner.  Therefore, these 
findings suggest the presence of the 3' hydroxyl group on the B-ring of luteolin is 
associated with decreased inhibition of cellular growth, as compared to apigenin, 
following combination treatment with DDMN in HCT116 colon cancer cells.   Taken 
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together, our research demonstrates for the first time the antagonistic anti-proliferative 
effects of luteolin and DDMN in combination in HCT116 colon cancer cells.  
 
2.2 Keywords 
Flavonoids, diet-based strategies, combination, cancer chemoprevention, colorectal 
cancer, flavonoid metabolites, anti-proliferative, antagonistic, additive, non-synergistic, 
flavones, secondary plant metabolites, interaction, flavonoid structure 
 
2.3 Abbreviations 
DDMN: 3',4'-didemethylnobiletin; ACF: aberrant crypt foci; PMF: polymethoxyflavone; 
AOM: azoxymethane; DMH: dimethylhydrazine 
 
2.4 Introduction 
Colorectal cancer is the third most commonly occurring cancer in the United 
States currently diagnosed in both men and women (Siegel, Miller et al. 2017).  Rates of 
incidence and mortality have continued to decline in the 50-65+ age group; some of these 
changes have been attributed to decreased consumption of red meat, increased use of 
daily aspirin and the avoidance of smoking.  Advances in colon cancer prognosis have 
also been made in recent years through early diagnosis.  However, troubling statistics 
indicate that incidence and mortality rates have been increasing in younger adults age 
<50 by 22% (2000 to 2013) and 13% (2000-2014) respectively; more research is needed 
to better understand the mechanisms involved and to identify efficacious treatments that 
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can be used for extended periods of time with no toxicity, to prevent or halt the 
carcinogenic process.   
Diet-based strategies for the chemoprevention of colorectal cancer are of 
particular interest due to their low toxicity and anti-cancer effects.  In addition, dietary 
components come into direct contact with the colon, avoiding many of the bioavailability 
challenges often encountered in other cancers with diminished delivery of the active 
components into the bloodstream and to the target organ of interest.  Therefore, the 
dietary components direct contact with the colon is likely to result in more of the parent 
compound and its active metabolites successfully reaching the colon for their therapeutic 
effects (Sak 2014; Ullah, Bhat et al. 2016).  
Flavonoids are secondary plant metabolites, a group of polyphenolic compounds 
with anti-carcinogenic, anti-inflammatory and antioxidant properties (Pan, Lai et al. 
2010; Gonzalez, Ballester et al. 2011).  An abundance of flavonoids can be found in 
many fruits, vegetables, herbs and tea (Hoensch and Oertel 2011).  Many anti-cancer 
effects of flavonoids have been identified in cellular colorectal cancer model systems 
(Kuo 1996).  Further investigation in animal models suggest flavonoids may play a role 
in the inhibition of abherrant crypt foci (ACF) and colonic polyps, both of which can be 
precursors of colorectal cancer (Miyamoto, Yasui et al. 2010).  Clinical and 
epidemiological evidence has been mixed, with a number of studies suggesting a 
decrease in colorectal cancer risk is associated with flavonoid consumption, whereas 
some studies find no significant correlation exists (Theodoratou, Kyle et al. 2007; Bobe, 
Sansbury et al. 2008; Nimptsch, Zhang et al. 2016).  Remarkably, other clinical findings 
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have shown flavonoids can decrease the recurrence of colon cancer tumors after surgical 
removal (Hoensch, Groh et al. 2008).   
More than 4000 flavonoids have been identified and are categorized based on 
their structure.  The flavonoid basic structure consists of two benzene rings (A and B) 
connected with three carbons in an oxygenated heterocycle ring (C) (Liu 2004).   It is 
variations on this C ring that determines the organization of the flavonoids into six 
different subgroups most commonly found in the diet as flavones, flavonols, flavanols, 
flavanones, anthocyanidins  and isoflavones (Beecher 2003).  Notably, of these flavonoid 
subgroups the flavones (luteolin, apigenin and nobiletin) have shown significant anti-
cancer effects in animal and cellular models of colorectal cancer (Figure 2.1).  
 
   
 
 
   
 
 
 
 
Figure 2.1.  Chemical structures of (A) apigenin,  (B) luteolin and (C) DDMN  
(3',4'-didemethylnobiletin) 
Apigenin Luteolin  
3 
 
(A) (B) 
(C) 
(3',4',5,7-tetrahydroxyflavone) (4',5,7.-trihydroxyflavone) 
Hydrolysis 
DDMN 
(3',4'-didemethylnobiletin) 
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Luteolin is found in celery, parsley, apple skin, cabbage, carrots, broccoli and 
green peppers.  In vitro studies suggest luteolin can operate its effects in multiple cell 
signaling pathways associated with colorectal cancer.  Researchers using a cellular model 
of intestinal inflammation found luteolin treatment to exhibit anti-inflammatory effects 
through the inhibition of the JAK/STAT pathway (Nunes, Almeida et al. 2017).   
Luteolin treatment in HT29 colon cancer cells initiates the induction of apoptosis and cell 
cycle arrest accompanied by a decrease in insulin-like growth factor-1 receptor (IGF-1R) 
signaling that leads to a reduction in activation of the PI3K/Akt and ERK1/pathways 
(Lim, Cho et al. 2012).  Chemotherapeutic resistant colon cancer cell lines treated with 
luteolin were found to have increased sensitivity to oxaliplatin’s anticancer effects; these 
results appear to be correlated with inhibition of the Nrf2 pathway and HO-1 expression 
(Chian, Li et al. 2014).  Aberrant crypt foci (ACF) are one of the first signs of 
carcinogenic change that occurs in the colonic mucosa followed by the formation of 
colonic polyps which potentially can lead to the development of colon cancer.  Luteolin 
appears to operate in both the initiation and promotion stage of the colorectal 
carcinogenic process.  Treatment with luteolin significantly decreased the occurrence of 
aberrant crypt foci (ACF) in azoxymethane (AOM) induced colon carcinogenesis in mice 
(Ashokkumar and Sudhandiran 2008).  In studies utilizing the dimethylhydrazine 
(DMH)-induced animal model of colon carcinogenesis in rats, luteolin treatment 
significantly decreased colon cancer incidence, number of colonic polyps and tumors, 
both in number and size (Manju and Nalini 2007; Osman, Said et al. 2015).   
Apigenin, a flavone found in chamomile, grapefruit, onions, celery and parsley 
has been credited for its’ powerful anti-carcinogenic and anti-tumor effects (Shukla and 
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Gupta 2010).  Moreover, apigenin has been shown to favorably modulate cell cycle-
related signaling proteins such as p53 and p21; both important for the regulation of cell 
cycle progression in colorectal carcinogenesis. Apigenin appears to stabilize p53 in 
normal cells but also displays anti-cancer effects in p53 mutant cells.  A p53 independent 
mechanism is responsible for apigenin induced G2/M cell cycle arrest and upregulation 
of p21 expression in the p53 mutant colon cancer cell line HT29 (Takagaki, Sowa et al. 
2005).  Examination of HCT116 p53 wild-type colon cancer cells following apigenin 
treatment revealed a dose dependent suppression of cell proliferation with G2/M cell 
cycle arrest accompanied by increased expression of p53 and p21 (Lee, Sung et al. 2014).   
Additional investigation by Zhong et al in Apcmin+ mice, a colorectal cancer animal 
model, discovered apigenin treatment resulted in a decrease in polyp number and a 
concurrent increase in p53 activation (Zhong, Krisanapun et al. 2010).  Other animal 
models of colon carcinogenesis have displayed similar positive effects with an inhibition 
of ACF in the distal region of the mouse colon and a decreased number of high 
multiplicity ACF observed following apigenin treatment in azoxymethane (AOM) 
induced CF-1 mice and AOM treated rats respectively (Au, Li et al. 2006; Leonardi, 
Vanamala et al. 2010). 
Nobiletin a polymethoxyflavone (PMF), is found primarily in the peel of sweet 
(C. sinensis) and bitter (C. aurantium) orange.  Accumulating evidence reveals nobiletin 
can operate in multiple signaling cascades associated with various disease processes to 
bring about positive effects (Luo, Guan et al. 2008; Lee, Cha et al. 2010; Huang, Li et al. 
2016).  In addition, studies indicate nobiletin is effective in the inhibition of colorectal 
cancer cell growth with G1 cell cycle arrest and upregulation of p21 (Morley, Ferguson et 
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al. 2007; Wu, Song et al. 2015).  Results from preclinical studies using animal models 
confirm these cellular findings.  In AOM /DSS treated mice expression of p21 and p53 
were upregulated in colonic mucosa following nobiletin dietary treatment; these findings 
were associated with a significant reduction in incidence and multiplicity of colonic 
tumors (Wu, Song et al. 2015).   Nobiletin dietary treatment resulted in the inhibition of 
ACF, decreased cell proliferation and expression of prostaglandin E2 in the colonic 
mucosa of azoxymethane (AOM)-induced rat colon carcinogenesis (Kohno, Yoshitani et 
al. 2001; Suzuki, Kohno et al. 2004).  Similar findings in F344 rats revealed nobiletin 
significantly reduced the number of colonic aberrant crypt foci (Tang, Ogawa et al. 
2011). 
Flavonoid metabolites are of great interest to researchers as they are present at 
higher concentrations than their parent compounds in both blood and colonic tissue; 
therefore it is likely the metabolites are responsible for many of the positive effects.  
Accumulating evidence appears to suggest flavonoid metabolites have different 
biological and antioxidant properties than their associated parent compound, often more 
potent in their response (Williamson and Clifford 2010; Lotito, Zhang et al. 2011).  
Nobiletin and its major metabolites as a mixture, in the same proportion as that found in 
the colon of mice fed nobiletin, upregulated the Nrf-2 pathway in RAW 264.7 cells and 
increased expression of p53 in HCT116 colon cancer cells (Wu, Song et al. 2017).  
Colonic concentration of nobiletin in the mouse is much lower than its three primary 
metabolites of which 3',4'-didemethylnobiletin (DDMN) has been identified as the 
metabolite with the strongest anti-proliferative effects in HCT116 colon cancer cells (Wu, 
Song et al. 2015).  DDMN appears to inhibit multiple signaling pathways associated with 
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inflammation and carcinogenesis (Lai, Li et al. 2008; Su, Yen et al. 2012).  Recent 
findings have shown 3',4'-didemethylnobiletin (DDMN), a primary metabolite of 
nobiletin in the mouse to have even stronger anti-inflammatory and  anti-cancer effects 
than its parent compound nobiletin (Li, Sang et al. 2007; Lo, Pan et al. 2010; Su, Yen et 
al. 2012; Wu, Song et al. 2015).  Indeed, anti-inflammatory properties of DDMN have 
been identified in RAW264.7 cells with DDMN exhibiting potent inhibition in the 
induction of iNOS, such that it greatly exceeds nobiletin’s anti-inflammatory response 
(Li, Sang et al. 2007).  DDMN initiates G2/M cell cycle arrest with an upregulation of 
p21 in HCT116 colon cancer cells; demonstrating stronger growth inhibition and 
induction of apoptosis than nobiletin in both HCT116 and HT29 cell lines (Wu, Song et 
al. 2015).  
Combination of dietary components has shown many enhanced effects in various 
cancers (DiMarco-Crook and Xiao 2015).  Multiple pathways dysregulated in the 
carcinogenic process warrants the use of several components with complementary 
mechanisms.  Although many studies have examined the positive effects of individual 
flavonoids, few animal or clinical studies have investigated flavonoid to flavonoid 
combinations in colorectal cancer; however some positive findings have been reported 
(Tanaka, Makita et al. 1997; Hoensch, Groh et al. 2008).  In a small clinical study of 29 
patients with resected colon cancer and polyp removal half were given a combination of 
20mg apigenin and 20mg epigallocatechin-gallate, (found in green tea) and matched to 
untreated controls.  Interestingly, the untreated group had a 47% recurrence rate of colon 
cancer whereas the flavonoid treatment group had only a 7% recurrence.  Synergistic 
anti-inflammatory and anti-oxidant effects have also been reported in RAW 264.7 cells 
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with a number of flavonoid to flavonoid combinations (Harris, Qian et al. 2006; Funaro, 
Wu et al. 2016; Phan 2017).  Moreover, multiple colorectal cancer cell lines including 
HCT116, HT29, SW480 and Caco-2 cells have been used with flavonoid to flavonoid 
combination treatments and have demonstrated significant synergistic inhibition of cell 
proliferation (Wang, VanAlstyne et al. 2004; Lambert, Kwon et al. 2008; Gomez-Alonso 
2012; Jaramillo-Carmona 2014).  Remarkably, no studies have been done thus far to our 
knowledge using a combination treatment of a flavonoid to flavonoid metabolite to 
examine the inhibition of cell growth in colorectal cancer. 
Based on these findings, the aim of this study is to examine the anti-proliferative 
effects in HCT116 colon cancer cells of two structurally related flavones, apigenin or 
luteolin in combination with 3'4'- didemethylnobiletin (DDMN), a primary metabolite of 
nobiletin in the mouse.  Although apigenin, luteolin and DDMN are each effective in the 
inhibition of HCT116 colon cancer cells individually no information currently exists 
examining the potential synergy, additive or antagonistic effects of either flavone in 
combination with the metabolite DDMN.  Therefore, for the first time this study 
distinguishes between the structurally related flavones apigenin or luteolin and their 
interaction with the flavone metabolite DDMN to determine their combinatory anti-
proliferative effects in HCT116 colon cancer cells.  
 
2.5 Materials and Methods 
2.5.1 Cell Culture  
 HCT-116 human colon cancer cells were purchased from American Type Cell 
Collection (ATCC, Manassas, VA, USA).  RPMI 1640 media (Mediatech, Herndon, VA, 
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USA) comprised of 5% fetal bovine serum (FBS), 100U/ml of penicillin and 0.1mg/ml of 
streptomycin was used as the growth medium for the cells and changed every several 
days.  The HCT116 colon cancer cells were held in an incubator at 37
o
C with 5% CO
2
 
and the cells selected for the experiments were between 3 to 25 passages.   
 
2.5.2 Cell Treatments 
Luteolin (>98%) and apigenin ( >98%) were obtained from Quality Phytochemicals Inc. 
(Edison, New Jersey).  The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after 
a multi-step process with its chemical structure verified using MS and NMR spectra 
methods as described (Li, Pan et al. 2007; Li, Sang et al. 2007).  DMSO was used for the 
delivery of DDMN and curcumin to the cells in each experiment, resulting in a final 
concentration of 0.1% DMSO. 
 
2.5.3 Cell Viability Assay  
  HCT-116 cells were seeded at 2,000 cells per well in 96-well plates and 
treatments of DDMN, apigenin, luteolin or their combination were administered in serial 
concentrations after 24 hour incubation in 200 µl of serum complete media. Once the 
associated treatment times were met, the replacement of media with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) containing media (Sigma-
Aldrich) was performed to quantify cell viability as outlined in prior experiments (Qiu, 
Dong et al. 2010).  
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2.5.4 Analyses of Synergy 
The analyses of synergy utilized a linear regression model based on the Chou 
Talahay method with some alterations as previously described (Chou and Talalay 1984; 
Xiao, Zhang et al. 2008; Guo, Qiu et al. 2012).  Results were examined using the R 
program and synergy was categorized utilizing the interaction index parameters, with the 
combination interaction (CI) characterized as exhibiting additivity (=1), synergy (<1), or 
antagonism (>1).    
 
2.6 Results and Discussion 
2.6.1 Apigenin and DDMN Additively Inhibit Cell Viability in HCT116 Colon 
Cancer Cells 
HCT116 human colon cancer cells were treated with serial doses of DDMN 
(3µM-15µM) and apigenin (3µM-15µM) individually and at half-dose serial 
concentrations in combination for 48 hours to determine growth inhibitory effects using 
the MTT assay.  Cell viability as measured by the MTT assay revealed that combined 
treatment with DDMN and apigenin exhibited growth inhibitory effects after 48 hours of 
compound exposure (Figure 2.2).  Individual treatment with DDMN alone provided only 
minimal inhibition of growth (13%-15%) at low concentrations (3µM-6µM) but was 
substantially more effective at inhibition of growth (30%) with the highest concentration 
(15µM).  Apigenin individual treatment exhibited a dose dependent response with a much 
stronger inhibition (18%-91%) of growth at all concentrations (3µM-15µM) than 
DDMN.  Combination of DDMN and apigenin at half-dose serial concentrations 
inhibited cell viability in a dose dependent manner with an additive effect that appeared 
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to not greatly differ from the individual treatment effects therefore no apparent 
interaction occurred as determined by the combination index previously described.  
Additive was defined as combination interaction index CI = 1.   
 
Figure 2.2  Growth inhibitory effects of apigenin and DDMN individually and in 
combination following serial concentrations of compound treatments in HCT116 human 
colon cancer cells.  Cell viability was measured by MTT assay as previously described in 
Section 2.2. 
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Figure 2.3  Combined treatment with apigenin and DDMN exhibited additive growth 
inhibitory effects after 48 hr of compound exposure.  (A)  Median effect plot of apigenin, 
DDMN and their combination on growth inhibition of HCT116 cells.  (B)  Interaction index 
plot for the combination effects of apigenin and DDMN on growth inhibitory effects of 
HCT116 colon cancer cells.  Additive was defined as CI interaction index = 1.  Median 
effect plot and interaction index plot constructed as described in Materials and Methods. 
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2.6.2 Luteolin and DDMN Demonstrate Antagonism in the Inhibition of Cell 
Viability in HCT116 Colon Cancer Cells 
 HCT116 human colon cancer cells were treated with serial doses of DDMN 
(3µM-15µM) and luteolin (3µM-15µM) individually and at half-dose serial 
concentrations in combination for 48 hours to determine growth inhibitory effects using 
the MTT assay.  Cell viability as measured by the MTT assay revealed that combined 
treatment with DDMN and luteolin displayed growth inhibitory effects after 48 hours of 
compound exposure (Figure 2.3).  Individual treatment with DDMN alone provided 
inhibition of growth (25%-32%) at low concentrations (3µM-6µM) but was substantially 
more effective at inhibition of growth (56%) with the highest concentration (15µM).  
Luteolin individual treatment exhibited a dose dependent response with a similar 
inhibition (23%-56%) of growth at all concentrations (3µM-15µM) as DDMN.  The 
combination of DDMN and luteolin at half-dose serial concentrations inhibited cell 
viability in a dose dependent manner exhibiting an antagonistic effect of less inhibition 
than the individual treatments separately, as determined by the combination index 
previously described.  Antagonism was defined as combination interaction index CI > 1. 
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Figure 2.4  Growth inhibitory effects of luteolin and DDMN individually and in 
combination following serial concentrations of compound treatments in HCT116 human 
colon cancer cells.  Cell viability was measured by MTT assay as previously described in 
Section 2.2. 
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Figure 2.5  Combined treatment with luteolin and DDMN exhibited antagonistic growth 
inhibitory effects after 48 hr of compound exposure.  (A)  Median effect plot of luteolin, 
DDMN and their combination on growth inhibition of HCT116 cells.  (B)  Interaction index 
plot for the combination effects of luteolin and DDMN on growth inhibitory effects of 
HCT116 colon cancer cells.  Antagonism was defined as CI interaction index > 1.  Median 
effect plot and interaction index plot constructed as described in Materials and Methods. 
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2.6.3 Discussion 
Studies identifying specific vegetables and fruits exhibiting anti-proliferative 
activity conclude the inhibitory effects on cellular growth are likely due to individual 
components or a class of phenolic components present in the vegetable or fruit (Chu, Sun 
et al. 2002; Sun, Chu et al. 2002).  Flavonoids are one such group of polyphenolic 
compounds found abundantly in vegetables and fruits (Liu 2004).  A number of flavonoid 
interactions have been described as synergistic with enhanced anti-proliferative, anti-
oxidant and anti-inflammatory effects (Freeman, Eggett et al. 2010; Hidalgo 2010; 
Gomez-Alonso 2012; Jaramillo-Carmona 2014).  Although studies suggest flavonoids in 
combination can contribute to greater health promoting effects; other findings are mixed, 
pointing to the need to investigate flavonoids in combination to determine if their positive 
attributes are unchanged (additive) or negatively impacted resulting in antagonistic 
effects and diminished benefit (Freeman, Eggett et al. 2010; Colon and Nerin 2016).  In 
addition, few studies have examined the combination of a flavonoid with a flavonoid 
metabolite offering the potential for greater anti-cancer effects using a colon cancer 
cellular model.  Therefore, we report for the first time on the anti-proliferative effects of 
luteolin or apigenin both flavones, in combination with 3',4'- didemethylnobiletin 
(DDMN), a primary metabolite of the flavone nobiletin in the mouse in HCT116 colon 
cancer cells; findings indicate no interaction (additive) between apigenin and the 
metabolite occurred whereas an antagonistic combination response with luteolin and 
DDMN appears to exist.  These results suggest the flavones although similar in structure 
can display divergently different interactions with the metabolite of a 
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polymethoxyflavone, exhibiting a range of response from no additional benefit to a 
reduction in anti-proliferative effectiveness.   
Multiple studies have explored the relationship between the flavonoid structure 
and its anti-proliferative, anti-oxidant and/or anti-inflammatory effects (Kuo 1996; 
Chidambara Murthy, Kim et al. 2012).  Results indicate flavonoid inhibition of cell 
growth is associated with the presence of a double bond at C2-C3 of which luteolin, 
apigenin and DDMN all possess; additional variations of the C ring appear to be 
accompanied by a reduction or loss of inhibitory activity (Agullo, Gamet-Payrastre et al. 
1996; Depeint, Gee et al. 2002; Chang, Mi et al. 2008).  Some researchers report 
heightened or diminished inhibition of cell growth can occur by flavonoids due to the 
location and/or number of hydroxyl groups on the flavonoid structure; whereas others 
find anti-proliferative effects do not appear to be impacted by hydroxyl group variations 
(Agullo, Gamet-Payrastre et al. 1996; Kuntz, Wenzel et al. 1999; Chang, Mi et al. 2008; 
Chidambara Murthy, Kim et al. 2012).  The structure of apigenin (4',5,7-
trihydroxyflavone) and luteolin (3',4',5,7-tetrahydroxyflavone) differ only in one 
hydroxyl group located on the B ring at the 3' position that luteolin contains but apigenin 
does not (Figure 2.1).  Free radical scavenging activity has been associated with a greater 
number of hydroxyl groups on the B ring particularly the di-hydroxy at 3' and 4' is very 
important for strong radical absorbing activity; therefore luteolin exhibits a higher 
antioxidant activity with its di-hydroxy groups at 3' and 4' position as compared to 
apigenin that lacks a hydroxyl group at the 3' position (Rice-Evans, Miller et al. 1996; 
Kumar and Pandey 2013).  Additional anti-oxidant and anti-inflammatory effects appear 
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to be correlated with the presence of the di-hydroxy groups at 3' and 4' (Cao, Sofic et al. 
1997; Ueda 2002).   
Polymethoxylated flavonoids (PMFs) such as nobiletin, have a benzo-γ-pyrone 
structure with a minimum of four methoxyl groups on the A, B and/or C ring (Li 2008; 
Ho 2012).  High anti-proliferative activity has been associated with a C-8 methoxyl group 
as part of the polymethoxyflavone structure in a number of cancer cell lines (Kawaii, 
Tomono et al. 1999).  Biotransformation of nobiletin (5,6,7,8,3',4'-hexamethoxyflavone) 
occurs on the B ring at the 3' and 4' positions; such that 3',4'-didemethylnobiletin (Figure 
1), a primary metabolite of nobiletin in CD-1 mice has recently been identified and found 
to have greater anti-proliferative, anti-oxidant and anti-cancer effects than the parent 
compound nobiletin  (Li 2009).  In contrast, other flavonoid metabolites are reported to 
have diminished anti-proliferative effects as compared to their parent compound 
(Delgado, Fernandes et al. 2014).  Indeed, accumulating research of flavonoids and their 
metabolites suggests the number of methoxyl and hydroxyl groups and their position on 
the flavonoid structure can greatly influence their biological effects and antioxidant 
capacity (Rice-Evans, Miller et al. 1996; Tripoli 2007; Li 2008; Hidalgo 2010; Lotito, 
Zhang et al. 2011; Delgado, Fernandes et al. 2014; Kongpichitchoke, Hsu et al. 2015; 
Chen, Teng et al. 2016).   
The concentrations used in this study for apigenin, luteolin and DDMN 
suppressed cell growth at all concentrations in a dose dependent manner (Figures 2.2 & 
2.3).  Individual treatment with apigenin was substantially more potent in its inhibitory 
effects than individual treatment with luteolin or DDMN.  The absence of a hydroxyl 
group at the 3' position of apigenin does not have a diminished effect on apigenin’s 
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individual anti-proliferative inhibition in this study using HCT116 colon cancer cells; 
rather apigenin exceeds luteolin in its inhibition of cell growth demonstrating the lack of 
a 3' hydroxyl group is associated with a greater reduction of cell proliferation in this cell 
line.  The anti-proliferative effects of the individual compounds on HCT116 colon cancer 
cells were greatest in apiginen > luteolin > DDMN based on their inhibitory potency in 
this study.  These findings are in agreement with the results of a comparison study of 
different flavones to determine their inhibition of  HCT116 colon cancer cells; 
researchers found apigenin to exhibit the strongest anti-cancer inhibitory effects of 
decreased cell proliferation of all the flavones tested, including luteolin (Zhong, 
Krisanapun et al. 2010).  In contrast, Manthey et al conducted a comparison of the anti-
proliferative actions of flavones in HT29 colon cancer cells and found luteolin to have 
greater inhibitory effects than apigenin (Manthey and Guthrie 2002).  Similarly, using the 
same HT29 cell line other researchers find flavonoids that lack the 3' hydroxyl (such as 
apigenin) are not as effective in the inhibition of cell growth as those with the 3' hydroxyl 
as a part of their flavonoid structure (Agullo, Gamet-Payrastre et al. 1996).  Based on 
these findings and the results of this study, cell specificity appears to be involved in the 
measured anti-proliferative response of apigenin or luteolin in different colon cancer cell 
lines.   
DDMN, a metabolite of nobiletin in the mouse was not examined in either of the 
aforementioned comparison studies however DDMN’s dose dependent suppression of 
cell growth in this study is consistent with the anti-proliferative effects of DDMN 
previously described by Wu et al in HCT116 colon cancer cells (Wu, Song et al. 2015).  
Both luteolin and DDMN contain a di-hydroxy at the 3'- and 4'-position of the B-ring and 
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differ structurally only in the A-ring of which luteolin has hydroxyl groups at the 5- and 
7-position whereas DDMN contains methoxyl groups at the 5-, 6-, 7- and 8-position.  As 
such, DDMN structurally distinct from luteolin, with methoxyl groups on the A-ring is 
found in this study to be associated with a smaller anti-proliferative effect than that 
observed in luteolin in HCT116 colon cancer cells. 
Luteolin and apigenin both flavones, have displayed synergism in the 
enhancement of anti-proliferative and anti-carcinogenic properties when combined with 
flavonoids in several cellular models of cancer (Amin, Wang et al. 2010; Shih, Liu et al. 
2010; Huang, Wei et al. 2016).  A synergistic combinatorial effect is likely due to 
complimentary mechanisms of food components used in combination; as such an 
antagonistic interaction could occur in a combination of food components with opposing 
mechanisms, however more research is needed as much remains to be determined (Pappa, 
Strathmann et al. 2007; Funaro, Wu et al. 2016).  Our findings suggest the combinations 
of DDMN with apigenin or luteolin are not synergistic in the inhibition of cell 
proliferation; such that no interaction is apparent between DDMN and apigenin whereas 
an antagonistic interaction appears to occur in the combination of DDMN with luteolin 
(Figures 2.4 & 2.5).   
Although the results of this study can indicate the nature of the interaction and its 
effects on anti-proliferation in combination these findings cannot determine causative 
mechanisms; they do however warrant further investigation through examination of the 
literature regarding luteolin’s antagonistic interactions with other food components to 
offer insight into our finding of an antagonistic combination of luteolin and DDMN.   
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Luteolin has been reported to exhibit an antagonistic interaction with another 
flavone in several research studies.  Notably, luteolin appears to have an antagonistic 
effect on the polymethoxyflavone nobiletin, the parent compound of DDMN in Caco-2 
colon cancer cells, an intestinal absorption model; luteolin inhibited nobiletin uptake by 
26%, researchers speculate this finding suggests the two flavones share the same 
transporter perhaps due to the similarity of their structures (Kimura, Ohta et al. 2014).  In 
this study, the metabolite DDMN structurally distinct from its parent compound nobiletin 
containing a di-hydroxy at 3' and 4'of the B ring exhibits an antagonistic interaction with 
luteolin upon examination of anti-proliferative effects in HCT116 colon cancer cells.   
Indeed, the difference in structure of apigenin and luteolin suggests the absence of the 3' 
hydroxyl is associated with no interaction or an additive response when apigenin is 
combined with DDMN whereas the presence of the 3' hydroxyl on the luteolin structure 
is associated with an antagonistic response with diminished anti-proliferative effects in 
combination with DDMN.  The ratio or proportion of luteolin that is used in combination 
has also been shown to be influential in determining an antagonistic or synergistic 
interaction with apigenin in the examination of cell cycle arrest.  In SW480 p53 mutant 
colon cancer cells, the combination of luteolin at low concentrations (5µM-30µM) with 
apigenin at 20µM, significantly increased G2/M cell cycle arrest whereas luteolin at high 
concentrations (>30µM) combined with apigenin at 20µM resulted in antagonism with a 
significant decrease in the level of G2/M cell cycle arrest (Wang, VanAlstyne et al. 
2004).  The low concentrations of luteolin (3µM-15µM) used in this study in 
combination with the low concentrations of DDMN (3µM-15µM) were not synergistic in 
the suppression of cell growth rather luteolin in low concentrations exhibited antagonism 
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in a dose dependent manner when combined with DDMN resulting in a decreased anti-
proliferative effect in HCT116 p53 wild-type colon cancer cells.   
Interestingly, luteolin has recently been identified as a negative regulator of p53 
with the significant down-regulation of p21, a downstream target of p53 that is involved 
in mediating G2 cell cycle arrest in HCT116 p53 wild type colon cancer cells (Sakai 
2012).  In contrast, both DDMN and apigenin individually have been found to 
significantly increase the induction of p21 in HCT116 p53 wild type cells (Zhong, 
Krisanapun et al. 2010; Wu, Song et al. 2015).  As such, further research is warranted to 
explore whether an antagonistic interaction between luteolin and DDMN in HCT116 p53 
wild type colon cancer cells could potentially occur in part due to luteolin possessing an 
opposing mechanism to DDMN in the regulation of p53 and subsequent downregulation 
of p21. 
 
2.7  Conclusion 
In summary, we report for the first time to our knowledge luteolin in combination 
with 3',4'-didemethylnobiletin (DDMN), the primary metabolite of nobiletin in the 
mouse, to exhibit antagonism in the inhibition of anti-proliferative effects in HCT116 
colon cancer cells.  Furthermore, these antagonistic effects appear to be associated with 
the presence of the 3' hydroxyl group on the B-ring of luteolin.  Taken together, more 
research is needed to fully characterize the mechanism responsible for this antagonistic 
combinatory interaction of luteolin with DDMN and to determine if diminished anti-
proliferative effects occur in other flavonoid metabolite combinations. 
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CHAPTER 3 
SYNERGISTIC ANTI-CANCER EFFECTS OF CURCUMIN AND FLAVONOID 
METABOLITE IN COMBINATION FOR CHEMOPREVENTION OF 
COLORECTAL CANCER 
 
3.1 Abstract 
Chemoprevention strategies employing the use of multiple dietary bioactive components 
in combination offer advantages due to their relative low toxicity and potential 
synergistic interactions, however research is needed to determine their overall 
combination effects.  Herein, we evaluate the combination of curcumin and 3', 4' 
didemethylnobiletin (DDMN) a primary metabolite of nobiletin in the mouse, to 
determine their anti-carcinogenic combinatory effects in HCT116 colon cancer cells.  
Isobologram analysis reveals a synergistic interaction exists between curcumin and 
DDMN in the inhibition of colon cancer cell growth in HCT116 colon cancer cells.   
Additionally, combination treatment induced significant G2/M cell-cycle arrest and 
extensive apoptosis, which greatly exceeded the effects of individual treatments with 
curcumin or DDMN.  Proteins associated with these heightened anti-carcinogenic effects 
were p53, p21, HO-1, c-PARP, cdc2 and cdc25c; each of the proteins was confirmed to 
be substantially impacted by the combination treatment, more than by individual 
treatments alone.  This newly identified synergy between curcumin and DDMN should 
be explored further to determine its chemopreventive value and potential contribution to 
colorectal cancer in vivo. 
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3.2 Keywords: 
Dietary bioactive components, combination, cancer chemoprevention, colorectal cancer, 
flavonoid metabolite, curcumin, turmeric, nobiletin, polymethoxyflavone, synergistic 
3.3 Abbreviations 
DDMN: 3',4'-didemethylnobiletin; ACF: aberrant crypt foci; PMF: polymethoxyflavone; 
AOM: azoxymethane; DMH: dimethylhydrazine 
 
3.4 Introduction 
Dietary bioactive components offer a viable option to current therapies for many 
diseases as they appear to be beneficial for  their prevention and early treatment through 
the modulation of deregulated signaling pathways (Garcia-Lafuente, Guillamon et al. 
2009; Pan, Lai et al. 2009; Tunon, Garcia-Mediavilla et al. 2009).  Colorectal cancer is a 
complex disease characterized by multiple deregulated signaling pathways that are 
responsible for the promotion and progression of the carcinogenic process (Bird 1995).  
Multi-drug therapy is often used in the treatment of cancer as an alternative to targeting 
one gene or one signaling cascade; however toxicity and dosage tolerance remains a 
concern (Goldin and Mantel 1957; Humphrey, Brockway-Lunardi et al. 2011).  Similarly, 
the use of drugs for the chemoprevention of colorectal cancer are limited due to 
undesirable side effects associated with their long-term use (Psaty and Potter 2006; Das, 
Arber et al. 2007; DuPont, Arguedas et al. 2007).  Numerous in vitro and in vivo studies 
have highlighted the anti-carcinogenic effects of natural compounds found in food 
(Tsuda, Ohshima et al. 2004; Chen and Kong 2005; Fresco, Borges et al. 2006).  
Accumulating evidence suggests dietary bioactive components in combination may play 
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an important role in the chemoprevention of many cancers (DiMarco-Crook and Xiao 
2015).  Indeed, a multi-agent strategy of combination treatment utilizing several bioactive 
components is desirable as the dietary components are likely to have complementary 
effects thereby eliciting a more powerful anti-inflammatory and anti-cancer response with 
low toxicity (Liu 2003; Murakami, Takahashi et al. 2003; Rather, Bhat et al. 2013; 
DiMarco-Crook and Xiao 2015).  .   
Polymethoxyflavones (PMFs) are a group of dietary bioactive components being 
investigated for their beneficial effects; a class of citrus flavonoids found primarily in 
citrus peel that have demonstrated anti-carcinogenic properties in a variety of cancer 
model systems (Sergeev, Ho et al. 2007; Xiao, Yang et al. 2009; Qiu, Dong et al. 2010; 
Lai, Tsai et al. 2011).  PMFs also appear to offer an increased potential for absorption 
and bioavailability as compared to their polyhydroxylated flavonoid counterparts; due to 
the methoxyl groups on the PMF structure PMFs are more lipophilic and thus may result 
in higher permeability of the small intestine and subsequent higher absorption into the 
bloodstream (Li, Lo et al. 2006).  Nobiletin, a polymethoxyflavone of particular interest 
has been reported to inhibit carcinogenesis in colon, prostate and breast cancer models 
(Tang, Ogawa et al. 2011; Chen, Ono et al. 2014).  Notably, 3',4'-didemethylnobiletin 
(DDMN), the second most abundant metabolite of nobiletin in the mouse and the most 
potent of the metabolites, is reported to be present at a much higher concentration in 
mouse colonic mucosa than nobiletin; therefore, these findings suggest many of the 
observed positive effects of nobiletin could be attributed to its’ metabolite DDMN 
(Zheng, Bi et al. 2015).  Indeed, numerous research studies demonstrate 
3',4'didemethylnobiletin (DDMN) a primary metabolite of nobiletin in the mouse (Figure 
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1), exhibits a much stronger anti-oxidant, anti-inflammatory and anti-carcinogenic 
response than the parent compound nobiletin (Li, Sang et al. 2007; Lai, Li et al. 2008; Lo, 
Pan et al. 2010; Su, Yen et al. 2012).   
 
  
 
 
 
Curcumin, a bioactive component found in turmeric, (Figure 3.1) has been 
investigated as an alternative strategy for the chemoprevention of colorectal cancer and is 
widely credited for its anti-carcinogenic effects that include the downregulation of pro-
inflammatory signaling cascades, initiation of cell cycle arrest and induction of pro-
apoptotic pathways (Teiten, Eifes et al. 2010; Chen, Wang et al. 2014).  The frequent use 
of turmeric in the diet among residents of India and the low occurrence of colorectal 
cancer reported within this population has led researchers to explore the role of curcumin 
in the chemoprevention of colorectal cancer (Ferrucci, Daniel et al. 2010; Park and 
Conteas 2010).  Indeed, an accumulating body of research demonstrates curcumin 
operates within the same deregulated signaling pathways associated with the 
development of colorectal cancer, yet without the reported negative side effects of 
chemopreventive drugs.   Although curcumin has displayed limited bioavailability in 
vivo, clinical studies examining curcumin intervention in patients for the prevention and 
treatment of colorectal cancer have generated positive preliminary findings of anti-cancer 
Hydrolysis 
DDMN 
(3’,4’-didemethylnobiletin) 
Curcumin 
Figure 3.1  Chemical Structures of DDMN (3',4'-didemethylnobiletin) and curcumin 
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effects (Carroll, Benya et al. 2011; Gupta, Patchva et al. 2013).  Direct contact of 
curcumin with the colon overcomes some of the bioavailability challenge; however an 
effective combination treatment utilizing curcumin can also be beneficial in lowering the 
dosage required to obtain the maximum treatment effect of curcumin in vivo.  
Curcumin and polymethoxyflavones (PMFs) have interacted synergistically with 
a number of other dietary bioactive components in combination, however no information 
currently exists that examines the anti-cancer effects of the combination of curcumin with 
a polymethoxyflavone metabolite in colon cancer.  (Majumdar, Banerjee et al. 2009; 
Pesakhov, Khanin et al. 2010; Guo, Qiu et al. 2012; Funaro, Wu et al. 2016).  Based on 
this information we will evaluate for the first time the anti-cancer inhibitory effects of the 
combination of curcumin and 3',4'-didemethylnobiletin (DDMN), a primary metabolite of 
nobiletin in the mouse, in the HCT116 human colon cancer cell line.  
 
3.5 Materials and Methods 
3.5.1 Cell Culture 
HCT-116 human colon cancer cells were purchased from American Type Cell Collection 
(ATCC, Manassas, VA, USA).  RPMI 1640 media (Mediatech, Herndon, VA, USA) 
comprised of 5% fetal bovine serum (FBS), 100U/ml of penicillin and 0.1mg/ml of 
streptomycin was used as the growth medium for the cells and changed every several 
days.  The HCT116 colon cancer cells were held in an incubator at 37
o
C with 5% CO
2
 
and the cells selected for the experiments were between 3 to 25 passages.   
 
 
80 
 
3.5.2   Cell Treatments  
Curcumin (96%) was obtained from Quality Phytochemicals, LLC (New Jersey, USA).  
The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after a multi-step process 
with its chemical structure verified using MS and NMR spectra methods as described (Li, 
Pan et al. 2007; Li, Sang et al. 2007).  DMSO was used for the delivery of DDMN and 
curcumin to the cells in each experiment, resulting in a final concentration of 0.1% 
DMSO. 
 
3.5.3   Cell Viability Assay  
HCT-116 human colon cancer cells were seeded in 96-well plates and treatments of 
DDMN, curcumin or their combination were administered in serial concentrations after 
24 hour incubation.  Once the associated treatment times were met, the replacement of 
media with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
containing media (Sigma-Aldrich) was performed to quantify cell viability.  Further detail 
as outlined above and in prior experiments (Qiu, Dong et al. 2010). 
  
3.5.4 Analyses of Synergy 
The analyses of synergy utilized a linear regression model based on the Chou Talahay 
method with some alterations as previously described (Chou and Talalay 1984; Xiao, 
Zhang et al. 2008; Guo, Qiu et al. 2012).  Results were examined using the R program 
and synergy was categorized utilizing the interaction index parameters, with the 
combination interaction (CI) characterized as exhibiting additivity (=1), synergy (<1), or 
antagonism (>1).   
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3.5.5   Cell Cycle Analyses 
HCT-116 cells were seeded in 6-well plates at a rate of 8 x 104 cells per well. Once cells 
were attached following 24h incubation, treatments of DDMN, curcumin or their 
combination were added to cells for another 24h incubation period.  In preparation for 
analysis following incubation, previously adhered cells were removed using trypsin 
((0.25% trypsin-EDTA; Mediatech) and were combined with the floating cells.  Further 
steps necessary for analysis were undertaken as previously described (Qiu, Dong et al. 
2010).  BD LSRII flow cytometry was used to examine cell cycle distribution and the 
subsequent data produced was analyzed with Modifit LT software.  
 
3.5.6   Apoptosis Detection 
HCT-116 cells were seeded in 6-well plates (8 x 104 cells per well), incubated for 24 
hours and prepared for analysis as outlined above.  Apoptotic cells were calculated 
following 48h treatments using BD LSRII flow cytometry and the Annexin V/PI double 
staining assay to distinguish between early apoptotic cells as Annexin V-positive/PI-
negative cells and late apoptotic cells as Annexin V-positive/PI-positive cells.  
 
3.5.7 Immunoblotting 
HCT-116 cells were seeded in 15cm petri dishes, incubated for 24h and then treated with 
DDMN, curcumin or their combination for another 24h or 48h incubation.  Whole cell 
lysate was isolated and retrieved for each treatment after cells were washed with iced 
PBS.  Preparation for Western Blot and the subsequent analysis was performed as 
previously described (Xiao, Zhang et al. 2008; Qiu, Dong et al. 2010; Guo, Qiu et al. 
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2012).  Antibodies for p53, p21Cip1/Waf1, poly ADP ribose polymerase (PARP), cdc-2 (cdk-
1), and cdc25c were each acquired from Cell Signaling Technology (Beverly, MA, USA); 
antibody for β-actin was obtained from Sigma Aldrich. 
 
3.5.8 Statistical Analysis 
Results are conveyed as the mean ± standard deviation (SD).  To compare the differences 
between more than 2 groups the analysis of variance model (ANOVA) was used.  In 
addition, for multiple comparisons the Post-hoc test Tukey Range Honesty Significant 
Difference was employed.  A 1% level of significance was established for all tests.   
 
3.6  Results and Discussion 
3.6.1 Curcumin and DDMN Synergistically Inhibit Cell Viability in HCT116 
Colon Cancer Cells 
HCT116 human colon cancer cells were treated with serial dosages of DDMN (3µM-
15µM) and curcumin (2µM-10µM) individually and at half-dose serial concentrations in 
combination for 48 hours to determine growth inhibitory effects using the MTT assay 
(Figure 3.2).  Cell viability as measured by the MTT assay revealed that combined 
treatment with DDMN and curcumin potentiated the growth inhibitory effects after 48 
hours of compound exposure.  Individual treatment with DDMN alone provided only 
minimal inhibition of growth (10%-12%) at low concentrations (3µM-9µM) but was 
substantially more effective at inhibition of growth (27%) with the highest concentration 
(15µM).  Curcumin individual treatment exhibited a dose dependent response with a 
much stronger inhibition (20%-79%) of growth at all concentrations (2µM-10µM) than 
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DDMN.  Remarkably, the combination of DDMN and curcumin at half-dose serial 
concentrations synergistically inhibited cell viability in a dose dependent manner with a 
more pronounced effect than individual treatments as determined by the combination 
index previously described in Section 2.3.  Synergy was defined as combination 
interaction index CI < 1 (Figure 3.3). 
 
 
 
Figure 3.2  Growth inhibitory effects of curcumin and DDMN individually and in 
combination following serial concentrations of compound treatments for 72 hours in 
HCT116 human colon cancer cells.  Cell viability was measured by MTT assay as 
previously described in Section 2.2. 
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Figure 3.3  (A)  Median effect plot of DDMN, curcumin and their combination on growth 
inhibition of HCT116 cells.  (B)  Interaction index plot for the combination effects of 
DDMN and curcumin on growth inhibitory effects of HCT116 colon cancer cells.  Synergy 
was defined as CI interaction index < 1.  Median effect plot and interaction index plot 
constructed as described in Materials and Methods. 
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3.6.2 Combination of Curcumin and DDMN induce extensive apoptosis as 
compared to individual compounds in HCT116 Colon Cancer Cells 
To investigate the role of apoptosis on the observed inhibition of cell growth, HCT116 
colon cancer cells were subjected to 48 hour treatment of 5µM curcumin and 7.5 µM 
DDMN alone and in combination then analyzed to determine the level of early and late 
apoptotic cells attributed to each treatment (Figure 3.4).  Individual treatment 
concentrations of 5µM curcumin, 7.5µM DDMN, half dose combination treatment with 
2.5µM curcumin+3.75µM DDMN and full dose combination treatment with 5µM 
curcumin +7.5µM DDMN were found to increase early apoptotic cells by 5.3-fold, 1.7-
fold, 5.4-fold and 28.2-fold respectively whereas, the late apoptotic cells increased 3.3-
fold, 1.7-fold, 3-fold and 7.9-fold respectively.  Surprisingly, the full dose combination 
treatment resulted in a 28-fold increase in early apoptotic cells, a finding that greatly 
exceeded the 5.4-fold increase observed following half dose combination treatment, 
similar to the 5.3-fold increase exhibited by curcumin alone.  The full dose combination 
treatment also exhibited a greater increase in late apoptotic cells of 7.9-fold, more than 
double the 3-fold increase produced in response to the half dose combination treatment, 
once again similar to the 3.3-fold increase of curcumin alone.  These results demonstrated 
significant induction of apoptosis by the full dose combination as compared to control 
(Figure 3.3), with a substantial increase in early and late apoptotic cells, based on 
ANOVA followed by Tukey’s HSD post-hoc test (p< 0.01, n=3).  
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Figure 3.4  Effects of DDMN, curcumin, and DDMN/curcumin full dose combination on 
apoptosis in HCT116 colon cancer cells.  HCT116 cells were seeded in 6-well plates then 
treated with concentrations as noted above at 24 hours.  After another 48 hours cells were 
collected and apoptosis analyses were performed as previously described.  Annexin V/PI 
dot plots indicate a much greater intensity in early apoptosis induction by the full-dose 
combination treatment as compared to the control or individual treatments.  
 
 
 
 
 
 
Control Curcumin 5 µM DDMN 7.5 µM  
DDMN 3.75 µM + 
Curcumin 2.5 µM 
 
 
 
 
DDMN 7.5 µM + 
Curcumin 5 µM 
 
 
 
 
Late Apoptosis 
Cells 
Early Apoptosis 
Cells 
Live 
Cells 
87 
 
            
                                    
Figure 3.5  Quantification of effects by curcumin, DDMN and full-dose combination on 
apoptosis in HCT116 colon cancer cells.  All data represents the mean ± SD.  The 
asterisk in the bar charts represents statistical significance of DDMN/curcumin full-dose 
combination treatment group as compared to the control, DDMN or curcumin treatment 
groups at full concentrations based on ANOVA followed by Tukey’s HSD post-hoc test 
(p ˂ 0.01, n=3). 
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3.6.3 Combination of Curcumin and DDMN exhibits greater G2/M cell-cycle 
arrest than individual compounds in HCT116 Colon Cancer Cells 
To further investigate the mechanism responsible for the anti-proliferative effects of the 
combination treatment, cell-cycle analysis was conducted.  Figure 3.4 shows the results 
of curcumin, DDMN and the combination of curcumin + DDMN on cell-cycle arrest in 
HCT116 colon cancer cells.  Treatment concentrations of 7.5 µM DDMN and 5 µM 
curcumin were evaluated individually, in half dose combination treatment and in full 
dose combination treatment in HCT116 cells after 24 hour incubation.  Increased G2/M 
phase cell-cycle arrest was observed for the individual curcumin treatment (5µM) 
although not significant and was much stronger than DDMN individual treatment 
(7.5µM) which increased G2/M arrest only nominally.  Interestingly, when combined at 
half-dose the effect was similar to curcumin alone but a significant accumulation of cells 
in the G2/M phase occurred when the full dose combination treatment was examined as 
compared to control, based on ANOVA followed by Tukey’s HSD post-hoc test (p < 
0.01, n=3).   
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Figure 3.6  Effects of DDMN, curcumin, and DDMN/curcumin combination on cell 
cycle arrest in HCT116 colon cancer cells.  HCT116 cells were seeded in 6-well plates 
then treated with concentrations as noted above at 24 hours.  After another 24 hours cells 
were collected and cell cycle analyses were performed as previously described.  Flow 
cytometer analyses revealed full-dose combination treatment significantly increased cell 
cycle arrest in G2M phase as compared to control or individual treatments. 
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Figure 3.7  Quantification of effect by curcumin, DDMN and full-dose combination 
treatment on cell cycle in HCT116 colon cancer cells.  All data represents the mean ± SD.  
The asterisk in the bar chart represents the statistical significance of DDMN/curcumin 
full-dose combination treatment to increase G2/M phase cell cycle arrest as compared to 
the control, DDMN and curcumin treatment groups at full concentrations based on 
ANOVA followed by Tukey’s HSD post-hoc test (p ˂ 0.01, n=3). 
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3.6.4 Combination treatment exhibited a pronounced effect on the modulation of 
proteins involved in cell-cycle and apoptosis signaling 
Additional analysis was conducted to explore the mechanisms responsible for the 
heightened cell-cycle G2/M arrest and induction of apoptosis observed following the 
combined full dose treatment of curcumin 5µM and DDMN 7.5µM in HCT116 colon 
cancer cells.  Immunoblot examination of proteins that have been identified to be 
involved in these processes revealed the proteins of interest were greatly impacted by the 
combination treatment.  Indeed, full dose concentrations of curcumin 5µM combined 
with DDMN 7.5µM in HCT116 colon cancer cells significantly increased expression of 
p21, p53, HO-1 and cleaved PARP whereas the combination significantly decreased 
expression of cdc2 and cdc25c (Figure 3.5).   
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Figure 3.8  Effects of curcumin, DDMN and their combination on proteins associated with 
cell cycle and apoptosis.  Full-dose combination treatment was found to potently alter key 
oncogenic markers in HCT 116 colon cancer cells.  The number below each protein band 
represents the relative intensity of each band as measured by Image J software. 
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3.6.5   Discussion 
Combination regimens are increasingly being explored for the chemoprevention 
of colorectal cancer (Zhou, Cheng et al. 2012; Mohammed, Janakiram et al. 2013).   
Multiple in vitro studies reveal pharmacological agents in combination with natural 
dietary bioactive components or their metabolites can result in heightened 
chemopreventive effects (Lev-Ari, Strier et al. 2005; Meyskens, McLaren et al. 2008; 
Kanthamneni, Chaudhary et al. 2010; Chaudhary, Sutaria et al. 2011; Wu, Song et al. 
2017).  Interestingly, a growing number of studies suggest several dietary bioactive 
components in combination can have similar anti-inflammatory and anti-cancer 
properties as observed in pharmacological agent combinations but without the side 
effects often associated with their use (Liu 2003; Murakami, Takahashi et al. 2003; 
Rather, Bhat et al. 2013; DiMarco-Crook and Xiao 2015).  Moreover, the use of two or 
more dietary components in combination has been found to exhibit enhanced anti-
carcinogenic effects in colorectal cancer both in vitro and in vivo (Bose, Hao et al. 2007; 
Nakamura, Yogosawa et al. 2009).   
The combination of curcumin with pharmacological agents or other dietary 
components has been examined for anti-cancer effects in a number of colon cancer model 
systems (Lev-Ari, Strier et al. 2005; Cruz-Correa, Shoskes et al. 2006; Howells, Mitra et 
al. 2007; Majumdar, Banerjee et al. 2009).  This study is the first to examine the 
combination of curcumin with 3',4'-didemethylnobiletin, a primary metabolite of 
nobiletin in the mouse.  Our findings of decreased cellular growth, increased apoptosis 
and G2/M cell-cycle arrest in response to individual DDMN or curcumin treatment are 
consistent with other researcher’s findings however combination effects have not yet 
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been explored (Moragoda, Jaszewski et al. 2001; Wu, Song et al. 2015).  This study for 
the first time has shown the combination of DDMN (7.5µM) + curcumin (5µM) results in 
synergistic inhibition of cell growth, extensive induction of apoptosis and G2/M cell-
cycle arrest in HCT116 colon cancer cells that is greater than individual treatment effects.  
Surprisingly, a significant increase in apoptosis or cell cycle arrest was not observed in 
the half dose combination of curcumin (2.5µM) + DDMN (3.75µM) although decreased 
cell viability was found to be synergistic at these combination levels.  Others have 
reported differing mechanisms involved in curcumin’s anti-cancer effects that are 
concentration based, with low concentrations of curcumin exhibiting an antioxidant effect 
and higher concentrations of curcumin demonstrating a pro-apoptotic effect (Park and 
Conteas 2010).  A key step that indicates apoptosis has occurred is the cleavage of PARP; 
as Figure 3.5 demonstrates after 48 hour treatment the cleavage of PARP was 
substantially increased with curcumin (5µM) individual treatment (620%) and DDMN 
(7.5µM) individual treatment (70%), however a combined full dose treatment resulted in 
a much higher increase (780%) of cleaved PARP.  Our findings of increased levels of 
cleaved PARP following individual treatment of HCT116 colon cancer cells with DDMN 
or curcumin are in agreement with other researcher’s findings (Moragoda, Jaszewski et 
al. 2001; Wu, Song et al. 2015).  Remarkably, we now find in this study that the 
combination of these two compounds results in a more pronounced cleavage of PARP 
than by DDMN or curcumin alone.   
Proteins p21 and p53, reported to be important for the apoptotic process of many 
cancers, were shown to have a heightened increase in expression following DDMN 
(7.5µM) + curcumin (5µM) combination treatment as compared to control.  After 24 hour 
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treatments with DDMN (7.5µM), curcumin (5µM), or full dose (5µM+7.5µM) 
combination, expression of p21was elevated by 280%, 300% and 650% respectively, 
with the greatest effect observed as a result of the combination treatment.  Similarly, 
following 24 hour exposure the full dose combination treatment exhibited a substantial 
110% increase in p53 expression as compared to control, resulting in a much stronger 
response than  individual curcumin (70%) or DDMN (10%) treatments.  Research 
examining the role of p53 and p21 in apoptosis following curcumin treatment has had 
mixed findings (Jee, Shen et al. 1998; Choudhuri, Pal et al. 2002; Radhakrishna Pillai, 
Srivastava et al. 2004; Watson, Hill et al. 2008; Watson, Hill et al. 2010).  Watson et al 
suggests curcumin utilizes a p-53 and p-21 independent mechanism to promote apoptosis 
in HCT116 colon cancer cells although evidence does exist to suggest that p21 may play 
a role in decreasing cell proliferation via cell-cycle arrest.  Other researchers compared 
curcumin sensitivity in p53 wild type HCT116 colon cancer cells with a p53 knockout 
HCT116 cell line to conclude that both wild type p53 and p21 are required for curcumin 
sensitivity (Howells, Mitra et al. 2007).  Interestingly, clinical findings following 
curcumin treatment in colorectal cancer patients suggest a correlation exists between an 
increased expression of p53 in tumor tissue with an increase in apoptotic tumor cells and 
increased body weight (He, Shi et al. 2011).  To our knowledge this is the first time 
DDMN has been investigated individually to determine its effect on the expression of 
p53 and in our study individual treatment of DDMN at a concentration of 7.5 µM 
increased p53 only nominally by 10% as compared to control.  Again, we find for the 
first time the combination of DDMN and curcumin is more effective in the induction of 
p21 and p53 than by individual treatments in HCT116 colon cancer cells.   
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Two of the key proteins involved in cell cycle control, cdc2 and cdc25c were 
markedly reduced in response to DDMN (7.5µM) + curcumin (5µM) combination 
treatment whereas levels of cdc2 and cdc25c showed only a small reduction in expression 
following 24 hour exposure to individual compounds of DDMN or curcumin.  Cdc2, a 
part of the cdc2/cyclinB1 complex that is required to enter mitosis from the G2 phase, 
was decreased only nominally by individual treatments of curcumin (5uM) 10% and 
DDMN (7.5uM) 20% as compared to control however full dose combination treatment 
exhibited a pronounced 50% decrease in expression.  Likewise cdc25c, a protein 
necessary for the activation of cdc2 was also less impacted by individual treatments with 
curcumin or DDMN resulting in a decrease in expression of only 10% and 30% 
respectively.  In contrast, the combined full dose treatment of curcumin + DDMN 
resulted in a dramatic 60% reduction in cdc25c expression.  Some research has suggested 
the binding of p21 to the cdc2/cyclin B complex can keep cdc2 inactive in the nucleus 
preventing cdc25c activation (Collett and Campbell 2004).   Interestingly, other 
researchers have demonstrated that the addition of p53 to p53-null HCT116 cells down 
regulated both cdc2 and cdc25c promoters thereby implicating the involvement of p53 in 
the decreased expression of cdc2 and cdc25c (Le Gac, Esteve et al. 2006).  Our research 
reveals for the first time the decreased expression of cdc2 and cdc25c by DDMN both 
alone and in combination with curcumin in HCT116 colon cancer cells.  Moreover, we 
discovered the combination treatment of DDMN (7.5uM) + curcumin (5uM) markedly 
downregulated cdc2 and cdc25c as compared to control and individual treatments. 
Heme oxygenase-1 (HO-1), a phase 2 enzyme induced in response to oxidative 
stress was found to dramatically increase following our treatment of HCT116 colon 
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cancer cells with DDMN (7.5µM), curcumin (5µM) or full dose combination treatment 
by 490%, 10% and 770% respectively.  Murphy et al reports curcumin treatment of 
HCT116 cells resulted in expression of HO-1 accompanied by cell shrinkage, membrane 
blebbing, apoptotic bodies and chromatin condensation (Murphy, Testa et al. 2014).  To 
our knowledge, DDMN’s effect on HO-1 has not yet been explored in a colon cancer 
model but DDMN has been found to increase induction of HO-1 in PC12 cells, a cell line 
used to study neuronal differentiation and cell death (Su, Yen et al. 2012).  Controversy 
currently exists regarding the role of HO-1 in carcinogenesis as many reports of HO-1 
expression have been associated with a pro-tumor effect that has been implicated in a 
variety of different cancers (Jozkowicz, Was et al. 2007).  Other pre-clinical findings 
suggest an anti-carcinogenic role for HO-1 in prostate and colon cancer (Gueron, De 
Siervi et al. 2009; Andres, Fermento et al. 2014).  Investigation using a chemical induced 
animal model of colon cancer found the degree of tumor progression was directly 
correlated with increasing amounts of HO-1 protein.  This finding is in agreement with a 
study of Korean colon cancer patients that found a higher level of HO-1 expression was 
present in tumor tissues than in adjacent normal tissues (Kang, Maeng et al. 2012).  
Clinical findings from several other studies appear to support the positive role of HO-1 in 
colon cancer; demonstrating colonic HO-1 expression is associated with a greater long 
term survival rate in colorectal cancer patients (Becker, Fukui et al. 2007; Andres, 
Fermento et al. 2014).  Researchers have conducted further analysis to explore the 
mechanism involved in the anti-cancer effects of HO-1 in HCT116 p53wt and p53-/- 
colon cancer cells.  Results indicate the induction of cell-cycle arrest and apoptosis is 
dependent upon a fully functioning p53 protein that also is associated with a requirement 
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for increased p21 expression in order for the full expression of HO-1 and its’ apoptotic 
effects to occur.  Other research appears to support the integral role of a functioning p53; 
Kalo et al have found that HO-1 displays an anti-apoptotic effect in Caco-2 colon cancer 
cells with a mutant p53 and in other p53 mutant variants (Busserolles, Megias et al. 2006; 
Kalo, Kogan-Sakin et al. 2012).  Taken together, our research for the first time indicates 
the combination of curcumin (5µM) and DDMN (7.5µM) results in a pronounced 
increase in HO-1 expression that is also associated with the increased induction of p53 
and p21 accompanied by increased apoptosis in HCT116 colon cancer cells.  
 
3.7 Conclusion 
In this study, curcumin and DDMN demonstrate synergism in combination as 
compared to individual treatments for the decreased proliferation of HCT116 colon 
cancer cells.  These findings appear to be attributed to the G2/M cell-cycle arrest 
exhibited after 24 hour treatment and dramatic induction of apoptosis following 
prolonged 48 hour exposure of curcumin and DDMN in combination.  Therefore, this 
article reports for the first time that the combination of curcumin and DDMN, a primary 
metabolite of nobiletin in the mouse, is synergistic in decreasing cell proliferation, 
potentiating G2/M cell-cycle arrest and induction of apoptosis in HCT116 colon cancer 
cells.  In addition, our research suggests the involvement of p53, p21, HO-1, c-PARP, 
cdc2 and cdc25c proteins in these enhanced anti-cancer effects of the combination 
treatment.  These significant findings warrant further investigation into the synergistic 
properties and chemopreventive potential of curcumin and DDMN in combination for 
colorectal cancer. 
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CHAPTER 4 
SYNERGISTIC ANTI-INFLAMMATORY EFFECTS OF CURCUMIN AND 
FLAVONOID METABOLITE IN COMBINATION IN VITRO 
 
4.1 Abstract 
Chronic inflammation of the colon or inflammatory bowel disease (IBD) is associated 
with an increased risk of developing colon cancer.  Clinical studies suggest the longer the 
duration of IBD and the higher the degree of inflammation the greater the colon cancer 
risk.  Effective long-term anti-inflammatory dietary strategies free of undesirable side 
effects are urgently needed for the prevention of IBD-related colon cancer.  Previously 
we identified the synergistic interaction between curcumin and 3', 4' didemethylnobiletin 
(DDMN) a primary metabolite of nobiletin in the mouse, to exhibit enhanced anti-
carcinogenic combinatory effects in HCT116 p53 wild-type colon cancer cells.  A p53 
mutation is an early event in inflammatory colon cancer and a defining event in the 
adenoma to carcinoma transition of sporadic colon cancer; therefore in this study we 
explored the anti-proliferative effects of the combination in HT29 colon cancer cells, a 
p53 mutated cell line.  To further characterize the synergism of this combination we also 
examined the anti-inflammatory effects of DDMN (5µM-25µM), curcumin (3µM-15µM) 
and their half- dose serial concentrations in combination at a 1.7:1 ratio in RAW 264.7 
cells.  Non-synergistic and diminished anti-proliferative effects were observed in the p53 
mutated colon cancer cell line HT29 following combination treatment; whereas 
isobologram analysis reveals a synergistic interaction exists between curcumin and 
DDMN in the inhibition of LPS induced inflammation as evidenced by decreased NO 
production in RAW 264.7 cells.  The anti-inflammatory synergy between curcumin and 
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DDMN offers a potential novel mechanism for the interaction of curcumin and nobiletin 
in vitro and warrants further investigation. 
 
4.2 Keywords: 
Dietary bioactive components, combination, anti-inflammatory, colon cancer, flavonoid 
metabolite, curcumin, nobiletin, synergistic, antagonistic, chronic intestinal inflammation 
 
4.3 Abbreviations 
DDMN: 3',4'-didemethylnobiletin; iNOS: inducible nitric oxide synthase; NO: nitric 
oxide; IBD: inflammatory bowel disease; UC: ulcerative colitis; ROS: reactive oxygen 
species; PMF: polymethoxyflavone; RNS: reactive nitrogen species; RONS: reactive 
oxygen nitrogen species 
 
4.4 Introduction 
 Inflammation has been reported to play a key role in the establishment or 
progression of many diseases including atherosclerosis, obesity, arthritis, diabetes and 
cancer.  The prevalence of inflammation in such a broad array of chronic disease states 
emphasizes the urgent need to develop anti-inflammatory diet-based strategies to alter the 
course of disease.  Acute inflammation can be protective of healthy cells, transitory and 
self-limiting whereas chronic or long-term inflammation has been correlated with an 
increased incidence of tumor development in epidemiological and clinical studies (Pal, 
Bhattacharjee et al. 2014).  Indeed, evidence suggests inflammation plays a prominent 
role in the establishment and promotion of many cases of colon cancer (Lakatos and 
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Lakatos 2008; Terzic, Grivennikov et al. 2010; Zhu and Li 2012). Inflammatory bowel 
disease (IBD) or chronic intestinal inflammation has afflicted an estimated 3.1 million 
Americans and appears to be occurring more frequently in the U.S. in recent years; 
however the reason for this increase is not fully understood (Siegel, Miller et al. 2017).  
Ulcerative colitis (UC) and Crohn’s disease are the two most frequently reported types of 
IBD.  Findings indicate the more colonic surface that is involved in the IBD-related 
inflammation and the longer the duration of IBD the greater the colon cancer risk 
(Itzkowitz and Yio 2004).  
One of the leading theories of inflammation has involved the integral role of 
oxidative stress in the development of cancerous growth in chronic inflammation.  It is 
this oxidative stress that is also associated with cellular damage and the pathogenesis of 
IBD.  Oxidative stress refers to the harmful effects of uncontrolled reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) accumulation to cells, also referred to 
as reactive oxygen nitrogen species collectively (RONS).  Normal cell processes involve 
reactive oxygen species (ROS) at low levels (Kalo, Kogan-Sakin et al. 2012).  Chronic 
inflammation generates an accumulation of RONS or free radicals that can operate as 
mutagenic agents in combination with increased cell proliferation and potentially bring 
about oncogenic transformation in epithelial cells; DNA damaged cells may be allowed 
to proceed through the cell cycle without being repaired to reproduce leading to 
tumorigenesis (Mladenova and Kohonen-Corish 2012).   
A mutation in the tumor suppressor gene p53 is found to occur frequently as an 
early initiating event in inflammatory colon cancer and is also considered one of the 
defining events in the promotion of an adenoma to a carcinoma in sporadic colon cancer, 
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occurring in approximately 40-50% of diagnosed cases (Itzkowitz and Yio 2004; Li, 
Zhou et al. 2015).  A fully functioning p53 is important in apoptosis for the destruction of 
cancer cells and suppression of the carcinogenic process; for this reason p53 is often 
referred to as the “guardian of the genome”(Cooks, Harris et al. 2014).  Accumulating 
research suggests p53 is also important for the inhibition of inflammation (Gudkov, 
Gurova et al. 2011).  A high occurrence of p53 mutations have been reported in the 
inflamed mucosa of ulcerative colitis (UC) patients that do not have cancer suggesting a 
p53 mutation is associated with chronic inflammation of the colon (Hussain, Amstad et 
al. 2000).  Notably, in IBD when cancerous lesions are found they are typically located in 
the colonic mucosa involved with inflammation (Rubin, Haggitt et al. 1992).     
Current treatment modalities for chronic colon inflammation are limited due to 
undesirable side effects associated with their long-term use.  Research has shown diet to 
be a powerful manipulator in the prevention and promotion of inflammation.  Many 
studies suggest individual dietary food components exhibit anti-inflammatory properties, 
yet little research exists examining these dietary components in combination (Benavente-
Garcia and Castillo 2008; Pan, Lai et al. 2009; Tunon 2009).  Preliminary pre-clinical 
studies appear to demonstrate synergistic anti-inflammatory effects in the combination of 
dietary components (Hemalswarya 2006; Cheung, Khor et al. 2009).  
Polymethoxyflavones (PMFs) are one such group of dietary bioactive components being 
investigated; a class of citrus flavonoids found primarily in peels that have been credited 
with operating in a variety of capacities including exhibiting potent anti-inflammatory 
effects (Li, Lo et al. 2006; Walle 2007).  
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Nobiletin, a polymethoxyflavone (PMF) of particular interest for its anti-
inflammatory effects, has shown significant inhibition of key proteins necessary for the 
promotion of the inflammatory process (Murakami, Nakamura et al. 2000; Tanaka, Sato 
et al. 2004; Harada, Tominari et al. 2011).   Guo et al reports the combination of 
nobiletin, (the parent compound of DDMN) and sulforaphane results in potent synergistic 
anti-inflammatory effects in RAW 264.7 macrophage cells that include enhanced 
inhibition of nitric oxide (NO) and expression of heme oxygenase-1 (HO-1) that is 
greater than individual treatments (Guo, Qiu et al. 2012).  Curcumin, the dietary 
component found in turmeric, is well established for its anti-inflammatory properties and 
has shown strong activity in the induction of HO-1 along with the inhibition of NO and 
iNOS in RAW 264.7 macrophages (Kim, Pae et al. 2008).  Synergistic anti-inflammatory 
effects were observed in the combination of curcumin and sulforaphane in RAW 264.7 
macrophages; the combination was found to synergistically down-regulate NO and 
upregulate the induction of heme-oxygenase-1 (HO-1) (Cheung, Khor et al. 2009).  
Although both nobiletin and curcumin have demonstrated synergism with sulforaphane in 
RAW 264.7 cells, their anti-inflammatory effects in combination with each other have yet 
to be explored.   
Some researchers find the more potent anti-inflammatory effects of flavonoids are 
associated with the metabolites rather than their parent compounds (Warner, Zhang et al. 
2016).  Interestingly, research examining 3',4'-didemethylnobiletin (DDMN), a major 
metabolite of nobiletin in the mouse demonstrates anti-inflammatory effects with 
decreased transcription of nitric oxide synthase (iNOS) when topically applied to a TPA-
induced mouse skin inflammation model (Lai, Li et al. 2008).  Indeed, DDMN was found 
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to have stronger anti-inflammatory effects than nobiliten its parent compound in vitro 
with suppression of LPS induced nitric oxide (NO) production and downregulation of 
inducible nitric oxide synthase (iNOS). 
Herein, to our knowledge this will be the first time DDMN and curcumin are 
investigated in combination in HT29 p53 mutant colon cancer cells and RAW 264.7 
macrophage cells, to further characterize the synergistic interaction observed between 
DDMN and curcumin in HCT116 p53 wild-type colon cancer cells.  This research will 
aid in the determination of whether the synergistic anti-proliferative effects of DDMN 
and curcumin in combination in HCT116 cells appear to utilize a p53-dependent or p53-
independent mechanism for the inhibition of colon cancer in vitro. In addition, the 
investigation of an anti-inflammatory mechanism will be beneficial in establishing a basis 
for nobiletin and curcumin in combination for future application with inflammatory colon 
cancer and other inflammatory related diseases. 
 
4.5 Materials and Methods 
4.5.1 Cell Culture   
HT29 cells were received from the American Type Culture Collection (ATCC, Manassas, 
VA) and prepared as previously described; maintained in RPMI-1640 media with added 
5% heat-inactivated fetal bovine serum (FBS).  RAW 264.7 cells were obtained from the 
American Type Culture Collection (ATTC, Rockville, MD) and cultured in RPMI-1640 
media with added 10% heat-inactivated FBS (Medistech, Herndon, VA) along with 100 
units/ml of penicillin, and 0.1 mg/mL of streptomycin (Sigma-Aldrich, St. Louis, MO) at 
37 ͦ C with 5% CO2 and 95% air.   
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4.5.2 Cell Treatments 
Curcumin (96%) was obtained from Quality Phytochemicals, LLC (New Jersey, USA).  
The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after a multi-step process 
with its chemical structure verified using MS and NMR spectra methods as described (Li, 
Pan et al. 2007; Li, Sang et al. 2007).  DMSO was used for the delivery of DDMN and 
curcumin to the cells in each experiment, resulting in a final concentration of 0.1% 
DMSO. 
 
4.5.3 Cell Viability Assay 
HT-29 human colon cancer cells were seeded in 96-well plates (2000 cells per well) and 
treatments of DDMN, curcumin or their combination were administered in serial 
concentrations after 24 hour incubation.  Once the associated treatment times were met, 
the replacement of media with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) containing media (Sigma-Aldrich) was performed to quantify cell 
viability.  Further detail as outlined above and in prior experiments (Qiu, Dong et al. 
2010). 
 
4.5.4 Nitrite Assay 
NO production by the Griess reaction will be determined by measuring the nitrite 
concentration.  The culture media will be mixed with an equal amount of Griess reagent 
A at 1% sulfanilamide in 5% phosphoric acid and reagent B at 0.1% 
naphthylethylenediamine dihydrochloride in water.  The absorbance at 540 nm is read 
using a plate reader (Elx800TM absorbance microplate reader, BioTek Instrument, 
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Winooski, VT).  The concentrations of nitrite will be calculated utilizing a standard curve 
with sodium nitrite as a standard. 
 
4.5.5 Analyses of Synergy  
The analyses of synergy will be determined utilizing a linear regression model based on 
the Chou Talahay method with some alterations as previously described (Chou and 
Talalay 1984; Xiao, Zhang et al. 2008; Guo, Qiu et al. 2012).  Results were examined 
using the R program and synergy was categorized utilizing the interaction index 
parameters with the combination interaction (CI) characterized as exhibiting additivity 
(=1), synergy (<1), or antagonism (>1).   
 
4.6  Results and Discussion 
4.6.1 Curcumin and DDMN Demonstrate Synergism in the Inhibition of NO in 
RAW 264.7 macrophage cells 
To establish nontoxic dose ranges for DDMN and curcumin in RAW 264.7 cells; 
the effects of these compounds were determined on cell viability utilizing the MTT assay 
as previously described.  We found that DDMN and curcumin concentrations up to 25µM 
and 15µM respectively as well as their combined treatment did not cause a significant 
decrease on the viability of RAW 264.7 cells.  These nontoxic dose ranges were then 
used to determine the inhibition of NO production by DDMN, curcumin and their 
combination in LPS-stimulated RAW 264.7 macrophage cells.   The cells were treated 
with serial concentrations of DDMN (5µM-25µM) and curcumin (3µM-15µM) 
individually and at half-dose serial concentrations in combination at a 1.7:1 ratio to 
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determine nitric oxide (NO) inhibitory effects using the nitrite assay (Figure 4.1).  NO 
inhibition as measured by the nitrite assay revealed that combined treatment with DDMN 
and curcumin, each at half-dose synergistically potentiated the NO inhibitory effects.  
Individual treatment with DDMN alone exhibited a dose dependent response and 
provided inhibition of NO (5%-45%) at all concentrations (5µM-25µM).  Curcumin 
individual treatment at concentrations (3µM-15µM) exhibited a dose dependent response 
with a slightly stronger inhibition (5%-56%) of NO production than DDMN at similar 
concentrations.  Remarkably, the combination of DDMN and curcumin at half-dose serial 
concentrations synergistically inhibited NO with a more pronounced effect (21%-56%) 
than individual treatments as determined by the combination index previously described 
in Section 2.3.  Notably, combined treatments at the lower half-dose concentrations of 
DDMN (2.5µM-5µM) and curcumin (1.5µM-2.5µM) exhibited the strongest synergy 
with inhibition of NO production by the combination (21%-33%) more than doubling the 
NO inhibition of each individual (5%-16%) treatment (Figure 4.2).  Synergy was defined 
as combination interaction index CI < 1. 
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Figure 4.1  Percentage of inhibition on NO production by curcumin and DDMN 
individually and in combination in LPS-stimulated RAW 264.7 macrophage cells.  Cells 
were treated with LPS as a positive control or LPS with serial concentrations of 
curcumin, DDMN or their combination. 
 
 
 
 
 
 
 
 
 
 
0 5 10 15 20 25
0
20
40
60
80
100
0 3 6 9 12 15
DDMN (µM)
In
h
ib
it
io
n
 o
f 
N
O
(%
)
Curcumin (µM)
Curcumin
DDMN
Combination
114 
 
      
          
 
 
 
 
 
 
 
0
1
2
0 0.25 0.5 0.75 1
In
te
ra
ct
io
n
 In
d
e
x 
(I
I)
Survival Rate
Figure 4.2  (A)  Median effect plot of DDMN, curcumin and their combination on 
inhibition of NO production in LPS-stimulated RAW 264.7 macrophage cells.  (B)  
Interaction index plot for the combination effects of DDMN and curcumin on NO 
production in LPS-stimulated RAW 264.7 macrophage cells.  Synergy was defined as CI 
interaction index < 1.  Median effect plot and interaction index plot constructed as 
described in Materials and Methods. 
(A) 
(B) 
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4.6.2 Curcumin and DDMN Demonstrate Antagonism in the Inhibition of Cell 
Viability in HT29 p53 Mutant Human Colon Cancer Cells 
 HT29 p53 mutant human colon cancer cells were treated with serial doses of 
DDMN (3µM-15µM) and curcumin (2µM-10µM) individually and at half-dose serial 
concentrations in combination to determine growth inhibitory effects using the MTT 
assay.  Cell viability as measured by the MTT assay revealed that combined treatment 
with DDMN and curcumin displayed growth inhibitory effects after 48 hours of 
compound exposure (Figure 4.3).  Individual treatment with DDMN alone provided only 
minimal inhibition of growth (4%-12%) at low concentrations (3µM-6µM) but was 
substantially more effective at inhibition of growth (35%) with the highest concentration 
(15µM).  Curcumin individual treatment exhibited a dose dependent response with a 
much stronger inhibition (25%-56%) of growth at concentrations 6µM-10µM as 
compared to DDMN at similar concentrations.  The combination of DDMN and 
curcumin at half-dose serial concentrations inhibited cell viability in a dose dependent 
manner with an additive effect at lower concentrations of 3µM-5µM + 1µM-2µM 
respectively that appeared to not greatly differ from the individual treatment effects.  
Combination of DDMN and curcumin at higher concentrations of 4.5µM-7.5µM + 3µM-
5µM respectively exhibited an antagonistic effect of less inhibition of growth than the 
individual treatments, as determined by the combination index previously described 
(Figure 4.4).  Additive was defined as combination interaction index CI=1.  Antagonism 
was defined as combination interaction index CI > 1. 
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Figure 4.3  Growth inhibitory effects of curcumin and DDMN individually and in 
combination following serial concentrations of compound treatments in HT29 p53 mutant 
human colon cancer cells.  Cell viability was measured by MTT assay as previously 
described in Section 2.3. 
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Figure 4.4  Combined treatment with curcumin and DDMN exhibited additive and 
antagonistic growth inhibitory effects in HT29 p53 mutant human colon cancer cells after 48 
hr of compound exposure.  (A)  Median effect plot of curcumin, DDMN and their 
combination on growth inhibition of HT29 p53 mutant cells.  (B)  Interaction index plot for 
the combination effects of curcumin and DDMN on growth inhibitory effects of HT29 p53 
mutant colon cancer cells.  Antagonism was defined as CI interaction index > 1.  Median 
effect plot and interaction index plot constructed as described in Materials and Methods. 
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4.6.3  Discussion 
Many factors point to the importance of addressing chronic intestinal 
inflammation both preventively and early in treatment, as progression to colon cancer is 
more likely to occur in cases with an earlier onset of disease, prolonged duration and 
severity of inflammation; each greatly increasing the risk of developing colon cancer 
(Terzic, Grivennikov et al. 2010; Jawad, Direkze et al. 2011).  As of this date, a cure 
remains elusive and pharmaceutical drugs have been limited in their capability to alter the 
disease process (Lakatos and Lakatos 2008).  The inflammatory progression of IBD often 
leads to unwanted surgery, complications and serious side effects associated with the 
drugs used to treat advanced stages of IBD.  An accumulating body of research suggests 
dietary components exhibit anti-inflammatory properties within the same deregulated 
signaling pathways as chronic intestinal inflammation yet without the unwanted side 
effects; offering a viable alternative for the prevention and treatment of intestinal 
inflammation (Benavente-Garcia and Castillo 2008; Pan, Lai et al. 2009).  Moreover, 
using dietary components in combination offers the potential for a synergistic interaction, 
thereby eliciting a more powerful anti-inflammatory response with low toxicity.   
Nobiletin and curcumin each have shown significant anti-inflammatory properties 
individually in cellular and animal models (Murakami, Nakamura et al. 2000; Tanaka, 
Sato et al. 2004; Harada, Tominari et al. 2011).  Recently we demonstrated a primary 
metabolite of nobiletin, 3',4' – didemethylnobiletin (DDMN) and curcumin were 
synergistic in the inhibition of cell growth in HCT116 colon cancer cells.  In this study 
our findings of decreased nitric oxide (NO) production in LPS stimulated RAW 264.7 
cells by individual DDMN or curcumin treatment are consistent with research conducted 
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by others however the anti-inflammatory effects of DDMN and curcumin in combination 
to our knowledge have not yet been examined (Li, Sang et al. 2007; Kim, Pae et al. 2008; 
Cheung, Khor et al. 2009).  Therefore, we report for the first time on the synergistic anti-
inflammatory inhibition of NO production by the combination of DDMN and curcumin 
in LPS stimulated RAW 264.7 macrophage cells.  NO inhibition is an important target for 
the prevention of chronic intestinal inflammation and IBD-related colon cancer as IBD is 
characterized by elevated levels of inducible NO synthase (iNOS) resulting in high levels 
of nitric oxide (NO).  Indeed, inducible NO synthase (iNOS) is elevated in both inflamed 
colonic mucosa and in colonic tumors (Hussain, Amstad et al. 2000).  Peroxynitrate a 
product of the reaction of superoxide and nitric oxide (NO) is correlated with colonic 
inflammation and IBD type pathogenesis in vivo (Zhu and Li 2012).   
This study for the first time has shown the combination of DDMN and curcumin 
in half-dose serial concentrations results in synergistic inhibition of NO production in 
LPS stimulated RAW 264.7 macrophage cells.  Surprisingly, the lower half-dose 
concentrations of DDMN (2.5µM-5µM) + curcumin (1.5µM-2.5µM) in combination 
exhibited the greatest synergism; therefore a saturation or ceiling appears to potentially 
exist at which higher concentrations of the compounds are not as potent or efficacious in 
their anti-inflammatory effects when combined.  Excitingly, the enhanced anti-
inflammatory effect of the lower dose combinations provides an opportunity for further 
investigation as an effective small dose for a prolonged period of time with low toxicity 
would be of great benefit for those with inflammation related diseases for the inhibition 
of NO production. 
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The relationship between NO and p53 appears to be pivotal in determining the 
outcome of inflammation and tumorigenesis.  Researchers suggest NO can be protective 
at early stages of chronic inflammation from IBD-related colon cancer before alteration 
of the p53 protein is involved (Goodman, Hofseth et al. 2004).  As such, p53 under low 
stress conditions has been found to be protective from NO induced DNA damage when 
activation is triggered by iNOS and the production of NO in the colons of UC patients 
facilitates a negative feedback loop with p53 (Hofseth, Saito et al. 2003).  Nitric oxide 
appears to have opposing roles, acting either as pro-tumorigenic or anti-tumorigenic 
depending on the status of p53.  The negative feedback loop of p53 and NO is comprised 
with NO initiating the accumulation of p53 which then leads to the suppression of iNOS 
thereby limiting NO production (Forrester, Ambs et al. 1996; Ambs, Ogunfusika et al. 
1998).  The increased p53 activity leads to apoptosis, cell cycle arrest and the elimination 
of damaged cells promoting anti-tumorigenesis.  In cells lacking a wild-type p53, NO 
production leads to cell proliferation as a result of cells no longer taking part in apoptosis 
and cell cycle arrest.  In mice without p53 when iNOS is deleted sarcomas and lymphoma 
are reduced suggesting the negative feedback loop of p53 and NO is involved in the 
regulation of tumorigenesis (Hussain, Trivers et al. 2004; Tatemichi, Tazawa et al. 2004).  
P53 also plays the role of antagonist in the inflammatory process.  The nuclear 
factor-kappa B (NF-κB) pathway is the primary regulator of both acute and chronic 
inflammation (Ben-Neriah and Karin 2011).  Gudkov et al identifies p53 as an antagonist 
of NF-κB resulting in the inhibition of inflammation (Gudkov and Komarova 2016).  The 
relationship between p53 and NF-κB has been described as generally antagonistic in most 
cell systems with both participating in a cross talk regulated by multiple mechanisms that 
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are still not fully defined (Schneider and Kramer 2011).  NF-κB is activated and present 
in biopsies of inflamed mucosa of IBD patients and can trigger iNOS to produce NO with 
its pro-inflammatory and potential carcinogenic effects (Rogler, Brand et al. 1998; 
Yamamoto and Gaynor 2001).  Inhibition of NF-κB activity in inflammation associated 
colon cancer mouse models halts tumor growth and suppresses tumors in xenograft 
studies (Gurova, Hill et al. 2005; Gasparian, Burkhart et al. 2011; Sunami and Wirth 
2011; Vlantis, Wullaert et al. 2011).  Interestingly, nobiletin was shown to inhibit the 
DNA binding of the pro-inflammatory transcription factor NFκB in LPS stimulated RAW 
264.7 macrophage cells and prevent the nuclear NFκB translocation from the cytoplasm 
and its expression into the nucleus in BV-2 microglia cells, a neuroinflammation model. 
(Choi, Hwang et al. 2007; Cui, Wu et al. 2010).  It is the deregulation of NF-κB  at any 
point in the NF-κB pathway that is attributed with the constant activation of NF-κB 
leading to chronic inflammation and the potential transformation to cancer (Balkwill and 
Coussens 2004; Lin and Karin 2007; Natarajan, Komarov et al. 2014).  P53 has proven to 
have the capacity to suppress the activity of NF-κB resulting in the attenuation of 
inflammation and its effects; likewise deregulation of NF-κB as observed in chronic 
inflammation can suppress p53 and its’ role as a tumor suppressor (Gudkov and 
Komarova 2016).   
As evidence suggests p53 plays a key role in the regulation of chronic intestinal 
inflammation and tumorigenesis, a p53 mutation can have broad negative effects on the 
IBD pathogenesis and colon cancer development.  Mutation of the p53 protein results in 
the loss of its tumor suppressor role and a gain of new functions that include increased 
cell proliferation and the promotion of oncogenic transformation and invasiveness.  
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Cooks et al demonstrates an extended and magnified activation of the inflammatory 
response by mutated p53 in addition to the absence of anti-inflammatory properties 
frequently observed in the non-mutated wild-type p53 (Cooks, Pateras et al. 2013).   
Free radicals are generated in the inflammatory process potentially targeting 
genes and proteins important for homeostasis of colonocytes.  Upon excessive ROS and 
free radical accumulation in cells a protective mechanism activates the transcription of a 
number of detoxifying enzymes that includes heme-oxygenase-1 (HO-1) which in turn 
inactivates the ROS halting any further damaging effects (Kalo, Kogan-Sakin et al. 
2012).  Heme-oxygenase-1 an inducible phase II enzyme, has been characterized as an 
endogenous inflammatory regulator, as such HO-1 knockout mice develop chronic 
inflammatory disease (Paine, Eiz-Vesper et al. 2010).  Lipopolysaccharide (LPS) 
stimulated macrophages induce (HO-1) which decreases inflammatory indicators of NO, 
iNOS and COX-2.  Interestingly, HO-1 mRNA and protein expression have been 
identified in intestinal cell lines and human IBD tissue samples, suggestive of an innate 
protective response that exists to limit tissue damage through the release of HO-1 (Paine, 
Eiz-Vesper et al. 2010).   
The p53 protein can be targeted by these free radicals and ROS accumulation if 
left unchecked resulting in p53 mutations early in the pathogenesis of IBD; p53 
mutations occur at a higher rate in the inflamed mucosa of IBD patients shifting the 
progression of inflammation to one of dysplasia and increased risk of colon cancer 
development (Matkowskyj, Chen et al. 2013).  This sequence can be described as the 
“inflammation-dysplasia-carcinoma” sequence characteristic in IBD.  The degree of IBD 
related dysplasia to carcinoma appears to correlate with the level of p53 mutations 
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(Gerrits, Chen et al. 2011).  The changes in p53 early in the pathogenesis of IBD suggest 
it is an effective marker for screening of chronic inflammation of the colon and 
subsequent risk of colon cancer development (Matkowskyj, Chen et al. 2013). 
The role of p53 in chronic inflammation and carcinogenesis is complex and multi-
faceted.  This study is the first to report on the non-synergistic anti-proliferative effects of 
DDMN in combination with curcumin in the p53 mutant cell line HT29; findings indicate 
no interaction (additive) occurred at low combinatory concentrations of DDMN at 
1.5µM-3µM + curcumin at 1µM-2µM whereas an antagonistic combination response 
with a reduction in anti-proliferative effects appears to exist at higher concentrations of 
DDMN (4.5µM-7.5µM) curcumin (3µM-5µM).  These findings are in contrast to our 
results in the p53 wild type cell line HCT116 in which the combination demonstrated 
synergistic anti-proliferative effects.  Our findings suggest two different mechanisms are 
at work in HT29 p53 mutated cells, one an additive interaction at low concentrations of 
DDMN + curcumin and the other an antagonistic interaction at higher concentrations of 
the combination.  Others have reported differing mechanisms involved in curcumin’s 
anti-cancer effects that are concentration based, with low concentrations of curcumin 
exhibiting an antioxidant effect and higher concentrations of curcumin demonstrating a 
pro-apoptotic effect (Park and Conteas 2010).    
Research examining apoptosis following curcumin treatment and the role of p53 
has had mixed findings (Jee, Shen et al. 1998; Choudhuri, Pal et al. 2002; Radhakrishna 
Pillai, Srivastava et al. 2004; Watson, Hill et al. 2008; Watson, Hill et al. 2010).  Watson 
et al suggests curcumin utilizes a p-53 independent mechanism to promote apoptosis in 
HCT116 colon cancer cells.  Other researchers compared curcumin sensitivity in p53 
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wild type HCT116 colon cancer cells with a p53 knockout HCT116 cell line to conclude 
that wild type p53 is required for curcumin sensitivity (Howells, Mitra et al. 2007).  
Interestingly, clinical findings following curcumin treatment in colorectal cancer patients 
suggest a correlation exists between an increased expression of p53 in tumor tissue with 
an increase in apoptotic tumor cells and increased body weight (He, Shi et al. 2011).   
Our prior study demonstrated extensive induction of apoptosis and a significant 
increase in p53 and HO-1 expression was associated with the synergistic inhibition of cell 
growth by the combination of DDMN (7.5µM) + curcumin (5µM) in HCT116 p53 wild 
type colon cancer cells.  Indeed, the full dose combination treatment of DDMN (7.5µM) 
+ curcumin (5µM) exhibited a substantial 110% increase in p53 expression as compared 
to control, resulting in a much stronger response than individual curcumin (70%) or 
DDMN (10%) treatments.  Likewise, heme oxygenase-1 (HO-1), a phase 2 enzyme 
induced in response to oxidative stress was found to dramatically increase following our 
treatment of HCT116 p53 wild type colon cancer cells with DDMN (7.5µM), curcumin 
(5µM) or full dose combination treatment increasing HO-1 expression by 490%, 10% and 
770% respectively.  Researchers have explored the mechanism involved in the apoptotic 
and anti-cancer effects of HO-1 in HCT116 p53wt and p53-/- colon cancer cells.  Results 
indicate the induction of apoptosis is dependent upon a fully functioning p53 protein in 
order for the full expression of HO-1 and its’ apoptotic effects to occur.  Other research 
appears to support the integral role of a functioning p53.  Kalo et al have found that HO-1 
displays an anti-apoptotic effect in Caco-2 p53 mutant colon cancer cells and in other p53 
mutant variants (Busserolles, Megias et al. 2006; Kalo, Kogan-Sakin et al. 2012).  
Mutated p53 has also been associated with a reduction in phase II enzymes such as HO-
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1and a resistance to cellular death.  Taken together these findings suggest that HO-1 and 
p53 play an important role in the synergism of DDMN and curcumin in combination in 
HCT116 p53 wild type colon cancer cells and potentially can contribute in part to explain 
the differing antagonistic combination response in HT29 p53 mutant colon cancer cells. 
 
4.7 Conclusions 
 
In conclusion, this study for the first time has shown that the combination of DDMN and  
 
curcumin synergistically inhibits LPS-induced inflammation in RAW 264.7 macrophage 
cells as demonstrated by the inhibition of nitric oxide (NO) production.  In addition, for 
the first time we have identified a non-synergistic interaction occurs in the combination 
of DDMN and curcumin in HT29 p53 mutant colon cancer cells resulting in diminished 
anti-proliferative effects that are less than individual treatments.  Our results provide new 
insights into the characterization of the synergistic combination of DDMN and curcumin 
in HCT116 p53 wild-type colon cancer cells.  The synergistic anti-cancer activity of this 
combination could be in part due to its mode of action in its ability to induce p53 in 
HCT116 colon cancer cells perhaps resulting in the inhibition of inflammatory pathways 
and the promotion of apoptosis.  Further investigation is warranted for the development 
of new dietary combination strategies that will disrupt the transformation of chronic 
inflammation to potentially prevent and reduce the occurrence of IBD-related colon 
cancer.   
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CHAPTER 5 
CONCLUSIONS 
 
 Research has shown diet to be a powerful manipulator in the prevention and 
promotion of cancer and inflammation.  Excitingly, many studies suggest dietary 
components exhibit anti-cancer and anti-inflammatory properties with low or no toxicity, 
yet little research exists examining these dietary components in combination.  As we do 
not eat these compounds in isolation it is important to examine the interaction of dietary 
components when combined; examination of the biological activities and interactions of 
their metabolites with other dietary components can aid in eliciting a better understanding 
of the possible mechanisms involved in vivo.   
 Although numerous studies show that complementary mechanisms of individual 
dietary components can result in enhanced anti-cancer and anti-inflammatory effects 
when used in combination, caution is warranted as certain dietary component 
combinations can be antagonistic with diminished anti-cancer or anti-inflammatory 
effects and in some instances can even act as a promoter of carcinogenesis.  In these 
cases, it is critical to understand how these components interact within the particular 
combinations so that recommendations can be made to avoid potential adverse effects.  
These findings underscore the need to further investigate and characterize new dietary 
component combination strategies that have the potential to elicit a more potent 
synergistic anti-cancer and anti-inflammatory response for cancer chemoprevention and 
inflammation. 
 
132 
 
BIBLIOGRAPHY 
 
 
Agullo, G., L. Gamet-Payrastre, et al. (1996). "Comparative effects of flavonoids on the 
growth, viability and metabolism of a colonic adenocarcinoma cell line (HT29 cells)." 
Cancer Lett 105(1): 61-70. 
Altenburg, J. D., A. A. Bieberich, et al. (2011). "A synergistic antiproliferation effect of 
curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not 
explained by the effects of either compound alone." BMC Cancer 11: 149. 
Ambs, S., M. O. Ogunfusika, et al. (1998). "Up-regulation of inducible nitric oxide 
synthase expression in cancer-prone p53 knockout mice." Proc Natl Acad Sci U S A 
95(15): 8823-8828. 
Amin, A. R., D. Wang, et al. (2010). "Enhanced anti-tumor activity by the combination 
of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of 
p53." J Biol Chem 285(45): 34557-34565. 
Andres, N. C., M. E. Fermento, et al. (2014). "Heme oxygenase-1 has antitumoral effects 
in colorectal cancer: involvement of p53." Exp Mol Pathol 97(3): 321-331. 
Ashokkumar, P. and G. Sudhandiran (2008). "Protective role of luteolin on the status of 
lipid peroxidation and antioxidant defense against azoxymethane-induced experimental 
colon carcinogenesis." Biomed Pharmacother 62(9): 590-597. 
Au, A., B. Li, et al. (2006). "Effect of dietary apigenin on colonic ornithine 
decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different 
experimental models." Nutr Cancer 54(2): 243-251. 
Balkwill, F. and L. M. Coussens (2004). "Cancer: an inflammatory link." Nature 
431(7007): 405-406. 
Barrera, L. N., I. T. Johnson, et al. (2013). "Colorectal cancer cells Caco-2 and HCT116 
resist epigenetic effects of isothiocyanates and selenium in vitro." Eur J Nutr 52(4): 1327-
1341. 
Basu, A. and V. Imrhan (2007). "Tomatoes versus lycopene in oxidative stress and 
carcinogenesis: conclusions from clinical trials." Eur J Clin Nutr 61(3): 295-303. 
Becker, J. C., H. Fukui, et al. (2007). "Colonic expression of heme oxygenase-1 is 
associated with a better long-term survival in patients with colorectal cancer." Scand J 
Gastroenterol 42(7): 852-858. 
Beecher, G. R. (2003). "Overview of dietary flavonoids: nomenclature, occurrence and 
intake." J Nutr 133(10): 3248S-3254S. 
133 
 
Ben-Neriah, Y. and M. Karin (2011). "Inflammation meets cancer, with NF-kappaB as 
the matchmaker." Nat Immunol 12(8): 715-723. 
Benavente-Garcia, O. and J. Castillo (2008). "Update on uses and properties of citrus 
flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity." J 
Agric Food Chem 56(15): 6185-6205. 
Bird, R. P. (1995). "Role of aberrant crypt foci in understanding the pathogenesis of 
colon cancer." Cancer Lett 93(1): 55-71. 
Bobe, G., L. B. Sansbury, et al. (2008). "Dietary flavonoids and colorectal adenoma 
recurrence in the Polyp Prevention Trial." Cancer Epidemiol Biomarkers Prev 17(6): 
1344-1353. 
Bonnesen, C., I. M. Eggleston, et al. (2001). "Dietary indoles and isothiocyanates that are 
generated from cruciferous vegetables can both stimulate apoptosis and confer protection 
against DNA damage in human colon cell lines." Cancer Res 61(16): 6120-6130. 
Bose, M., X. Hao, et al. (2007). "Inhibition of tumorigenesis in ApcMin/+ mice by a 
combination of (-)-epigallocatechin-3-gallate and fish oil." J Agric Food Chem 55(19): 
7695-7700. 
Boursi, B. and N. Arber (2007). "Current and future clinical strategies in colon cancer 
prevention and the emerging role of chemoprevention." Curr Pharm Des 13(22): 2274-
2282. 
Brahmbhatt, M., S. R. Gundala, et al. (2013). "Ginger phytochemicals exhibit synergy to 
inhibit prostate cancer cell proliferation." Nutr Cancer 65(2): 263-272. 
Busserolles, J., J. Megias, et al. (2006). "Heme oxygenase-1 inhibits apoptosis in Caco-2 
cells via activation of Akt pathway." Int J Biochem Cell Biol 38(9): 1510-1517. 
Butler, L. M., A. H. Wu, et al. (2010). "A vegetable-fruit-soy dietary pattern protects 
against breast cancer among postmenopausal Singapore Chinese women." Am J Clin 
Nutr 91(4): 1013-1019. 
Canene-Adams, K., B. L. Lindshield, et al. (2007). "Combinations of tomato and broccoli 
enhance antitumor activity in dunning r3327-h prostate adenocarcinomas." Cancer Res 
67(2): 836-843. 
Cao, G., E. Sofic, et al. (1997). "Antioxidant and prooxidant behavior of flavonoids: 
structure-activity relationships." Free Radic Biol Med 22(5): 749-760. 
Carroll, R. E., R. V. Benya, et al. (2011). "Phase IIa clinical trial of curcumin for the 
prevention of colorectal neoplasia." Cancer Prev Res (Phila) 4(3): 354-364. 
134 
 
Challa, A., D. R. Rao, et al. (1997). "Interactive suppression of aberrant crypt foci 
induced by azoxymethane in rat colon by phytic acid and green tea." Carcinogenesis 
18(10): 2023-2026. 
Chang, H., M. Mi, et al. (2008). "Structurally related cytotoxic effects of flavonoids on 
human cancer cells in vitro." Arch Pharm Res 31(9): 1137-1144. 
Chaudhary, A., D. Sutaria, et al. (2011). "Chemoprevention of colon cancer in a rat 
carcinogenesis model using a novel nanotechnology-based combined treatment system." 
Cancer Prev Res (Phila) 4(10): 1655-1664. 
Chen, C. and A. N. Kong (2005). "Dietary cancer-chemopreventive compounds: from 
signaling and gene expression to pharmacological effects." Trends Pharmacol Sci 26(6): 
318-326. 
Chen, C., M. Ono, et al. (2014). "Antiproliferative and apoptosis-inducing activity of 
nobiletin against three subtypes of human breast cancer cell lines." Anticancer Res 34(4): 
1785-1792. 
Chen, J., F. L. Wang, et al. (2014). "Modulation of apoptosis-related cell signalling 
pathways by curcumin as a strategy to inhibit tumor progression." Mol Biol Rep 41(7): 
4583-4594. 
Chen, L., H. Teng, et al. (2016). "Modifications of dietary flavonoids towards improved 
bioactivity: An update on structure-activity relationship." Crit Rev Food Sci Nutr: 1-15. 
Cheung, K. L., T. O. Khor, et al. (2009). "Synergistic effect of combination of phenethyl 
isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of 
inflammation." Pharm Res 26(1): 224-231. 
Chian, S., Y. Y. Li, et al. (2014). "Luteolin sensitizes two oxaliplatin-resistant colorectal 
cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway." Asian 
Pac J Cancer Prev 15(6): 2911-2916. 
Chidambara Murthy, K. N., J. Kim, et al. (2012). "Differential inhibition of human colon 
cancer cells by structurally similar flavonoids of citrus." Food Chem 132(1): 27-34. 
Choi, S. Y., J. H. Hwang, et al. (2007). "Nobiletin from citrus fruit peel inhibits the 
DNA-binding activity of NF-kappaB and ROS production in LPS-activated RAW 264.7 
cells." J Ethnopharmacol 113(1): 149-155. 
Chou, T. C. (2006). "Theoretical basis, experimental design, and computerized 
simulation of synergism and antagonism in drug combination studies." Pharmacol Rev 
58(3): 621-681. 
Chou, T. C. and P. Talalay (1984). "Quantitative analysis of dose-effect relationships: the 
combined effects of multiple drugs or enzyme inhibitors." Adv Enzyme Regul 22: 27-55. 
135 
 
Choudhuri, T., S. Pal, et al. (2002). "Curcumin induces apoptosis in human breast cancer 
cells through p53-dependent Bax induction." FEBS Lett 512(1-3): 334-340. 
Chu, Y. F., J. Sun, et al. (2002). "Antioxidant and antiproliferative activities of common 
vegetables." J Agric Food Chem 50(23): 6910-6916. 
Collett, G. P. and F. C. Campbell (2004). "Curcumin induces c-jun N-terminal kinase-
dependent apoptosis in HCT116 human colon cancer cells." Carcinogenesis 25(11): 
2183-2189. 
Colon, M. and C. Nerin (2016). "Synergistic, antagonistic and additive interactions of 
green tea polyphenols." Eur Food Res Technol 242: 211-220 
 
Constantinou, A. I., B. E. White, et al. (2005). "The soy isoflavone daidzein improves the 
capacity of tamoxifen to prevent mammary tumours." Eur J Cancer 41(4): 647-654. 
Cooks, T., C. C. Harris, et al. (2014). "Caught in the cross fire: p53 in inflammation." 
Carcinogenesis 35(8): 1680-1690. 
Cooks, T., I. S. Pateras, et al. (2013). "Mutant p53 prolongs NF-kappaB activation and 
promotes chronic inflammation and inflammation-associated colorectal cancer." Cancer 
Cell 23(5): 634-646. 
Crim, K. C., L. M. Sanders, et al. (2008). "Upregulation of p21Waf1/Cip1 expression in 
vivo by butyrate administration can be chemoprotective or chemopromotive depending 
on the lipid component of the diet." Carcinogenesis 29(7): 1415-1420. 
Cruz-Correa, M., D. A. Shoskes, et al. (2006). "Combination treatment with curcumin 
and quercetin of adenomas in familial adenomatous polyposis." Clin Gastroenterol 
Hepatol 4(8): 1035-1038. 
Cui, Y., J. Wu, et al. (2010). "Anti-neuroinflammatory activity of nobiletin on 
suppression of microglial activation." Biol Pharm Bull 33(11): 1814-1821. 
Dagne, A., T. Melkamu, et al. (2011). "Enhanced inhibition of lung adenocarcinoma by 
combinatorial treatment with indole-3-carbinol and silibinin in A/J mice." Carcinogenesis 
32(4): 561-567. 
Das, D., N. Arber, et al. (2007). "Chemoprevention of colorectal cancer." Digestion 
76(1): 51-67. 
Davis, C. D., N. J. Emenaker, et al. (2010). "Cellular proliferation, apoptosis and 
angiogenesis: molecular targets for nutritional preemption of cancer." Semin Oncol 
37(3): 243-257. 
Delgado, L., I. Fernandes, et al. (2014). "Anti-proliferative effects of quercetin and 
catechin metabolites." Food Funct 5(4): 797-803. 
136 
 
Depeint, F., J. M. Gee, et al. (2002). "Evidence for consistent patterns between flavonoid 
structures and cellular activities." Proc Nutr Soc 61(1): 97-103. 
DiMarco-Crook, C. and H. Xiao (2015). "Diet-based strategies for cancer 
chemoprevention: the role of combination regimens using dietary bioactive components." 
Annu Rev Food Sci Technol 6: 505-526. 
Dong, X., W. Xu, et al. (2013). "Combination of low dose of genistein and daidzein has 
synergistic preventive effects on isogenic human prostate cancer cells when compared 
with individual soy isoflavone." Food Chem 141(3): 1923-1933. 
DuPont, A. W., M. R. Arguedas, et al. (2007). "Aspirin chemoprevention in patients with 
increased risk for colorectal cancer: a cost-effectiveness analysis." Aliment Pharmacol 
Ther 26(3): 431-441. 
Fan, S., Q. Meng, et al. (2006). "BRCA1 and BRCA2 as molecular targets for 
phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells." Br J 
Cancer 94(3): 407-426. 
Ferrucci, L. M., C. R. Daniel, et al. (2010). "Measurement of spices and seasonings in 
India: opportunities for cancer epidemiology and prevention." Asian Pac J Cancer Prev 
11(6): 1621-1629. 
Forrester, K., S. Ambs, et al. (1996). "Nitric oxide-induced p53 accumulation and 
regulation of inducible nitric oxide synthase expression by wild-type p53." Proc Natl 
Acad Sci U S A 93(6): 2442-2447. 
Freeman, B. L., D. L. Eggett, et al. (2010). "Synergistic and antagonistic interactions of 
phenolic compounds found in navel oranges." J Food Sci 75(6): C570-576. 
Fresco, P., F. Borges, et al. (2006). "New insights on the anticancer properties of dietary 
polyphenols." Med Res Rev 26(6): 747-766. 
Funaro, A., X. Wu, et al. (2016). "Enhanced Anti-Inflammatory Activities by the 
Combination of Luteolin and Tangeretin." J Food Sci 81(5): H1320-1327. 
Garcea, G., D. P. Berry, et al. (2005). "Consumption of the putative chemopreventive 
agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and 
their pharmacodynamic consequences." Cancer Epidemiol Biomarkers Prev 14(1): 120-
125. 
Garcia-Lafuente, A., E. Guillamon, et al. (2009). "Flavonoids as anti-inflammatory 
agents: implications in cancer and cardiovascular disease." Inflamm Res 58(9): 537-552. 
Gasparian, A. V., C. A. Burkhart, et al. (2011). "Curaxins: anticancer compounds that 
simultaneously suppress NF-kappaB and activate p53 by targeting FACT." Sci Transl 
Med 3(95): 95ra74. 
137 
 
George, J., M. Singh, et al. (2011). "Synergistic growth inhibition of mouse skin tumors 
by pomegranate fruit extract and diallyl sulfide: evidence for inhibition of activated 
MAPKs/NF-kappaB and reduced cell proliferation." Food Chem Toxicol 49(7): 1511-
1520. 
Gerrits, M. M., M. Chen, et al. (2011). "Biomarker-based prediction of inflammatory 
bowel disease-related colorectal cancer: a case-control study." Cell Oncol (Dordr) 34(2): 
107-117. 
Goldin, A. and N. Mantel (1957). "The employment of combinations of drugs in the 
chemotherapy of neoplasia: a review." Cancer Res 17(7): 635-654. 
Gomez-Alonso, S. (2012). "Inhibition of colon adenocarcinoma cell proliferation by 
flavonols is linked to a G2/M cell cycle block and reduction in cyclin D1 expression." 
Food Chemistry 130: 493-500. 
Gonzalez, R., I. Ballester, et al. (2011). "Effects of flavonoids and other polyphenols on 
inflammation." Crit Rev Food Sci Nutr 51(4): 331-362. 
Goodman, J. E., L. J. Hofseth, et al. (2004). "Nitric oxide and p53 in cancer-prone 
chronic inflammation and oxyradical overload disease." Environ Mol Mutagen 44(1): 3-
9. 
Greco, W. R., G. Bravo, et al. (1995). "The search for synergy: a critical review from a 
response surface perspective." Pharmacol Rev 47(2): 331-385. 
Greenwald, P. (2002). "Cancer chemoprevention." BMJ 324(7339): 714-718. 
Gudkov, A. V., K. V. Gurova, et al. (2011). "Inflammation and p53: A Tale of Two 
Stresses." Genes Cancer 2(4): 503-516. 
Gudkov, A. V. and E. A. Komarova (2016). "p53 and the Carcinogenicity of Chronic 
Inflammation." Cold Spring Harb Perspect Med 6(11). 
Gueron, G., A. De Siervi, et al. (2009). "Critical role of endogenous heme oxygenase 1 as 
a tuner of the invasive potential of prostate cancer cells." Mol Cancer Res 7(11): 1745-
1755. 
Guo, S., P. Qiu, et al. (2012). "Synergistic anti-inflammatory effects of nobiletin and 
sulforaphane in lipopolysaccharide-stimulated RAW 264.7 cells." J Agric Food Chem 
60(9): 2157-2164. 
Gupta, S. C., S. Patchva, et al. (2013). "Therapeutic roles of curcumin: lessons learned 
from clinical trials." AAPS J 15(1): 195-218. 
Gurova, K. V., J. E. Hill, et al. (2005). "Small molecules that reactivate p53 in renal cell 
carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors." 
Proc Natl Acad Sci U S A 102(48): 17448-17453. 
138 
 
Harada, S., T. Tominari, et al. (2011). "Nobiletin, a polymethoxy flavonoid, suppresses 
bone resorption by inhibiting NFkappaB-dependent prostaglandin E synthesis in 
osteoblasts and prevents bone loss due to estrogen deficiency." J Pharmacol Sci 115(1): 
89-93. 
Harper, C. E., L. M. Cook, et al. (2009). "Genistein and resveratrol, alone and in 
combination, suppress prostate cancer in SV-40 tag rats." Prostate 69(15): 1668-1682. 
Harris, G. K., Y. Qian, et al. (2006). "Luteolin and chrysin differentially inhibit 
cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit 
prostaglandin-E2 formation in RAW 264.7 cells." J Nutr 136(6): 1517-1521. 
He, Z. Y., C. B. Shi, et al. (2011). "Upregulation of p53 expression in patients with 
colorectal cancer by administration of curcumin." Cancer Invest 29(3): 208-213. 
Hemalswarya, S. (2006). "Potential synergism of natural products in the treatment of 
cancer." Phytotherapy Research 20: 239-249. 
Hidalgo, M. (2010). "Flavonoid-flavonoid interaction and its effect on their antioxidant 
activity." Food Chemistry 121: 691-696. 
Ho, C. (2012). "Polymethoxyflavones as Food Factors for the Management of 
Inflammatory Diseases." 337-341 
 
Hoensch, H., B. Groh, et al. (2008). "Prospective cohort comparison of flavonoid 
treatment in patients with resected colorectal cancer to prevent recurrence." World J 
Gastroenterol 14(14): 2187-2193. 
Hoensch, H. P. and R. Oertel (2011). "Emerging role of bioflavonoids in 
gastroenterology: Especially their effects on intestinal neoplasia." World J Gastrointest 
Oncol 3(5): 71-74. 
Hofseth, L. J., S. Saito, et al. (2003). "Nitric oxide-induced cellular stress and p53 
activation in chronic inflammation." Proc Natl Acad Sci U S A 100(1): 143-148. 
Horie, N., N. Hirabayashi, et al. (2005). "Synergistic effect of green tea catechins on cell 
growth and apoptosis induction in gastric carcinoma cells." Biol Pharm Bull 28(4): 574-
579. 
Howells, L. M., A. Mitra, et al. (2007). "Comparison of oxaliplatin- and curcumin-
mediated antiproliferative effects in colorectal cell lines." Int J Cancer 121(1): 175-183. 
Hsieh, T. C. and J. M. Wu (2008). "Suppression of cell proliferation and gene expression 
by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen 
receptor-positive MCF-7 breast cancer cells." Int J Oncol 33(4): 851-859. 
139 
 
Hsieh, T. C. and J. M. Wu (2009). "Targeting CWR22Rv1 prostate cancer cell 
proliferation and gene expression by combinations of the phytochemicals EGCG, 
genistein and quercetin." Anticancer Res 29(10): 4025-4032. 
Hsu, A., R. S. Bruno, et al. (2011). "Dietary soy and tea mitigate chronic inflammation 
and prostate cancer via NFkappaB pathway in the Noble rat model." J Nutr Biochem 
22(5): 502-510. 
Hsu, E. L., N. Chen, et al. (2009). "Modulation of CXCR4, CXCL12, and Tumor Cell 
Invasion Potential In Vitro by Phytochemicals." J Oncol 2009: 491985. 
Hu, Y., G. H. McIntosh, et al. (2013). "Combination of selenium and green tea improves 
the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic 
and epigenetic biomarkers." PLoS One 8(5): e64362. 
Huang, C., Y. X. Wei, et al. (2016). "Chrysin, Abundant in Morinda citrifolia Fruit 
Water-EtOAc Extracts, Combined with Apigenin Synergistically Induced Apoptosis and 
Inhibited Migration in Human Breast and Liver Cancer Cells." J Agric Food Chem 
64(21): 4235-4245. 
Huang, H., L. Li, et al. (2016). "The Multifunctional Effects of Nobiletin and Its 
Metabolites In Vivo and In Vitro." Evid Based Complement Alternat Med 2016: 
2918796. 
Humphrey, R. W., L. M. Brockway-Lunardi, et al. (2011). "Opportunities and challenges 
in the development of experimental drug combinations for cancer." J Natl Cancer Inst 
103(16): 1222-1226. 
Hussain, S. P., P. Amstad, et al. (2000). "Increased p53 mutation load in noncancerous 
colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease." 
Cancer Res 60(13): 3333-3337. 
Hussain, S. P., G. E. Trivers, et al. (2004). "Nitric oxide, a mediator of inflammation, 
suppresses tumorigenesis." Cancer Res 64(19): 6849-6853. 
Hutzen, B., W. Willis, et al. (2009). "Dietary agent, benzyl isothiocyanate inhibits signal 
transducer and activator of transcription 3 phosphorylation and collaborates with 
sulforaphane in the growth suppression of PANC-1 cancer cells." Cancer Cell Int 9: 24. 
Ip, C. and H. E. Ganther (1991). "Combination of blocking agents and suppressing agents 
in cancer prevention." Carcinogenesis 12(2): 365-367. 
Itzkowitz, S. H. and X. Yio (2004). "Inflammation and cancer IV. Colorectal cancer in 
inflammatory bowel disease: the role of inflammation." Am J Physiol Gastrointest Liver 
Physiol 287(1): G7-17. 
140 
 
Iwuchukwu, O. F., R. J. Tallarida, et al. (2011). "Resveratrol in combination with other 
dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in 
Caco-2 cells." Life Sci 88(23-24): 1047-1054. 
Jaramillo-Carmona, S. (2014). "Combination of Quercetin and Kaempferol enhances in 
vitro Cytotoxicity on Human Colon Cancer (HCT116) Cells " Records of Natural 
Products 8(3): 262-271. 
Jawad, N., N. Direkze, et al. (2011). "Inflammatory bowel disease and colon cancer." 
Recent Results Cancer Res 185: 99-115. 
Jee, S. H., S. C. Shen, et al. (1998). "Curcumin induces a p53-dependent apoptosis in 
human basal cell carcinoma cells." J Invest Dermatol 111(4): 656-661. 
Jemal, A., R. Siegal, et al. (2010). "Cancer Statistics, 2010." CA Cancer J Clin(60): 277-
300. 
Jeune, M. A., J. Kumi-Diaka, et al. (2005). "Anticancer activities of pomegranate extracts 
and genistein in human breast cancer cells." J Med Food 8(4): 469-475. 
Jozkowicz, A., H. Was, et al. (2007). "Heme oxygenase-1 in tumors: is it a false friend?" 
Antioxid Redox Signal 9(12): 2099-2117. 
Kalo, E., I. Kogan-Sakin, et al. (2012). "Mutant p53R273H attenuates the expression of 
phase 2 detoxifying enzymes and promotes the survival of cells with high levels of 
reactive oxygen species." J Cell Sci 125(Pt 22): 5578-5586. 
Kang, K. A., Y. H. Maeng, et al. (2012). "Involvement of heme oxygenase-1 in Korean 
colon cancer." Tumour Biol 33(4): 1031-1038. 
Kanthamneni, N., A. Chaudhary, et al. (2010). "Nanoparticulate delivery of novel drug 
combination regimens for the chemoprevention of colon cancer." Int J Oncol 37(1): 177-
185. 
Kawaii, S., Y. Tomono, et al. (1999). "Antiproliferative activity of flavonoids on several 
cancer cell lines." Biosci Biotechnol Biochem 63(5): 896-899. 
Kim, K. M., H. O. Pae, et al. (2008). "Involvement of anti-inflammatory heme 
oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory 
inducible nitric oxide synthase in RAW264.7 macrophages." Biomed Pharmacother 
62(9): 630-636. 
Kimura, O., C. Ohta, et al. (2014). "Carrier-mediated uptake of nobiletin, a citrus 
polymethoxyflavonoid, in human intestinal Caco-2 cells." Food Chem 154: 145-150. 
Klein, E. A., I. M. Thompson, Jr., et al. (2011). "Vitamin E and the risk of prostate 
cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA 
306(14): 1549-1556. 
141 
 
Kohno, H., S. Yoshitani, et al. (2001). "Dietary administration of citrus nobiletin inhibits 
azoxymethane-induced colonic aberrant crypt foci in rats." Life Sci 69(8): 901-913. 
Kolar, S. S., R. Barhoumi, et al. (2007). "Synergy between docosahexaenoic acid and 
butyrate elicits p53-independent apoptosis via mitochondrial Ca(2+) accumulation in 
colonocytes." Am J Physiol Gastrointest Liver Physiol 293(5): G935-943. 
Kongpichitchoke, T., J. L. Hsu, et al. (2015). "Number of Hydroxyl Groups on the B-
Ring of Flavonoids Affects Their Antioxidant Activity and Interaction with Phorbol Ester 
Binding Site of PKCdelta C1B Domain: In Vitro and in Silico Studies." J Agric Food 
Chem 63(18): 4580-4586. 
Kramer, F., I. T. Johnson, et al. (2009). "A comparison of the effects of soya 
isoflavonoids and fish oil on cell proliferation, apoptosis and the expression of oestrogen 
receptors alpha and beta in the mammary gland and colon of the rat." Br J Nutr 102(1): 
29-36. 
Kronbak, R., F. Duus, et al. (2010). "Effect of 4-methoxyindole-3-carbinol on the 
proliferation of colon cancer cells in vitro, when treated alone or in combination with 
indole-3-carbinol." J Agric Food Chem 58(14): 8453-8459. 
Kumar, R., V. Verma, et al. (2011). "Synergistic chemoprotective mechanisms of dietary 
phytoestrogens in a select combination against prostate cancer." J Nutr Biochem 22(8): 
723-731. 
Kumar, S. and A. K. Pandey (2013). "Chemistry and biological activities of flavonoids: 
an overview." ScientificWorldJournal 2013: 162750. 
Kumi-Diaka, J., K. Merchant, et al. (2010). "Genistein-selenium combination induces 
growth arrest in prostate cancer cells." J Med Food 13(4): 842-850. 
Kuntz, S., U. Wenzel, et al. (1999). "Comparative analysis of the effects of flavonoids on 
proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines." Eur J Nutr 
38(3): 133-142. 
Kuo, S. M. (1996). "Antiproliferative potency of structurally distinct dietary flavonoids 
on human colon cancer cells." Cancer Lett 110(1-2): 41-48. 
Lai, C. S., S. Li, et al. (2008). "Anti-inflammatory and antitumor promotional effects of a 
novel urinary metabolite, 3',4'-didemethylnobiletin, derived from nobiletin." 
Carcinogenesis 29(12): 2415-2424. 
Lai, C. S., M. L. Tsai, et al. (2011). "Chemoprevention of colonic tumorigenesis by 
dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice." Mol Nutr 
Food Res 55(2): 278-290. 
Lakatos, P. L. and L. Lakatos (2008). "Risk for colorectal cancer in ulcerative colitis: 
changes, causes and management strategies." World J Gastroenterol 14(25): 3937-3947. 
142 
 
Lambert, J. D., S. J. Kwon, et al. (2008). "Effect of genistein on the bioavailability and 
intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate." 
Carcinogenesis 29(10): 2019-2024. 
Lansky, E. P., W. Jiang, et al. (2005). "Possible synergistic prostate cancer suppression 
by anatomically discrete pomegranate fractions." Invest New Drugs 23(1): 11-20. 
Le Gac, G., P. O. Esteve, et al. (2006). "DNA damage-induced down-regulation of 
human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance 
DNA (cytosine-5) methyltransferase 1." J Biol Chem 281(34): 24161-24170. 
Lee, J. J., M. Kong, et al. (2007). "Interaction index and different methods for 
determining drug interaction in combination therapy." J Biopharm Stat 17(3): 461-480. 
Lee, Y., B. Sung, et al. (2014). "Apigenin-induced apoptosis is enhanced by inhibition of 
autophagy formation in HCT116 human colon cancer cells." Int J Oncol 44(5): 1599-
1606. 
Lee, Y. S., B. Y. Cha, et al. (2010). "Nobiletin improves hyperglycemia and insulin 
resistance in obese diabetic ob/ob mice." Biochem Pharmacol 79(11): 1674-1683. 
Legg, R. L., J. R. Tolman, et al. (2008). "Diets high in selenium and isoflavones decrease 
androgen-regulated gene expression in healthy rat dorsolateral prostate." Reprod Biol 
Endocrinol 6: 57. 
Leonardi, T., J. Vanamala, et al. (2010). "Apigenin and naringenin suppress colon 
carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats." Exp Biol 
Med (Maywood) 235(6): 710-717. 
Lev-Ari, S., L. Strier, et al. (2005). "Celecoxib and curcumin synergistically inhibit the 
growth of colorectal cancer cells." Clin Cancer Res 11(18): 6738-6744. 
Li, S. (2008). "Biological Activity, Metabolism and Separation of 
Polymethoxyflavonoids from Citrus Peels." Tree and Forestry Science and 
Biotechnology: 36-49. 
Li, S. (2009). "Chemistry and health effects of polymethoxyflavones and hydroxylated 
polymethoxyflavones." Journal of Functional foods: 2-12. 
Li, S., C. Y. Lo, et al. (2006). "Hydroxylated polymethoxyflavones and methylated 
flavonoids in sweet orange (Citrus sinensis) peel." J Agric Food Chem 54(12): 4176-
4185. 
Li, S., M. H. Pan, et al. (2007). "Isolation and syntheses of polymethoxyflavones and 
hydroxylated polymethoxyflavones as inhibitors of HL-60 cell lines." Bioorg Med Chem 
15(10): 3381-3389. 
143 
 
Li, S., S. Sang, et al. (2007). "Anti-inflammatory property of the urinary metabolites of 
nobiletin in mouse." Bioorg Med Chem Lett 17(18): 5177-5181. 
Li, W., J. X. Wu, et al. (2010). "Synergistic effects of tea polyphenols and ascorbic acid 
on human lung adenocarcinoma SPC-A-1 cells." J Zhejiang Univ Sci B 11(6): 458-464. 
Li, X. L., J. Zhou, et al. (2015). "P53 mutations in colorectal cancer - molecular 
pathogenesis and pharmacological reactivation." World J Gastroenterol 21(1): 84-93. 
Lim, D. Y., H. J. Cho, et al. (2012). "Luteolin decreases IGF-II production and 
downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon 
cancer cells." BMC Gastroenterol 12: 9. 
Lin, W. W. and M. Karin (2007). "A cytokine-mediated link between innate immunity, 
inflammation, and cancer." J Clin Invest 117(5): 1175-1183. 
Lindshield, B. L., N. A. Ford, et al. (2010). "Selenium, but not lycopene or vitamin E, 
decreases growth of transplantable dunning R3327-H rat prostate tumors." PLoS One 
5(4): e10423. 
Liu, R. H. (2003). "Health benefits of fruit and vegetables are from additive and 
synergistic combinations of phytochemicals." Am J Clin Nutr 78(3 Suppl): 517S-520S. 
Liu, R. H. (2004). "Potential synergy of phytochemicals in cancer prevention: mechanism 
of action." J Nutr 134(12 Suppl): 3479S-3485S. 
Lo, Y. H., M. H. Pan, et al. (2010). "Nobiletin metabolite, 3',4'-dihydroxy-5,6,7,8-
tetramethoxyflavone, inhibits LDL oxidation and down-regulates scavenger receptor 
expression and activity in THP-1 cells." Biochim Biophys Acta 1801(2): 114-126. 
Lotito, S. B., W. J. Zhang, et al. (2011). "Metabolic conversion of dietary flavonoids 
alters their anti-inflammatory and antioxidant properties." Free Radic Biol Med 51(2): 
454-463. 
Lund, E. (2003). "Non-nutritive bioactive constituents of plants: dietary sources and 
health benefits of glucosinolates." Int J Vitam Nutr Res 73(2): 135-143. 
Luo, G., X. Guan, et al. (2008). "Apoptotic effect of citrus fruit extract nobiletin on lung 
cancer cell line A549 in vitro and in vivo." Cancer Biol Ther 7(6): 966-973. 
Majumdar, A. P., S. Banerjee, et al. (2009). "Curcumin synergizes with resveratrol to 
inhibit colon cancer." Nutr Cancer 61(4): 544-553. 
Manju, V. and N. Nalini (2007). "Protective role of luteolin in 1,2-dimethylhydrazine 
induced experimental colon carcinogenesis." Cell Biochem Funct 25(2): 189-194. 
Manthey, J. A. and N. Guthrie (2002). "Antiproliferative activities of citrus flavonoids 
against six human cancer cell lines." J Agric Food Chem 50(21): 5837-5843. 
144 
 
Martin, K. R. (2006). "Targeting apoptosis with dietary bioactive agents." Exp Biol Med 
(Maywood) 231(2): 117-129. 
Martinez-Montemayor, M. M., E. Otero-Franqui, et al. (2010). "Individual and combined 
soy isoflavones exert differential effects on metastatic cancer progression." Clin Exp 
Metastasis 27(7): 465-480. 
Matkowskyj, K. A., Z. E. Chen, et al. (2013). "Dysplastic lesions in inflammatory bowel 
disease: molecular pathogenesis to morphology." Arch Pathol Lab Med 137(3): 338-350. 
McGrath, D. R. and A. D. Spigelman (2008). "Putative mechanisms of action for indole-
3-carbinol in the prevention of colorectal cancer." Expert Opin Ther Targets 12(6): 729-
738. 
Mertens-Talcott, S. U. and S. S. Percival (2005). "Ellagic acid and quercetin interact 
synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle 
arrest in human leukemia cells." Cancer Lett 218(2): 141-151. 
Meyskens, F. L., Jr., C. E. McLaren, et al. (2008). "Difluoromethylornithine plus sulindac 
for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, 
double-blind trial." Cancer Prev Res (Phila) 1(1): 32-38. 
Miyamoto, S., Y. Yasui, et al. (2010). "Dietary flavonoids suppress azoxymethane-
induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice." Chem Biol 
Interact 183(2): 276-283. 
Mladenova, D. and M. R. Kohonen-Corish (2012). "Review: Mouse models of 
inflammatory bowel disease--insights into the mechanisms of inflammation-associated 
colorectal cancer." In Vivo 26(4): 627-646. 
Mohammed, A., N. B. Janakiram, et al. (2013). "Multitargeted low-dose GLAD 
combination chemoprevention: a novel and promising approach to combat colon 
carcinogenesis." Neoplasia 15(5): 481-490. 
Moragoda, L., R. Jaszewski, et al. (2001). "Curcumin induced modulation of cell cycle 
and apoptosis in gastric and colon cancer cells." Anticancer Res 21(2A): 873-878. 
Morley, K. L., P. J. Ferguson, et al. (2007). "Tangeretin and nobiletin induce G1 cell 
cycle arrest but not apoptosis in human breast and colon cancer cells." Cancer Lett 
251(1): 168-178. 
Murakami, A., Y. Nakamura, et al. (2000). "Inhibitory effect of citrus nobiletin on 
phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice." 
Cancer Res 60(18): 5059-5066. 
Murakami, A., D. Takahashi, et al. (2003). "Synergistic suppression of superoxide and 
nitric oxide generation from inflammatory cells by combined food factors." Mutat Res 
523-524: 151-161. 
145 
 
Murphy, A., K. Testa, et al. (2014). "Impact of antioxidants on the ability of phenolic 
phytochemicals to kill HCT116 colon cancer cells." Free Radic Res 48(3): 313-321. 
Nakagawa, H., D. Yamamoto, et al. (2000). "Effects of genistein and synergistic action in 
combination with eicosapentaenoic acid on the growth of breast cancer cell lines." J 
Cancer Res Clin Oncol 126(8): 448-454. 
Nakamura, Y., S. Yogosawa, et al. (2009). "A combination of indol-3-carbinol and 
genistein synergistically induces apoptosis in human colon cancer HT-29 cells by 
inhibiting Akt phosphorylation and progression of autophagy." Mol Cancer 8: 100. 
Natarajan, V., A. P. Komarov, et al. (2014). "Peptides genetically selected for NF-
kappaB activation cooperate with oncogene Ras and model carcinogenic role of 
inflammation." Proc Natl Acad Sci U S A 111(4): E474-483. 
Neergheen, V. S., T. Bahorun, et al. (2010). "Targeting specific cell signaling 
transduction pathways by dietary and medicinal phytochemicals in cancer 
chemoprevention." Toxicology 278(2): 229-241. 
Nho, C. W. and E. Jeffery (2004). "Crambene, a bioactive nitrile derived from 
glucosinolate hydrolysis, acts via the antioxidant response element to upregulate quinone 
reductase alone or synergistically with indole-3-carbinol." Toxicol Appl Pharmacol 
198(1): 40-48. 
Nimptsch, K., X. Zhang, et al. (2016). "Habitual intake of flavonoid subclasses and risk 
of colorectal cancer in 2 large prospective cohorts." Am J Clin Nutr 103(1): 184-191. 
Nunes, C., L. Almeida, et al. (2017). "Luteolin suppresses the JAK/STAT pathway in a 
cellular model of intestinal inflammation." Food Funct 8(1): 387-396. 
Osaki, M., M. Oshimura, et al. (2004). "PI3K-Akt pathway: its functions and alterations 
in human cancer." Apoptosis 9(6): 667-676. 
Osman, N. H., U. Z. Said, et al. (2015). "Luteolin supplementation adjacent to aspirin 
treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats." 
Tumour Biol 36(2): 1179-1190. 
Paine, A., B. Eiz-Vesper, et al. (2010). "Signaling to heme oxygenase-1 and its anti-
inflammatory therapeutic potential." Biochem Pharmacol 80(12): 1895-1903. 
Pal, S., A. Bhattacharjee, et al. (2014). "Chronic inflammation and cancer: potential 
chemoprevention through nuclear factor kappa B and p53 mutual antagonism." J Inflamm 
(Lond) 11: 23. 
Pan, M. H., C. S. Lai, et al. (2009). "Modulation of inflammatory genes by natural dietary 
bioactive compounds." J Agric Food Chem 57(11): 4467-4477. 
146 
 
Pan, M. H., C. S. Lai, et al. (2010). "Anti-inflammatory activity of natural dietary 
flavonoids." Food Funct 1(1): 15-31. 
Pappa, G., J. Strathmann, et al. (2007). "Quantitative combination effects between 
sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in 
vitro." Carcinogenesis 28(7): 1471-1477. 
Park, J. and C. N. Conteas (2010). "Anti-carcinogenic properties of curcumin on 
colorectal cancer." World J Gastrointest Oncol 2(4): 169-176. 
Pesakhov, S., M. Khanin, et al. (2010). "Distinct combinatorial effects of the plant 
polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute 
myeloid leukemia cells." Nutr Cancer 62(6): 811-824. 
Phan, M. A. (2017). "Interactions between phytochemicals from fruits and vegetables: 
Effects on bioactivities and bioavailability." Critical Reviews in Food Science and 
Nutrition: 1-20. 
Powell, S. M., N. Zilz, et al. (1992). "APC mutations occur early during colorectal 
tumorigenesis." Nature 359(6392): 235-237. 
Power, K. A., J. M. Chen, et al. (2008). "Changes in biomarkers of estrogen receptor and 
growth factor signaling pathways in MCF-7 tumors after short- and long-term treatment 
with soy and flaxseed." J Steroid Biochem Mol Biol 112(1-3): 13-19. 
Power, K. A. and L. U. Thompson (2007). "Can the combination of flaxseed and its 
lignans with soy and its isoflavones reduce the growth stimulatory effect of soy and its 
isoflavones on established breast cancer?" Mol Nutr Food Res 51(7): 845-856. 
Pradhan, S. J., R. Mishra, et al. (2010). "Quercetin and sulforaphane in combination 
suppress the progression of melanoma through the down-regulation of matrix 
metalloproteinase-9." Exp Ther Med 1(6): 915-920. 
Psaty, B. M. and J. D. Potter (2006). "Risks and benefits of celecoxib to prevent recurrent 
adenomas." N Engl J Med 355(9): 950-952. 
Qiu, P., P. Dong, et al. (2010). "Inhibitory effects of 5-hydroxy polymethoxyflavones on 
colon cancer cells." Mol Nutr Food Res 54 Suppl 2: S244-252. 
Radhakrishna Pillai, G., A. S. Srivastava, et al. (2004). "Induction of apoptosis in human 
lung cancer cells by curcumin." Cancer Lett 208(2): 163-170. 
Radhakrishnan, S., L. Reddivari, et al. (2011). "Resveratrol potentiates grape seed extract 
induced human colon cancer cell apoptosis." Front Biosci (Elite Ed) 3: 1509-1523. 
Raj, M. H., Z. Y. Abd Elmageed, et al. (2008). "Synergistic action of dietary phyto-
antioxidants on survival and proliferation of ovarian cancer cells." Gynecol Oncol 
110(3): 432-438. 
147 
 
Ramos, S. (2008). "Cancer chemoprevention and chemotherapy: dietary polyphenols and 
signalling pathways." Mol Nutr Food Res 52(5): 507-526. 
Rao, C. V. and B. S. Reddy (2004). "NSAIDs and chemoprevention." Curr Cancer Drug 
Targets 4(1): 29-42. 
Rather, M. A., B. A. Bhat, et al. (2013). "Multicomponent phytotherapeutic approach 
gaining momentum: Is the "one drug to fit all" model breaking down?" Phytomedicine 
21(1): 1-14. 
Reagan-Shaw, S., M. Nihal, et al. (2008). "Combination of vitamin E and selenium 
causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 
ratio." Prostate 68(15): 1624-1634. 
Rice-Evans, C. A., N. J. Miller, et al. (1996). "Structure-antioxidant activity relationships 
of flavonoids and phenolic acids." Free Radic Biol Med 20(7): 933-956. 
Rogler, G., K. Brand, et al. (1998). "Nuclear factor kappaB is activated in macrophages 
and epithelial cells of inflamed intestinal mucosa." Gastroenterology 115(2): 357-369. 
Roy, M. J., S. Dionne, et al. (2009). "In vitro studies on the inhibition of colon cancer by 
butyrate and carnitine." Nutrition 25(11-12): 1193-1201. 
Rubin, C. E., R. C. Haggitt, et al. (1992). "DNA aneuploidy in colonic biopsies predicts 
future development of dysplasia in ulcerative colitis." Gastroenterology 103(5): 1611-
1620. 
Saarinen, N. M., K. Power, et al. (2006). "Flaxseed attenuates the tumor growth 
stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human 
breast cancer xenografts." Int J Cancer 119(4): 925-931. 
Saha, A., T. Kuzuhara, et al. (2010). "New role of (-)-epicatechin in enhancing the 
induction of growth inhibition and apoptosis in human lung cancer cells by curcumin." 
Cancer Prev Res (Phila) 3(8): 953-962. 
Sak, K. (2014). "Cytotoxicity of dietary flavonoids on different human cancer types." 
Pharmacogn Rev 8(16): 122-146. 
Sakai, R. (2012). "Luteolin overcomes resistance to benzyl Isothiocyanate-induced 
apoptosis in human colorectal cancer HCT-116." Journal of Food and Drug Analysis 20: 
389-393. 
Sakamoto, K. (2000). "Synergistic effects of thearubigin and genistein on human prostate 
tumor cell (PC-3) growth via cell cycle arrest." Cancer Lett 151(1): 103-109. 
Saw, C. L., M. Cintron, et al. (2011). "Pharmacodynamics of dietary phytochemical 
indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and 
148 
 
antioxidant genes and synergism with isothiocyanates." Biopharm Drug Dispos 32(5): 
289-300. 
Schneider, G. and O. H. Kramer (2011). "NFkappaB/p53 crosstalk-a promising new 
therapeutic target." Biochim Biophys Acta 1815(1): 90-103. 
Schwartz, B., Y. Birk, et al. (2004). "Nutritional-pharmacological combinations--a novel 
approach to reducing colon cancer incidence." Eur J Nutr 43(4): 221-229. 
Seeram, N. P., L. S. Adams, et al. (2004). "Total cranberry extract versus its 
phytochemical constituents: antiproliferative and synergistic effects against human tumor 
cell lines." J Agric Food Chem 52(9): 2512-2517. 
Seeram, N. P., L. S. Adams, et al. (2005). "In vitro antiproliferative, apoptotic and 
antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract 
are enhanced in combination with other polyphenols as found in pomegranate juice." J 
Nutr Biochem 16(6): 360-367. 
Sengupta, A., S. Ghosh, et al. (2003). "Tomato and garlic can modulate azoxymethane-
induced colon carcinogenesis in rats." Eur J Cancer Prev 12(3): 195-200. 
Sengupta, A., S. Ghosh, et al. (2004). "Modulatory influence of garlic and tomato on 
cyclooxygenase-2 activity, cell proliferation and apoptosis during azoxymethane induced 
colon carcinogenesis in rat." Cancer Lett 208(2): 127-136. 
Sergeev, I. N., C. T. Ho, et al. (2007). "Apoptosis-inducing activity of hydroxylated 
polymethoxyflavones and polymethoxyflavones from orange peel in human breast cancer 
cells." Mol Nutr Food Res 51(12): 1478-1484. 
Shen, G., T. O. Khor, et al. (2007). "Chemoprevention of familial adenomatous polyposis 
by natural dietary compounds sulforaphane and dibenzoylmethane alone and in 
combination in ApcMin/+ mouse." Cancer Res 67(20): 9937-9944. 
Shih, Y. L., H. C. Liu, et al. (2010). "Combination treatment with luteolin and quercetin 
enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-
regulating nicotinic acetylcholine receptors." J Agric Food Chem 58(1): 235-241. 
Shukla, S. and S. Gupta (2010). "Apigenin: a promising molecule for cancer prevention." 
Pharm Res 27(6): 962-978. 
Siegel, R. L., K. D. Miller, et al. (2017). "Colorectal cancer statistics, 2017." CA Cancer J 
Clin 67(3): 177-193. 
Siler, U., L. Barella, et al. (2004). "Lycopene and vitamin E interfere with 
autocrine/paracrine loops in the Dunning prostate cancer model." FASEB J 18(9): 1019-
1021. 
149 
 
Su, J. D., J. H. Yen, et al. (2012). "3',4'-didemethylnobiletin induces phase II 
detoxification gene expression and modulates PI3K/Akt signaling in PC12 cells." Free 
Radic Biol Med 52(1): 126-141. 
Sun, J., Y. F. Chu, et al. (2002). "Antioxidant and antiproliferative activities of common 
fruits." J Agric Food Chem 50(25): 7449-7454. 
Sunami, Y. and T. Wirth (2011). "Intestinal carcinogenesis: IKK can go all the way." J 
Clin Invest 121(7): 2551-2553. 
Suzuki, R., H. Kohno, et al. (2004). "Citrus nobiletin inhibits azoxymethane-induced 
large bowel carcinogenesis in rats." Biofactors 22(1-4): 111-114. 
Svehlikova, V., S. Wang, et al. (2004). "Interactions between sulforaphane and apigenin 
in the induction of UGT1A1 and GSTA1 in CaCo-2 cells." Carcinogenesis 25(9): 1629-
1637. 
Takagaki, N., Y. Sowa, et al. (2005). "Apigenin induces cell cycle arrest and p21/WAF1 
expression in a p53-independent pathway." Int J Oncol 26(1): 185-189. 
Tanaka, S., T. Sato, et al. (2004). "Prevention of UVB-induced photoinflammation and 
photoaging by a polymethoxy flavonoid, nobiletin, in human keratinocytes in vivo and in 
vitro." Biochem Pharmacol 68(3): 433-439. 
Tanaka, T., H. Makita, et al. (1997). "Chemoprevention of azoxymethane-induced rat 
colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin." 
Carcinogenesis 18(5): 957-965. 
Tang, F. Y., H. J. Cho, et al. (2009). "Concomitant supplementation of lycopene and 
eicosapentaenoic acid inhibits the proliferation of human colon cancer cells." J Nutr 
Biochem 20(6): 426-434. 
Tang, M. X., K. Ogawa, et al. (2011). "Effects of nobiletin on PhIP-induced prostate and 
colon carcinogenesis in F344 rats." Nutr Cancer 63(2): 227-233. 
Tang, S. N., C. Singh, et al. (2010). "The dietary bioflavonoid quercetin synergizes with 
epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, 
invasion, migration and epithelial-mesenchymal transition." J Mol Signal 5: 14. 
Tatemichi, M., H. Tazawa, et al. (2004). "Suppression of thymic lymphomas and 
increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric 
oxide synthase gene." Int J Cancer 111(6): 819-828. 
Teiten, M. H., S. Eifes, et al. (2010). "Curcumin-the paradigm of a multi-target natural 
compound with applications in cancer prevention and treatment." Toxins (Basel) 2(1): 
128-162. 
150 
 
Terzic, J., S. Grivennikov, et al. (2010). "Inflammation and colon cancer." 
Gastroenterology 138(6): 2101-2114 e2105. 
Theodoratou, E., J. Kyle, et al. (2007). "Dietary flavonoids and the risk of colorectal 
cancer." Cancer Epidemiol Biomarkers Prev 16(4): 684-693. 
Tolman, J. R., E. D. Lephart, et al. (2008). "Timing of supplementation of selenium and 
isoflavones determines prostate cancer risk factor reduction in rats." Nutr Metab (Lond) 
5: 31. 
Tripoli, E. (2007). "Citrus flavonoids:  Molecular structure, biological activity and 
nutritional properties:  A review." Food Chemistry 104: 466-479. 
Tsuda, H., Y. Ohshima, et al. (2004). "Cancer prevention by natural compounds." Drug 
Metab Pharmacokinet 19(4): 245-263. 
Tunon, M. (2009). "Potential of Flavonoids as Anti-inflammatory Agents:  Modulation of 
Pro-Inflammatory Gene Expression and Signal Transduction Pathways." Current Drug 
Metabolism 10: 256-271. 
Tunon, M. J., M. V. Garcia-Mediavilla, et al. (2009). "Potential of flavonoids as anti-
inflammatory agents: modulation of pro-inflammatory gene expression and signal 
transduction pathways." Curr Drug Metab 10(3): 256-271. 
Ueda, H. (2002). "Luteolin as an Anti-inflammatory and Anti-allergic Constituent of 
Perilla frutescens." Biol Pharm Bull 25(9): 1197-1202. 
Ullah, M. F., S. H. Bhat, et al. (2016). "Pharmacological Intervention through Dietary 
Nutraceuticals in Gastrointestinal Neoplasia." Crit Rev Food Sci Nutr 56(9): 1501-1518. 
Vaishampayan, U., M. Hussain, et al. (2007). "Lycopene and soy isoflavones in the 
treatment of prostate cancer." Nutr Cancer 59(1): 1-7. 
Velmurugan, B., A. Mani, et al. (2005). "Combination of S-allylcysteine and lycopene 
induces apoptosis by modulating Bcl-2, Bax, Bim and caspases during experimental 
gastric carcinogenesis." Eur J Cancer Prev 14(4): 387-393. 
Venkateswaran, V., N. E. Fleshner, et al. (2004). "Synergistic effect of vitamin E and 
selenium in human prostate cancer cell lines." Prostate Cancer Prostatic Dis 7(1): 54-56. 
Venkateswaran, V., L. H. Klotz, et al. (2009). "A combination of micronutrients is 
beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady 
transgenic model." Cancer Prev Res (Phila) 2(5): 473-483. 
Verma, S. P., E. Salamone, et al. (1997). "Curcumin and genistein, plant natural products, 
show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells 
induced by estrogenic pesticides." Biochem Biophys Res Commun 233(3): 692-696. 
151 
 
Vicinanza, R., Y. Zhang, et al. (2013). "Pomegranate Juice Metabolites, Ellagic Acid and 
Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth 
via Distinct Effects on Cell Cycle Control and Apoptosis." Evid Based Complement 
Alternat Med 2013: 247504. 
Vlantis, K., A. Wullaert, et al. (2011). "Constitutive IKK2 activation in intestinal 
epithelial cells induces intestinal tumors in mice." J Clin Invest 121(7): 2781-2793. 
Walle, T. (2007). "Methoxylated flavones, a superior cancer chemopreventive flavonoid 
subclass?" Semin Cancer Biol 17(5): 354-362. 
Wang, P., D. Heber, et al. (2012). "Quercetin increased bioavailability and decreased 
methylation of green tea polyphenols in vitro and in vivo." Food Funct 3(6): 635-642. 
Wang, W., P. C. VanAlstyne, et al. (2004). "Individual and interactive effects of apigenin 
analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines." Nutr Cancer 
48(1): 106-114. 
Wang, Z., S. Desmoulin, et al. (2008). "Synergistic effects of multiple natural products in 
pancreatic cancer cells." Life Sci 83(7-8): 293-300. 
Warner, E. F., Q. Zhang, et al. (2016). "Common Phenolic Metabolites of Flavonoids, but 
Not Their Unmetabolized Precursors, Reduce the Secretion of Vascular Cellular 
Adhesion Molecules by Human Endothelial Cells." J Nutr 146(3): 465-473. 
Watson, J. L., R. Hill, et al. (2008). "Curcumin induces apoptosis in HCT-116 human 
colon cancer cells in a p21-independent manner." Exp Mol Pathol 84(3): 230-233. 
Watson, J. L., R. Hill, et al. (2010). "Curcumin causes superoxide anion production and 
p53-independent apoptosis in human colon cancer cells." Cancer Lett 297(1): 1-8. 
Willard, S. T. and L. S. Frawley (1998). "Phytoestrogens have agonistic and 
combinatorial effects on estrogen-responsive gene expression in MCF-7 human breast 
cancer cells." Endocrine 8(2): 117-121. 
Williamson, G. and M. N. Clifford (2010). "Colonic metabolites of berry polyphenols: 
the missing link to biological activity?" Br J Nutr 104 Suppl 3: S48-66. 
Wu, X., M. Song, et al. (2017). "Nobiletin and its colonic metabolites suppress colitis-
associated colon carcinogenesis by down-regulating iNOS, inducing antioxidative 
enzymes and arresting cell cycle progression." J Nutr Biochem 42: 17-25. 
Wu, X., M. Song, et al. (2017). "A metabolite of nobiletin, 4'-demethylnobiletin and 
atorvastatin synergistically inhibits human colon cancer cell growth by inducing G0/G1 
cell cycle arrest and apoptosis." Food Funct. 
Wu, X., M. Song, et al. (2015). "Chemopreventive effects of nobiletin and its colonic 
metabolites on colon carcinogenesis." Mol Nutr Food Res 59(12): 2383-2394. 
152 
 
Xiao, H. and C. S. Yang (2008). "Combination regimen with statins and NSAIDs: a 
promising strategy for cancer chemoprevention." Int J Cancer 123(5): 983-990. 
Xiao, H., C. S. Yang, et al. (2009). "Monodemethylated polymethoxyflavones from sweet 
orange (Citrus sinensis) peel inhibit growth of human lung cancer cells by apoptosis." 
Mol Nutr Food Res 53(3): 398-406. 
Xiao, H., Q. Zhang, et al. (2008). "Combination of atorvastatin and celecoxib 
synergistically induces cell cycle arrest and apoptosis in colon cancer cells." Int J Cancer 
122(9): 2115-2124. 
Xu, G., G. Ren, et al. (2010). "Combination of curcumin and green tea catechins prevents 
dimethylhydrazine-induced colon carcinogenesis." Food Chem Toxicol 48(1): 390-395. 
Yamamoto, Y. and R. B. Gaynor (2001). "Therapeutic potential of inhibition of the NF-
kappaB pathway in the treatment of inflammation and cancer." J Clin Invest 107(2): 135-
142. 
Yang, J. and R. H. Liu (2009). "Synergistic effect of apple extracts and quercetin 3-beta-
d-glucoside combination on antiproliferative activity in MCF-7 human breast cancer cells 
in vitro." J Agric Food Chem 57(18): 8581-8586. 
Yi, W. and H. Y. Wetzstein (2011). "Anti-tumorigenic activity of five culinary and 
medicinal herbs grown under greenhouse conditions and their combination effects." J Sci 
Food Agric 91(10): 1849-1854. 
Zheng, J., J. Bi, et al. (2015). "Analysis of 10 metabolites of polymethoxyflavones with 
high sensitivity by electrochemical detection in high-performance liquid 
chromatography." J Agric Food Chem 63(2): 509-516. 
Zhong, Y., C. Krisanapun, et al. (2010). "Molecular targets of apigenin in colorectal 
cancer cells: involvement of p21, NAG-1 and p53." Eur J Cancer 46(18): 3365-3374. 
Zhou, J. R., L. Li, et al. (2007). "Dietary soy and tea combinations for prevention of 
breast and prostate cancers by targeting metabolic syndrome elements in mice." Am J 
Clin Nutr 86(3): s882-888. 
Zhou, J. R., L. Yu, et al. (2004). "Combined inhibition of estrogen-dependent human 
breast carcinoma by soy and tea bioactive components in mice." Int J Cancer 108(1): 8-
14. 
Zhou, J. R., L. Yu, et al. (2003). "Soy phytochemicals and tea bioactive components 
synergistically inhibit androgen-sensitive human prostate tumors in mice." J Nutr 133(2): 
516-521. 
Zhou, P., S. W. Cheng, et al. (2012). "Combination chemoprevention: future direction of 
colorectal cancer prevention." Eur J Cancer Prev 21(3): 231-240. 
153 
 
Zhu, H. and Y. R. Li (2012). "Oxidative stress and redox signaling mechanisms of 
inflammatory bowel disease: updated experimental and clinical evidence." Exp Biol Med 
(Maywood) 237(5): 474-480. 
Zuniga, K. E., S. K. Clinton, et al. (2013). "The interactions of dietary tomato powder 
and soy germ on prostate carcinogenesis in the TRAMP model." Cancer Prev Res (Phila) 
6(6): 548-557. 
 
 
